

Alexander Stojadinovic, MD, MBA, FACS

PERSONAL INFORMATION:

3509 EAST WEST HWY
Chevy Chase, MD 20815
240-505-4085 (Mobile)
Email: stojadinovicmd2011@gmail.com
astojadinovic@3rdcurve.com

Executive Leadership and Management Profile:

Results-oriented leader with extensive experience in providing visionary leadership and effective administration in areas of strategic planning, program development, team building, operations, innovation, research and development. Proven skills as a highly effective, collaborative and innovative leader. Extensive experience in surgical oncology; clinical and research leadership; student and resident education; and translational research. Highly focused with demonstrated ability to conceive large – scale strategic initiatives, integrate multi-disciplinary team and harness collective genius. Proven success in building effective and enduring international private-public partnerships based on mutual trust and shared vision to support cooperative multi-center clinical trials aimed at addressing relevant clinical needs. Excellent oral, written and inter-personal communication skills; open style of communication, using both disclosure and candid feedback, with genuine interest in people's needs and institutional productivity. Persuasive, flexible, adaptable, results-oriented, resilient, leader who adheres to the highest standards of integrity and excellence.

Executive education in **General Management** at the **Harvard Business School (HBS)** helped me refine analytical skills and decision-making frameworks needed to address complex problems, and further develop judgment and confidence to make important business decisions. That transformative Harvard learning experience helped me to further develop leadership skills key to building organizations that make a difference in the world, drive fundamental change, and achieve meaningful long-term performance through innovation and effective strategy. Influence is the key to leadership. The HBS program, comprised of a diverse group of leaders from 36 different countries and 38 industries, was a rich venue to establish a global network of leaders, mentors, advisors and friends.

I graduated at the top of my class in a healthcare-focused MBA from the Nation's preeminent physician-only degree program - **Physician Executive MBA (PEMBA)** at the **University of Tennessee-Knoxville** - with a thesis on competitive strategy, Precision Medicine, and service-line development. I am committed to continuous improvement as a leader in healthcare.

KEY LEADERSHIP POSITIONS and TITLES:

**Medical Director, Healthcare Management Services
Amerigroup, Texas, Anthem Inc.
DEC 2014 –**

Serving as surgery and oncology expert to educate, address and resolve clinical inquiries from external providers and internal partners. Providing clinical leadership and industry expertise supporting the development of strategies to improve quality, safety, outcomes, access to, usefulness and affordability of complex healthcare. Providing insights, medical management approaches, and sharing clinical science innovations impacting health care delivery and payment models and improving the health of the people we serve.

Acquired extensive experience in reviewing and judging quality of care based on national standard sets of quality measures established by peer-reviewed evidence-based medicine, the Joint Commission, CMS, hospitals, consumers - collectively the National Quality Forum. Breadth of experience stems from medical necessity determinations made for patients treated across the spectrum of healthcare - pediatric and adult out-patient and in-patient, medical and surgical care, and behavioral health, sub-acute and long-term care. To date, completed medical quality and necessity determinations on over 7,205 cases according to evidence-based medical necessity criteria guidelines, and I have adjudicated over 4,040 healthcare system 1st and 2nd level appeals.

**Consulting Surgical Oncologist and Healthcare Executive
DEC 2014 -**

- Providing consulting services to Innovate and grow healthcare entities and systems in competitive markets.
- Serving to guide physicians, executives and governance toward strategic goals.
- Consulting internationally in healthcare design and development.
- Leading implementation of healthcare service models employing integrated and well-coordinated, multi-disciplinary, patient-centered, evidence- and team-based approaches; with the primary aim of delivering superior patient value (through service excellence, integrated care delivery to attain high quality outcomes).
- As a surgical oncology consultant, I continue to actively contribute clinically, and I see patients and operate 1 day per week (Bon Secours-Mercy Healthcare System's Saint Mary's Hospital and HCA Healthcare's Henrico Doctor's Hospital – Forest, Parham & Retreat).

Chief Medical Innovation Officer
RPM Telehealth, LLC
DEC 2016 – FEB 2018

- Strategic advisor for telehealth start up
- Developing clinical decision algorithm design and integration into remote patient monitoring technology platform
- Developing brand and product positioning, and scaling the telemedicine-clinical decision support business model

Founding Partner
3rd Curve Healthcare
OCT 2016 –

3rd Curve Healthcare delivers practical, real-world solutions with quantifiable benefit for our clients and the communities they serve. We plan and assist in the implementation of innovative programs that improve physician, staff and patient satisfaction, improve healthcare efficiency and effectiveness, eliminate waste and non-value-added activities, reduce costs, improve quality and overall service performance and grow market share. Our team has >200 years of collective experience in key clinical, leadership and management, and it enables our clients to navigate the uncertainties of care delivery in today's rapidly changing environment.

Our service portfolio: Strategic Process & Roadmap; Competitive Market Share Modeling; Power BI Data Visualizaition; Medical Staff Development Planning; Serviceline Solutions; Operational Performance Scorecard & Dashboard Solutions; Evidence-Based Data Mining and Machine Learning; Strategic Site Optimization; Hospital & Health Sysytem Development.

- Strategic advisory for healthcare providers and independent support service entities locally, regionally and globally.
- Implementing business development and product repositioning for specialty pharmacies - 340B compliance and enhancement technology application.
- Assisting integrated health networks to design and frame effective planning infrastructure.
- Working with private multispecialty groups to support their repositioning with regional delivery system partners.
- Providing planning and development services for a potential private hospital north of Colombo, Sri Lanka.
- Initiating and identifying innovative services and products to support private health systems in Europe, the Middle East, and China.

**Regional Director, Bon Secours Cancer Institute (BSCI)
(NOV 2012 – NOV 2014)**

- Leader for national healthcare system-based cancer programs and innovations;
- Builder of a team dedicated to achieving BSCI strategic aims for cancer care;
- Architect of new programs and strategic alliances with academic, community-based, and industry collaborators to deliver value in cancer care;
- Leader for system-wide efforts to advance precision medicine patient-centered, value- and evidence-based, economically sustainable cancer care;
- Key collaborator with stakeholders and industry partners to develop strategies and innovations for distribution within BSCI and beyond Bon Secours Health System
- Lead agent working in collaboration with affiliated hospital leaders and allied health professionals to transform cancer care across the health system

Key deliverables:

- Strategized Cancer Institute turnaround by building multi-disciplinary, integrated, high-value cancer care - improving overall survival for four major cancers by 15%
- Jump started revenue generation; Direct Contribution Margin doubled in Year 1, tripled in Year 2, making the service line #1 bottom line producer

**President, P8 Medicine LLC
2013 –**

P8Medicine was established to serve and assist hospitals and healthcare systems with limited resources to achieve optimal value - defined by access to healthcare and quality of care over the cost of care.

Creating and initiating innovative services and products to support private health systems in China, the Middle East, and Europe. Providing pre-planning and development services for a potential private hospital north of Colombo, Sri Lanka.

P8 principles applied: Personalized, Predictive, Preventive, Portable, Promotional, Protective, Precision medicine with Patient engagement

Consulting services for:

- Accountable Care centered on optimizing access to quality care at a lower cost
- Evidence-based cancer service and line development
- Organizing cancer care into disease-specific integrated practice units (IPU) across the continuum of care
- Development, deployment, validation, licensing, and updating innovation as well as economic models or solutions to improve cancer care

- Development of strategic alliances to create integrated cancer systems across separate health care facilities, systems and regions
- Implementation of system-wide biobanking for clinical and commercial applications
- Establishing and growing a cancer clinical trials unit
- Developing Nurse Navigation Programs in cancer to implement survivorship programs across full cycle of cancer care
- Developing and implementing bedside to bench and bench to bedside translational cancer research programs
- Developing and implementing health system strategies to compete effectively in competitive market

**Professor of Surgery, Uniformed Services University of the Health Sciences
(2012 – 2015)**

**Professor of Medicine, Uniformed Services University of the Health Sciences
(2012 – 2015)**

- Earned academic rank of Professor in Surgery (Clinical Investigator Pathway), a rank seldom attained by medical officers on active duty within the Department of Defense.
- Dual professorship is a distinctly uncommon achievement within Military Medicine.

**Colonel, United States Army Medical Corps
(2009 – 2013)**

**Honorary Visiting Full Professor, The Chinese National Center for Colorectal Diseases,
the Third Affiliated Hospital of the Nanjing University of Chinese Medicine
2014 –**

**Honorary Visiting Professor, University of Novi Sad, Faculty of Medicine
2013 –**

**Vice President, International Union for Difficult-to-Treat Diseases
2014 –**

**Associate Editor-in-Chief, Chinese Approaches for Difficult Disease
2014 –**

**Associate Editor-in-Chief, New Approaches Combating Cancer and Aging
2014 –**

**Associate Editor-in-Chief, Chronic Disease Management and Subhealth Intervention
2014 –**

**Vice Chairman Department of Surgery, Walter Reed Army Medical Center
(2004-2009)**

- Coordinated clinical and administrative support to 13 surgical services within the largest Department of Surgery in the Department of Defense.
- Advised the Department Chair on all surgical care issues within WRAMC.
- Appointed by Surgeon General to develop DoD policy for early detection and control of cancer.
- Developed and directed multi-institutional collaborative clinical research initiatives for the Department of Surgery as its Principal Investigator.
- Directed \$10M in direct translational research funding placing me in the top tier of all DoD researchers.

**GI Cancer Program Leader, United States Military Cancer Institute
(2004 – 2013)**

- Directed the collaborative clinical research program since its inception.
- Conceptualized plan for integration of international leaders in surgical oncology into a cooperative clinical trials group.
- Developed a multi-center international research partnership to advance colon cancer therapy through dedicated translational research, generating over \$5M in peer-reviewed grant funding.
- Led an international multi-disciplinary cooperative group to complete the first randomized controlled trial showing that targeted nodal assessment and ultra-staging improves staging and patient outcomes in colon cancer.
- Developed private-public partnerships to advance precision medicine through the creation of clinical decision support tools for cancer care.
- Developed a strategic vision and led a collaborative, private-public research partnership that defined the importance of surgical and pathological quality and identified patients likely cured by surgery alone; the results of this multi-year international research effort were published on multiple occasions in surgery's #1 Journal (*Annals of Surgery*), and presented at the American Surgical Association.
- Established the first multi-disciplinary peritoneal surface malignancy program in the Department of Defense.
- Established the first advanced cancer surgical training program that expanded this multi-disciplinary cancer treatment capability across the Department of Defense;

this multi-year effort culminated in the establishment of the first USMCI-ACOSOG inter-group randomized clinical trial in peritoneal surface malignancy (NIH funded).

**Principal Investigator, Department of Surgery, WRAMC / WRNMMC
(2001 - 2013)**

- Developed, implemented and managed numerous state-of-the-art research protocols that enhanced the understanding of disease and patient care to support the mission and vision of the WRNMMC and USMCI.
- Distinguished myself as a surgeon-leader in the military and civilian medical community through successful development and leadership of translational research programs, with over 240 peer-reviewed publications.
- Developed, mobilized and led a multi-disciplinary team to conduct a pivotal, definitive, practice-transforming clinical trial in sentinel lymphatic mapping to advance care for patients with breast cancer - significantly improving pain associated with sentinel lymphatic mapping across the Department of Defense.
- The findings of this collaborative research trial were published in leading peer reviewed journals to include Lancet Oncology.

**Medical Director, Complex Wound and Limb Salvage Center, WRAMC/WRNMMC
(2006 – 2013)**

- Established and led this comprehensive, trans-disciplinary Center, the largest of its kind in the Department of Defense.
- Developed and executed the strategic vision to provide state-of-the-art diagnostic assessment, testing and evidence-based multi-disciplinary treatment of wounded warriors and healthcare beneficiaries with wounds across the full cycle of care.
- Competed successfully each year to secure over \$18M in funding since its inception (2006) to sustain and advance the Center, which is committed to contributing actively to the Department of Defense's center of gravity for complex surgical care through surgical education and research, and enhanced provider level of education.

**Director, Combat Wound Initiative Program (CWIP)
(2006 – 2013)**

- Founded and directed this translational research program of leading surgeons and scientists from around the globe.

- Raised over \$33M in programmatic funding to initiate and grow the CWIP.
- Expanded strategic national and international private-public partnerships (14 centers); integrated clinical and basic science research to assess and develop promising technologies and treatments to advance complex wound care.
- Successfully negotiated during the 2011 Base Realignment and Closure a key strategic merger effecting the transfer of the Armed Forces Institute of Pathology's Wound Research Division's cadre of senior scientists, state-of-the-art molecular and microbiological platform, biorepository, and logistics support to the CWI Program
- Established the Diagnostics and Translational Research Center in order to advance and expand the CWIP's mission and vision. This is a highly successful research team that has successfully garnered an average of \$6M dollars competitive in research funding each year.
- Expanded the CWIP's mission capability by establishing a critical research partnership with the Department of Medicine, Uniformed Services University, and established a new collaborative Wound Biology and Translational Research Program under a new University Charter.

Surgical Oncologist, WRAMC / WRNMMC (2001 – 2013)

- Mentored hundreds of medical students, surgical interns and residents over the course of my career.
- Inspired research residents to pursue academic surgical careers in the and actively supported their competitive applications for surgical fellowships, through dedicated mentorship and guided joint research endeavor, leading to numerous regional and national presentations and peer-reviewed publications.
- I completed Surgical Oncology fellowship training at Memorial Sloan Kettering Cancer Center and subsequently worked at the DoD's largest University-affiliated cancer program at Walter Reed Army Medical Center, and most recently worked at Bon Secours Cancer Institute
- As regional director at Bon Secours Cancer Institute I championed the concept that surgical oncology's role in advanced peritoneal malignancy is underutilized, and I developed programs to support multi-disciplinary care in advanced cancer

EDUCATION:

- University of Tennessee** Physician Executive MBA Nov 2014 – Dec 2015
- **Valedictorian UT-Knoxville MBA Class of 2015**
- Harvard Business School** General Management Program July 2014 – Nov 2014
- Fellowship:** Surgical Oncology July 1999 - June 2001
- Memorial Sloan Kettering Cancer Center, New York, NY
 - **1st Recipient of award named to recognize clinical research contributions while a fellow at MSKCC (MSKCC Award for Excellence in Clinical Research)**
- Residency:** General Surgery July 1992 - June 1997
- Walter Reed Army Medical Center, Washington, D.C.
 - **Recipient of awards for basic and clinical research excellence (Charles A. Hufnagel Research Award and Bailey K. Ashford Research Award)**
- Internship:** General Surgery July 1991 - June 1992
- Walter Reed Army Medical Center, Washington, D.C.
- Medical School:** Degree: Medical Doctor July 1987 - May 1991
- Uniformed Services University of the Health Sciences Bethesda, MD
- College / University:** Degree: Bachelor of Science July 1983 - May 1987
- United States Military Academy West Point, NY
 - On the Dean's List all four years at the academy
 - **Top 1% of graduating class of 1987**
- High school** Jul 1979 - June 1983
- Mira Mesa High School San Diego, CA
 - **Valedictorian**

Chronological Summary

7/79-6/83	Mira Mesa High School
7/83-5/87	United States Military Academy
7/87-7/91	Uniformed Services University of the Health Sciences
7/91-6/92	WRAMC – General Surgery Internship
7/92-6/97	WRAMC – General Surgery Residency

7/97-6/99	General Surgeon – DeWitt ACH, Fort Belvoir, VA
7/99-6/01	MSKCC – Surgical Oncology Fellowship
7/01-4/13	Surgical Oncologist – WRAMC/WRNMMC
11/12-11/14	Medical Director, BSCI, Richmond, VA
11/13-	President P8 Medicine, LLC
7/14-11/14	Harvard Business School - GMP
11/14-12/15	UT-Knoxville Physician Executive MBA
12/14-	Medical Director, Healthcare Management Services Anthem - Amerigroup, TX
12/14-	Consulting Surgical Oncologist / Healthcare Executive
10/16	Founding Partner, 3 rd Curve Healthcare
12/16	Chief Medical Innovation Officer, RPM Telehealth

PEER-REVIEWED / PROGRAMMATIC FUNDING:

North Atlantic Regional Medical Breast Cancer Screening Program:

- Developed, led DoD's 1st large scale breast cancer screening initiative to advance cancer risk identification in young ethnically diverse and underprivileged women.
- Competing for over \$3M in peer-reviewed funding.
- Led a multi-year multi-center prospective trial enrolling over 8,500 young women.
- Created a joint research enterprise, private-public partnership to develop a clinical decision support system in for breast cancer risk assessment.

Congressional grant = \$1.0M

USAMRMC grant = \$1.4M

TATRC grant, 2008 = \$350,000

TATRC grant, 2009 = \$299,000

TATRC grant, 2011 = \$300,000

Combat Wound Initiative translational research Program:

FY07 Congressional Grant = \$5.0M
FY08 Congressional Grant = \$2.0M
FY09 OSD Defense Acquisition Challenge Grant = \$3.22M
FY09 Congressional Grant = \$2.8M
FY10 Congressional Grant = \$2.4M
FY11 AFMSA Grant = \$992,000
FY12 USAMAA Grant = \$1.2M

Ultra-staging of Early Colon Cancer

NIH - R01 Grant CA090848–05A2:

PI - Anton Bilchik; AI – Alexander Stojadinovic

Level of Funding = \$430,000 (subcontract PI→AI)

Complex Wound and Limb Salvage Center:

FY09 GWOT Funding = \$2.7M
FY10 GWOT Funding = \$5.2M
FY11 GWOT Funding = \$4.5M
FY12 OCO Funding = \$1.9M
FY13 OCO Funding = \$3.2M

NCI Provocative Questions R21CA190076-01:

PI – Timothy J. Wallace; AI – Alexander Stojadinovic

Level of Funding = \$413,383

This collaborative research project addresses the question, do racial differences in the number or spectrum of tumor infiltrating lymphocytes (TILs) exist and can they help to explain Prostate Cancer (PCa) health disparities?

This study further addresses the following research questions:

- i) What is the profile of TILs in PCa specimens of African American (AA) men, versus Caucasian men, as determined by immunoscore?

- ii) Does the PCa immunoscore predict adverse clinical outcomes in AA men with localized PCa?
- iii) Given recent evidence that the androgen receptor (AR) mediates immune-related epithelial-to-mesenchymal transition (EMT) and PCa metastasis, does the added knowledge of AR status improve the ability of the immunoscore to stratify AA patients based on outcome?

Our prostate tissue biorepository collected during 2003-2013, contains over 6,500 archival formalin-fixed paraffin-embedded (FFPE) post-prostatectomy blocks, 25% (1,630) of which are from AA men.

The biorepository will enable testing of the reproducibility of the proposed methodology for determining the PCa immunoscore as well as test the following hypotheses:

- a. the levels of invading CD4⁺, CD8⁺, and CD3⁺ lymphocytes in non-metastatic PCa specimens from AA men are significantly higher than in Caucasianmen;
- b. the PCa immunoscore is an independent predictor of outcome after radical prostatectomy for AA men with localized PCa; and,
- c. AR status combined with PCa immunoscore will be a better predictor of clinical outcome than either factor alone.

ACADEMIC APPOINTMENTS:

Honorary Visiting Full Professor

The Chinese National Center of Colorectal Disease, the Third Affiliated Hospital, Nanjing University of Chinese Medicine, Nanjing, China
2014

Honorary Visiting Professor of Surgery

University of Novi Sad, Faculty of Medicine, Novi Sad, Republic of Serbia
2013

Professor of Surgery (Clinical Investigator Track)

Department of Surgery
Uniformed Services University of the Health Sciences, Bethesda, MD
2012 - 2015

Professor of Medicine

Department of Medicine
Uniformed Services University of the Health Sciences, Bethesda, MD
2012 – 2015

Associate Professor of Surgery

Department of Surgery
Uniformed Services University of the Health Sciences, Bethesda, MD
2006 - 2012

Assistant Professor of Surgery

Uniformed Services University of the Health Sciences
Bethesda, MD
2001 - 2006

Instructor in Surgery

Uniformed Services University of the Health Sciences
Bethesda, MD
1999 - 2001

PROFESSIONAL APPOINTMENTS (ACTIVE):

Member, American College of Healthcare Executives

2015 – Present

**Member, Haslam College of Business, Physician Executive Masters of
Business Administration Program Advisory Council**

2015 – Present

Fellow, American Surgical Association

2013 – Present

**Society of Surgical Oncology Representative to the American Joint
Committee on Cancer**

2013 - 2014

**Member, Education and Promotions Committee, American Joint
Committee on Cancer**

2013 - 2016

Member, Lower GI Expert Panel, American Joint Committee on Cancer

2013 - 2016

**Member, Molecular Modeler Working Group, American Joint Committee
on Cancer**

2013 - 2016

Governing Board of Directors, American College of Wound Healing and Tissue Repair

2013 - 2016

Member, Faculty and Educational Committee,

American College of Wound Healing and Tissue Repair

2010 - 2016

Member, Board of Directors,

American Society of Peritoneal Surface Malignancy,

2009 - 2015

Fellow, American College of Surgeons

2005 - Present

Grant Review: NCI RFA CA11-005, Advanced in vivo Imaging to Understand Cancer Systems RO1, Gaithersburg, MD; June 13th-14th, 2011

PROFESSIONAL APPOINTMENTS and ASSIGNMENTS (PREVIOUS):

Founder & Medical Director,

Complex Wound and Limb Salvage Center

2008 - 2013

Founder and Director,

Combat Wound Initiative translational research Program

2006 - 2013

Principal Investigator,

Department of Surgery, Walter Reed Army Medical Center

2004 - 2013

Program Leader,

Gastrointestinal Cancer Program, United States Military Cancer Institute

2004 - 2013

Chief of Surgery, Task Force 28

(Scope of responsibility and performance at the end of this document)

United States Forces Hospital
Sather Air Base, IRAQ
October 2009 – May 2010

Theater Surgical Consultant

Operation Iraqi Freedom
October 2009 – May 2010

Chief, Surgical Oncology

Walter Reed Army Medical Center
2006 - 2011

Head, Tumor Board

Walter Reed Army Medical Center
2006 - 2009

Vice Chairman, Department of Surgery

Walter Reed Army Medical Center
2004 - 2009

Consultant to the Food and Drug Administration

2004 - 2011

Committee Member, Scientific Review Board, USMCI

2004 - 2011

Surgeon General Appointee to the DoD Cancer Working Group

2004 - 2011

Joint Readiness Clinical Advisory Board, General Surgery

2004 - 2011

General Surgery Research Resident Coordinator/Mentor

2002 - 2010

**Department of Surgery Representative to the
Human Use Committee (Institutional Review Board)**

Walter Reed Army Medical Center
2002 - 2009

Program Director, Gary P. Wratten Army Surgical Symposium

2002

QI Coordinator, General Surgery Service

Walter Reed Army Medical Center

2001 - 2003

Assistant for Administration to the Chief, General Surgery

Walter Reed Army Medical Center
2001 - 2003

General Surgery Representative to the Clinical Investigations Committee

Walter Reed Army Medical Center
2001 - 2002

General Surgery Representative to the Performance Improvement/Risk Management Advisory Group

Walter Reed Army Medical Center
2001 - 2004

Co-investigator, Department of Medicine

Gastroenterology Division
Uniformed Services University of the Health Sciences
1995 - 1999

Diplomat, American Board of Surgery, September 1998

MEDICAL LICENSURE:

Michigan (4301062718; active)
District of Columbia (MD30874; active)
Virginia (0101252563; active)
New Jersey (25MA09821200; inactive)
NPI - 1689738403

MILITARY SERVICE:

United States Army: July 1983 – April 2013
Current Rank: Colonel (Retired)

MILITARY SCHOOLS/TRAINING:

AMEDD Officer Advance Course	1999
Medical Mgmt. Chemical Casualty	1999
Medical Def. Biological Warfare	1999
Acute Cardiac Life Support	1998
Acute Trauma Life Support (Instructor)	1995
Combat Casualty Course	1990
Airborne Training	1988
AMEDD Officer Basic Course	1987

(Entry Level Officer Leadership Course)
Air Assault Course 1985

MILITARY ASSIGNMENTS:

Operation Iraqi Freedom, Chief of Surgery, 28 th Combat Support Hospital Task Force	2009
Operation Iraqi Freedom, Theater Surgical Consultant, 28 th Combat Support Hospital Task Force	2009
Vice Chairman, Department of Surgery, Walter Reed Army Medical Center	2004
Attending General Surgeon, Walter Reed Army Medical Center	2004
Operation Iraqi Freedom, Combat Surgeon, 2 nd Armored Cavalry Regiment, Forward Surgical Team	2003
Attending General Surgeon, Walter Reed Army Medical Center	2001
Surgical Oncology Fellow, Memorial Sloan Kettering Cancer Center	1999
Attending General Surgeon, DeWitt Army Community Hospital, Fort Belvoir, Virginia	1997
Chief Resident, General Surgery, Walter Reed Army Medical Center	1996
Surgical research resident, Uniformed Services University of the Health Sciences	1995
Resident, General Surgery, Walter Reed Army Medical Center	1992
Intern, General Surgery, Walter Reed Army Medical Center	1991
Medical student, Uniformed Services University of the Health Sciences	1987
Cadet United States Military Academy, West Point	1983

MILITARY AWARDS:

Legion of Merit, 2013

- Awarded by The Surgeon General of the United States Army
- The Narrative reads:
For thirty years, Colonel Alexander Stojadinovic exemplified General Douglas MacArthur's "Duty-Honor-Country in a myriad of medical, surgical, and

administrative leadership positions in both garrison and deployed, reverently placing his Country, the Army, the Army Medical Department, and everyone entrusted to his care first. In 2003 while deployed to Iraq for 12 months as a trauma surgeon and earning his first Bronze Star, the United Nations in Baghdad suffered a terrorist attack at which then LTC Stojadinovic organized a base medical MASCAL plan, including triage, initial care and lifesaving surgery for which he was subsequently recognized for valor from the current Chairman of the Joint Chiefs of Staff, then MG Martin Dempsey. Recognized by LTG Hunzeker the USF-I Commander as the best Medical Task Force and Level III Hospital Chief Surgeon he had seen in Iraq, COL Stojadinovic also served as the Theater Surgical Consultant from 2009 to 2010 earning his second Bronze Star managing over 900 surgical cases (22,000 hours of operating room time) and legitimizing the Iraqi health care system by organizing and providing a series of didactic lectures to Iraqi providers and Coalition members. Recognized by BG Coots as one of the top surgeons in the command, he led the efforts developing novel treatments for complex battlefield wounds and during the BRAC, was invaluable in the safeguard of AFIP Translational Medicine biorepository capabilities, sustaining critical wound healing research. With a brilliant national and international reputation holding prominent leadership roles, COL Stojadinovic has amazingly produced 150 per-reviewed publications including cancer research and combat casualty care training, and generated programmatic findings in areas of breast cancer screening and other studies, generating millions of dollars in funding advancing lifesaving knowledge. The founding member of the highly successful Combat Wound Initiative and Limb Salvage Program that seeks to develop new technologies and personalized predictive models, he received the 2011 Major Jonathan Letterman Award for Medical Excellence. Attested by his current chain of command, he is the "ultimate combat surgeon, medical officer, and surgical researcher in the AMEDD today." A coach, teacher, mentor and staunch proponent for the advancement of medical processes and improved patient outcomes and quality of life, Colonel Stojadinovic, a member of the Order of Military Medical Merit, holder of the "A" Proficiency Designator, and Professor of Surgery and Medicine at USUHS, was recently awarded the 2011 Major Jonathan Letterman Award for Medical Excellence and is highly deserving of this unique distinction. He is a Soldier, Officer, Physician, and Leader who truly exemplifies "Serving to Heal. Honored to Serve."

Bronze Star Medal, First Oak Leaf Cluster, 2010

- For exceptionally meritorious service in a combat zone during Operation Iraqi Freedom, which contributed to the overwhelming success of the 28th Combat Support Hospital.

Certificate of Appreciation from United States Forces (USF) – IRAQ, 2010

- In recognition for expertise in Surgery and provision of subject matter expert advice to USF-1 Surgeon for all matters pertaining to Surgery in Operation Iraqi Freedom.

Certificate of Appreciation from Task Force 28 Commander – IRAQ, 2010

- In recognition of exceptional service and surgical support of America's Soldiers and Task Force 28 during Operation Iraqi Freedom.

“A” Proficiency designator, 2006

- Presented by the Army Surgeon General, the “A” designation is the highest award that the Army Medical Department can bestow to recognize professional expertise, exceptional ability, and outstanding achievement in both clinical and academic medicine.
- Few officers exhibit the requisite qualifications to successfully compete for it.

Order of Military Medical Merit, 2005

- An honor that recognizes the many significant contributions made to Army Medicine.
- Membership in the Order denotes distinguished service, recognized by the senior leadership of the Army Medicine.

Army Achievement Medal, 2005

- For skillful guidance, superb leadership and untiring devotion demonstrated during the 2005 Joint Commission for the Accreditation of Healthcare Organizations survey of Walter Reed Army Medical Center.
- Resulted in the Center's exceptional performance during the survey.

Combat Medical Badge, 2003

- In recognition of medical support of combat arms unit during active ground combat in Operation Iraqi Freedom

Army Commendation Medal - Valor, 2003

- In recognition of leadership in immediate response to the United Nations terrorist attack on August 19th 2003 and lifesaving care rendered to the victims of the worst attack in UN history.
- For organization of base medical operations to accept and triage mass casualties and provide initial stabilization of the wounded; for conducting life-saving surgery on the most severely wounded and heroically preserving the lives of fellow men; and, for coordinating air evacuation of the wounded.

Bronze Star Medal, 2003

- For exceptionally meritorious achievement while serving as the surgeon for the Forward Surgical Team, Regimental Support Squadron, 2nd Armored Cavalry Regiment in support of Operation Iraqi Freedom.
- For distinguished service that contributed to the health, safety, maintenance, sustainment and support of the Regimental Support Squadron.

Army Commendation Medal, 1998

- For meritorious service, insightful leadership and valuable clinical knowledge provided as Clinical Coordinator for the 1998 Joint Commission for the Accreditation of Healthcare Organizations survey of DeWitt Army Community Hospital, Fort Belvoir.
- Resulted in a score of 93 of 100, with no major deficiencies.

General Officer Letter of Commendation, 1997

- For outstanding contribution to the Walter Reed Army Medical Center Clinical Investigation Program during training as Chief Resident in the Department of Surgery from July 1993 to June 1997.
- For dedication to research that earned Dr. Stojadinovic the Bailey K. Ashford Clinical Research Award.

Army Commendation Medal, 1997

- For exceptionally meritorious achievement and dedication to research excellence recognized by the Bailey K. Ashford Award.

Army Achievement Medal, 1995

- For unselfish donation of time and knowledge and acceptance of increased responsibilities that were instrumental in the high quality of care within the Department of Surgery.
- For distinguished services to the General Surgery residents in helping his colleagues prepare for in-service examinations.

Parachute Badge

Air Assault Badge

Army Service Ribbon

Global War on Terrorism Service Medal

Global War on Terrorism Expeditionary Medal

Iraq Campaign Medal – Combat Service

Army Superior Unit Award

Presidential Unit Citation

National Defense Service Medal (2)

ACADEMIC / SERVICE AWARDS:

Charles A. Hufnagel Research Award, April 1995

Bailey K. Ashford Research Award, 1997

Memorial Sloan-Kettering Gorin Fellow in Sarcoma, 2001

Memorial Sloan-Kettering Award for Excellence in Clinical Research, 2001

- In recognition of unparalleled research productivity during surgical oncology fellowship; this compelled the Memorial Sloan Kettering Department of Surgery to recognize this unique contribution by the creation of a Chairman's Award for the finest researcher amongst the 30 graduating fellows in the Department.
- Coalesced multi-disciplinary teams to address important questions. Led, enrolled and studied a series of patients prospectively during the fellowship and beyond to address a clinically relevant question that many were curious about, but none had been willing to undertake.
- Continually assisted and enabled colleagues with statistical analysis or instruction to help them achieve their goals.
- Recognized for my team building initiatives and willingness to incorporate many others into the research world.

Major Jonathan Letterman Award for Medical Excellence, 2011

- Career achievement award in recognition of outstanding contributions to improving medical processes and patient outcomes through the Combat Wound Initiative Program (CWIP), which I created and directed.
- In partnership with civilian leaders in wound care and research and my team of clinicians and researchers provided cutting edge care through targeted clinical and translational research that incorporates advanced technology and treatment, tissue banking and bioinformatics.
- Addressing a previously unmet need in combat casualty care with an integrated approach to wound healing in the context of the CWIP.
- This leadership has enabled U.S. Army medicine to go beyond current medical science in helping our severely wounded troops lead a more manageable life.

John Wayne Cancer Institute Auxiliary Public Service Award, 2012

- The John Wayne Auxiliary Public Service Award recognizes an individual for his/her commitment to women's health and support of cancer research.
- The Public Service Award recognizes a career as a surgical oncologist and cancer researcher.
- For contributions instrumental in implementing programs for combat wound research and cancer screening at Walter Reed Army Medical Center.

- In recognition for outstanding contributions to medicine and to our country.

The Liberty Medal, 2013

- The Liberty Medal created by Don F. Wiegand with the Statue of Liberty Club for the Wiegand Foundation, Inc. Is presented "to outstanding individuals throughout the world who promote the ideals of liberty and freedom through their efforts, actions and deeds."
- "You were chosen to receive this prestigious award in recognition of your excellent contributions in support of liberty and freedom."

**Harvard Business School, General Management Program Scholarship,
Andrew Paul Healthcare Fund, 2014**

**University of Tennessee – Knoxville, Haslam College of Business, Physician Executive MBA Program –
Outstanding Physician Leader of the Year, 2015**

PROFESSIONAL MEMBERSHIP AND SOCIETIES:

Member, American College of Healthcare Executives
Fellow, American Surgical Association
Fellow, American College of Surgeons
Founding Member: International Consortium of Research Excellence (INCORE)
Member, American Association of Endocrine Surgeons
Member, United States Military Cancer Institute
Member, Society of Surgical Oncology
Member, International Society of Surgery

PROFESSIONAL MEMBERSHIP AND SOCIETIES:

Member, International Society of Gastrointestinal Oncology
Member, American Society of Clinical Oncology
Honorary Member, Israeli Society of Surgical Oncology
Member, 38th Parallel Medical Society
Member, Association of Military Surgeons of the United States
Member, Honor Society of Phi Kappa Phi
Member, International Association of Endocrine Surgeons

EDITORIAL BOARDS:

Journal of Surgical Oncology

Journal of Cancer, Editor
Clinical Medicine Insights: Oncology

Associate Editor-in-Chief, Chinese Approaches for Difficult Disease

2014 –

Associate Editor-in-Chief, New Approaches Combating Cancer and Aging

2014 –

Associate Editor-in-Chief, Chronic Disease Management and Subhealth Intervention

2014 –

SELECTED TRAINING:

Lean Six Sigma Champion

Sep 2015

Harvard Business School General Management Program

2014

FDA Clinical Investigator Training Course,

8-10 Nov 2010

Center for Professional Innovation & Education, Good Clinical Practice Course,

15-17 Nov 2010

Center for Professional Innovation & Education, Clinical Trial Design for Medical Devices Course,

02- 03 Dec 2010

Public Responsibility in Medicine and Research, Good Clinical Practice Course,

5 Dec 2010

BIBLIOGRAPHY:

Publications

1. **Stojadinovic A**, Kiang J, Galloway R, Smallridge R, Shea-Donohue T. Induction of heat shock protein-72 protects against ischemia / reperfusion injury in rat small intestine. *Gastroenterology* 1995; 109:505-515.
2. **Stojadinovic A**, Kiang J, Goldhill J, Smallridge R, Shea-Donohue T. Induction of the heat shock response prevents tissue injury during acute inflammation of the rat ileum. *Critical Care Medicine* 1997; 25(2):309-317.
3. **Stojadinovic A**, Miner TJ, Tavaf-Motamen H, Shea-Donohue T. Mucosal healing following ischemia / reperfusion injury of rat small intestine: role of mucus and lipid peroxidation. *Surgical Forum* 1997; XLVIII: 224-226. (American College of Surgeons) October 1997.
4. Bamberger PK, **Stojadinovic A**, Shaked G, Golocovsky M. Biliary-pleural fistula presenting as a massive pleural effusion after thoracoabdominal penetrating trauma. *Journal of Trauma* 1997; 43(1): 162-163.
5. **Stojadinovic A**, Shriver CD, Casler JD, York G, Jaques DP. Endoscopic laser excision of pyriform sinus parathyroid adenoma. *Archives of Surgery* 1998; 133:101-103.
6. Allen PJ, **Stojadinovic A**, Shriver CD, Jaques DP. Contributions from surgeons to clinical trials and research on the management of soft tissue sarcoma. *Annals of Surgical Oncology* 1998; 5(5):437-441.
7. Goldhill JM, **Stojadinovic A**, Kiang J, Smallridge R, Shea-Donohue T. Hyperthermia prevents functional, histological, and biochemical abnormalities induced during ileitis. *Neurogastroenterology and Motility* 1999; 11:60-76.
8. **Stojadinovic A**, Smallridge R, Shea-Donohue T. U74389F limits tissue injury in a rat model of ischemia / reperfusion. *Crit Care Med* 1999; 27(4): 764-70.
9. Eror AT, **Stojadinovic A**, Starnes BW, Makrides SC, Tsokos G, Shea-Donohue T. Antiinflammatory Effects of Soluble Complement Receptor Type 1 Promote Rapid Recovery of Ischemia/Reperfusion Injury in Rat Small Intestine. *Clinical Immunology* 1999; 90 (2): 266-275.
10. Miner TJ, Tavaf-Motamen H, **Stojadinovic A**, Shea-Donohue T. Ischemia – Reperfusion Protects the Rat Small Intestine Against Subsequent Injury. *Journal of Surgical Research* 1999; 82: 1-10.
11. **Stojadinovic A**, Allen PJ, Shriver CD. Metastatic Carcinoid Tumor Presenting as Hepatic Encephalopathy. *HPB Surgery* 2002; 4(1) 47-50.
12. **Stojadinovic A**, Karpoff HM, Antonescu CR, Shah JP, Singh B, Spiro RH, Dumornay W, Shaha AR. Dermatofibrosarcoma Protuberans of the Head and Neck. *Annals of Surgical Oncology* 2000; 7(9): 696-704.
13. **Stojadinovic A**, Hoos A, Karpoff HM, Leung DHY, Antonescu CR, Brennan MF, Lewis JJ. Soft tissue tumors of the abdominal wall: Analysis of patterns of disease and treatment. *Archives of Surgery* 2001; 136:70-79.
14. **Stojadinovic A**, Jaques DP, Leung DHY, Healey JH, Brennan MF. Amputation for recurrent soft tissue sarcoma of the extremity: indications and outcome. *Ann. Surg. Oncol.* 2001; 8(6): 509-518.
15. **Stojadinovic A**, Ghossein RA, Hoos A, Urist M, Spiro R, Shah JP, Brennan MF, Shaha AR, Singh B. Hurthle cell carcinoma: A critical histopathologic appraisal. *Journal of Clinical Oncology* 2001, 19:2616-2625.

16. Hoos A, Urist M, **Stojadinovic A**, Mastorides S, Dudas ME, Leung DHY, Kuo D, Brennan MF, Lewis JJ, Cordon-Cardo C. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens. *American Journal of Pathology* 2001; 158: 1245-1251.
17. Hoos A, **Stojadinovic A**, Mastorides S, Urist MJ, Polsky D, Di Como CJ, Brennan MF, Cordon-Cardo C. High Ki-67 proliferative index predicts disease-specific survival in patients with high-risk soft tissue sarcomas. *Cancer* 2001; 92:869-874.
18. Allen PJ, Busam K, Hill ADK, **Stojadinovic A**, Coit DG. Immunohistochemical analysis of sentinel lymph nodes from patients with Merkel Cell carcinoma. *Cancer* 2001; 19(6): 1650-1655.
19. **Stojadinovic A**, Allen PJ, Clary BM, Busam KJ, Coit DG. Value of frozen section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma. *Annals of Surgery* 2002; 235:92-98.
20. **Stojadinovic A**, Leung DHY, Hoos A, Jaques DP, Lewis JJ, Brennan MF. Analysis of the prognostic significance of microscopic margins in 2084 localized primary soft tissue sarcomas. *Annals of Surgery* 2002; 235(5): 424-34.
21. **Stojadinovic A**, Ghossein RA, Hoos A, Nissan A, Brennan MF, Jaques DP. Adrenocortical carcinoma: Clinical, morphological and molecular characterization. *Journal of Clinical Oncology* 2002; 20:941-950.
22. **Stojadinovic A (share first authorship)**, Hoos A, Ghossein RA, Dudas ME, Kuo D, Leung DHY, Shaha AR, Brennan MF, Cordon-Cardo C, Singh B. Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays. *American Journal of Pathology* 2002; 160:175-183.
23. **Stojadinovic A**, Shaha A, Orlikoff RF, Nissan A, Singh B, Boyle JO, Shah JP, Brennan MF, Kraus DH. A prospective voice assessment in patients undergoing thyroid surgery. *Annals of Surgery* 2002; 236(6):823-832.
24. **Stojadinovic A**, Hoos A, Ghossein RA, Urist M, Leung DHY, Spiro R, Shah JP, Brennan MF, Singh B, Shaha AR. Hurthle cell carcinoma: A 60-year experience. *Ann. Surg. Oncol.* 2002, 9(2): 197-203.
25. **Stojadinovic A**, Yea A, Brennan MF. Completely resected recurrent soft tissue sarcoma: primary anatomic site governs outcomes. *Journal of the American College of Surgeons* 2002; 194 (4):436-447.
26. **Stojadinovic A**, Hoos A, Brennan MF, Conlon KC. Prospective randomized clinical trials for pancreatic adenocarcinoma. *Surgical Oncology Clinics of North America*, 2002; 11(1): 207-229.
27. **Stojadinovic A**, Leung DHY, Allen PJ, Lewis JJ, Jaques DP, Brennan MF. Primary adult soft tissue sarcoma: Time-dependent influence of prognostic variables. *J. Clinical Oncology* 2002; 20:4344-4352.
28. Bains MS, **Stojadinovic A**, Minsky B, Rusch V, Turnbull A, Korst R, Ginsberg R, Kelsen DP, Ilson DH. Phase II trial of preoperative combined modality therapy for locally advanced esophageal carcinoma. *Journal of Cardiovascular and Thoracic Surgery* 2002; 124:270-277.
29. **Stojadinovic A**, Shoup M, Nissan A, Ghossein RA, Brennan MF, Shaha A, Shah JP. Role of operations for metastatic well differentiated thyroid carcinoma. *Surgery* 2002; 131:636-43.
30. **Stojadinovic A**, Shoup M, Nissan A, Ghossein RA, Shah JP, Brennan MF, Shaha AR. Recurrent Differentiated Thyroid Carcinoma: Biological Implications of Age, Method of Detection, Site and Extent of Recurrence. *Annals of Surgical Oncology*, 2002; 9(8):789-798.
31. Hoos A, Nissan A, **Stojadinovic A**, Shia J, Paty PB, Klimstra D, Cordon-Cardo C, Brennan MF, Wong WD. Tissue Microarray Molecular Profiling of early, node negative adenocarcinoma of the rectum: A comprehensive analysis. *Clinical Cancer Research*, 2002; 8:3841-3849.

32. Allen P, **Stojadinovic A**, Ben-Porat L, Gonen M, Kooby D, Blumgart L, Paty P, Fong Y. The management of variant arterial anatomy during hepatic arterial infusion pump placement. *Annals of Surgical Oncology* 2002; 9(9): 875-880.
33. Shia J, Tickoo SS, Guillem JG, Qin J, Nissan A, Hoos A, **Stojadinovic A**, Ruo L, Wong D, Paty PP, Minsky BD, Klimstra DS. Increased endocrine cells in treated rectal adenocarcinomas: A possible reflection of endocrine differentiation in tumor cells induced by chemo- and radiotherapy. *American Journal of Surgical Pathology* 2002; 26(7): 863-872.
34. Fleming SD, Starnes BW, Kiang JG, **Stojadinovic A**, Tsokos GC, Shea-Donohue T. Heat stress protection against mesenteric ischemia/reperfusion-induced alterations in intestinal rat mucosa. *American Journal of Physiology*. 2002; 92(6):2600-7.
35. **Stojadinovic A**, Hoos A, Nissan A, Cordon-Cardo C, Huvos AG, Shaha AR, Brennan MF, Singh B, Ghossein R. Parathyroid Neoplasms: Clinical, Histopathological, and Tissue Microarray-based Molecular Analysis. *Human Pathology* 2003; 34(1): 54-64.
36. **Stojadinovic A**, Brooks A, Hoos A, Jaques DP, Brennan MF, Conlon KC. An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. *Journal of the American College Surgeons*, 2003, 196(6): 954-964.
37. Shoup M, **Stojadinovic A**, Nissan A, Ghossein A, Freedman S, Garcia J, Brennan MF, Shah JP, Shaha AR. Prognostic indicators of outcome in patients with distant metastases from thyroid carcinoma. *Journal of the American College of Surgeons* 2003; 197(2): 191-197.
38. **Stojadinovic A**, Brennan MF, Hoos A, Omeroglu A, Leung DHY, Dudas ME, Nissan A, Cordon-Cardo C, Ghossein RA. Adrenocortical adenoma and carcinoma: Histological and molecular comparative analysis. *Modern Pathology* 2003; 16(8): 742-751.
39. Sumkin JH, **Stojadinovic A**, Huerbin M, Klym A, McHugh L, Sobran CM, Leader JK, Zheng B, Gur D. Impedance Measurements for Early Detection of Breast Cancer in Younger Women: A Preliminary Assessment. *Proc SPIE* 2003; 5034:197-203.
40. Swiecki C, **Stojadinovic A**, Anderson J, Zhao A, Dawson H, Shea-Donohue T. Effect of hyperglycemia and nitric oxide synthase inhibition on heat tolerance and induction of heat shock protein 72 kDa in vivo. *American Surgeon* 2003 Jul;69(7):587-92.
41. **Stojadinovic A**, Fields SI, Shriver CD, Lenington S, Ginor R, Peoples GE, Burch HB, Peretz T, Freund HR, Nissan A. Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: A Prospective Study. *Annals of Surgical Oncology* 2005; 12(2):152-160.
42. **Stojadinovic A**, Nissan A, Gallimidi Z, Lenington S, Logan W, Zuley M, Yeshaya A, Shimonov M, Melloul M, Fields S, Allweis T, Ginor R, Gur D, Shriver CD. Electrical Impedance Scanning for the Early Detection of Breast Cancer in Young Women: Preliminary Results of a Multi-Center Prospective Trial. *Journal of Clinical Oncology* 2005 Apr 20; 23(12):2703-15.
43. Sarkaria IS, **Stojadinovic A**, Talbot SG, Pham D, Hoos A, Dudas M, Shaha A, Shah JP, Brennan MF, Ghossein RA, Singh B. *Squamous cell carcinoma related oncogene (SCCRO)* is highly expressed in normal human adrenal tissue but not in aggressive adrenocortical carcinomas. *Surgery* 2004; 136(6):1122-8.
44. Arciero CA, Peoples GE, **Stojadinovic A**, Shriver CD. The Utility of a Rapid Parathyroid Assay for Uniglandular, Multiglandular and Recurrent Parathyroid Disease. *Am. Surgeon* 2004; 70(7):588-92.

- 45.** McLeod IK, Arciero C, Noordzij JP, **Stojadinovic A**, Peoples GE, Melder PC, Langley R, Bernet V, Shriver CD. The Use of Rapid Parathyroid Hormone Assay in Predicting Postoperative Hypocalcemia Following Total or Completion Thyroidectomy. *Thyroid* 2005 2006 16(3):259-65.
- 46.** Allen PJ, Nissan A, Picon AI, Kemeny N, Dudrick P, Ben-Porat, Espat J, **Stojadinovic A**, Cohen AM, Fong Y, Paty PB. Technical Complications and Durability of Hepatic Artery Infusion Pumps for Unresectable Colorectal Liver Metastases: An Institutional Experience of 544 Consecutive Cases. *Journal of the American College Surgeons*, 2005; 201(1):57-65.
- 47.** **Stojadinovic A**, Moskovitz O, Gallimidi Z, Fields S, Brooks AD, Brem R, Mucciola RN, Singh M, Maniscalco-Theberge ME, Gur D, Shriver CD. Prospective Study of Electrical Impedance Scanning for Identifying Young Women at Risk for Breast Cancer. *Breast Cancer Research and Treatment* 2006 May; 97(2):179-89. Epub 2006 Feb 21.
- 48.** **Stojadinovic A**, Allen PJ, Protic M, Potter JF, Shriver CD, Nelson JM, Peoples GE. Colon Sentinel Lymph Node Mapping: Practical Surgical Applications. *Journal of the American College of Surgeons* 2005; 201(2):297-313.
- 49.** Hueman MT, **Stojadinovic A**, Storrer CE, Gurney JM, Shriver CD, Ponniah S, Peoples GE. Levels of Circulating Regulatory CD4+CD25+ T Cells Are Decreased in Breast Cancer Patients after Vaccination with a HER2/neu Peptide (E75) Vaccine. *Breast Cancer Research and Treatment* 2006 Jul; 98(1):17-29.
- 50.** **Stojadinovic A**, Auton A, Peoples GE, McKnight GM, Shields C, Croll SM, Bleckner LL, Winkley J, Maniscalco-Theberge ME, Buckenmaier CC. Responding to Challenges in Combat Casualty Care: Innovative Use of Advanced Regional Anesthesia. *Pain Medicine* 2006 Jul-Aug; 7(4), 330-338.
- 51.** Cohen T, Prus D, Shia J, Abu-Wassal B, Pinto MG, Freund HR, **Stojadinovic A**, Grakaov A, Peretz T, Nissan A. Expression and Significance of p53, p27, Ki67 in Colorectal Cancer Patients of Various Ethnic Origins: Clinical, and Tissue Microarray-Based Molecular Analysis. *J Surg Oncol* 2008; Apr 1; 97(5):416-22.
- 52.** Hueman MT, **Stojadinovic A**, Storrer CE, Dehqanzada ZA, Gurney J, Shriver CD, Ponniah S, Peoples GE. Analysis of naive and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. *Cancer Immun Immunoth* 2007 Feb; 56(2):135-46.
- 53.** **Stojadinovic A**, Hooke JA, Shriver CD, Kovatich AJ, Nissan A, Ponniah S, Peoples GE, Moroni M. HYOU1/ ORP150 Expression in Breast Cancer. *Medical Science Monitor* 2007 Nov; 13(11):BR231-239.
- 54.** Nissan A, **Stojadinovic A**, Shiu J, Hoos A, Guillem JG, Klimstra D, Cohen AM, Minsky BD, Paty PB, Wong WD. Predictors of recurrence in patients with T2 and early T3, node negative adenocarcinoma of the rectum treated by surgery alone. *Journal of Clinical Oncology* 2006; Sep 1; 24:4078-4084.
- 55.** Buckenmaier C, Shields CH, Auton AA, Evans SL, Croll SM, Bleckner LL, Brown DS, **Stojadinovic A**. Continuous Peripheral Nerve Block in Anticoagulated Combat Casualties. *British Journal of Anaesthesia* 2006 Dec; 97(6):874-7.
- 56.** **Stojadinovic A**, Nissan A, Protic M, Adair CF, Prus D, Usaj S, Howard R, Radovanovic D, Breberina M, Shriver CD, Grinbaum R, Nelson JM, Brown TA, Freund HR, Potter JF, Peretz T, Peoples GE. Prospective Randomized Study Comparing Sentinel Lymph Node Evaluation with Standard Pathological Evaluation for the Staging of Colon Carcinoma: Results from the United States Military Cancer Institute Clinical Trials Group Study GI-01. *Annals of Surgery* June 2007; 245(6):846-857.

57. J. Esquivel, R. Sticca, P. Sugarbaker, E. Levine, T. D. Yan, R. Alexander, D. Baratti, D. Bartlett, R. Barone, P. Barrios, S. Bieligg, P. Bretcha-Boix, C. K. Chang, F. Chu, Q. Chu, S. Daniel, E. de Bree, M. Deraco, L. Dominguez-Parra, D. Elias, R. Flynn, J. Foster, A. Garofalo, F. N. Gilly, O. Glehen, A. Gomez-Portilla, L. Gonzalez-Bayon, S. Gonzalez-Moreno, M. Goodman, V. Gushchin, N. Hanna, J. Hartmann, L. Harrison, R. Hoefer, J. Kane, D. Kecmanovic, S. Kelley, J. Kuhn, J. LaMont, J. Lange, B. Li, B. Loggie, H. Mahteme, G. Mann, R. Martin, R. A. Misih, B. Moran, D. Morris, L. Onate-Ocana, N. Petrelli, G. Philippe, J. Pingpank, A. Pitroff, P. Piso, M. Quinones, L. Riley, L. Rutstein, S. Saha, S. Alrawi, A. Sardi, S. Schneebaum, P. Shen, D. Shibata, J. Spellman, **A. Stojadinovic**, J. Stewart, J. Torres-Melero, T. Tuttle, V. Verwaal, J. Villar, N. Wilkinson, R. Younan, H. Zeh, F. Zoetmulder and G. Sebbag. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement. *Ann Surg Oncol* 2007; 14(1): 128-133.
58. Schaden W, Thiele R, Köpl C, Pusch M, Nissan A, Attinger CE, Maniscalco-Theberge ME, Peoples GE, Elster EA, **Stojadinovic A**. Shock Wave Therapy for Acute and Chronic Soft Tissue Wounds: A Feasibility Study. *Journal of Surgical Research* 2007 Nov; 143(1):1-12.
59. **Stojadinovic A**, Mittendorf EA, Holmes JP, Hueman MT, Ponniah S, Peoples GE. Quantification and Phenotypic Characterization of Circulating Tumor Cells for Monitoring Response to Preventive Vaccine-based Immunotherapy for Breast Cancer: A Pilot Study. *Annals of Surgical Oncology*, 2007 Dec; 14(12):3359-3368.
60. Amin A, Shriver CD, Henry LR, Lenington S, Peoples GE, **Stojadinovic A**. Breast Cancer Screening Compliance among Young Women in a Free Access Healthcare System. *Journal of Surgical Oncology* 2008 Jan 1;97(1):20-4.
61. **Stojadinovic A**, Henry LR, Peoples GE, Mittendorf EA, Lenington S, Nissan A, Shriver CD. Satisfaction with Breast Cancer Screening and Future Screening Participation. *Medical Science Monitor* 2007, Oct; 13(10):CR422-9.
62. **Stojadinovic A**, Nissan A, Shriver CD, Mittendorf EA, Akin MD, Dickerson V, Lenington S, Platt LD, Stavros T, Goldstein SR, Moskovitz O, Gallimidi Z, Fields S, Yeshaya A, Allweis TM, Manassa R, Pappo T, Ginor RX, D'Agostino RB, Gur D. Electrical Impedance Scanning as a New Breast Cancer Risk Stratification Tool for Young Women. *Journal of Surgical Oncology* 2008, Feb 1; 97(2):112-120.
63. Forsberg JA, Elster EA, Andersen RC, Nylen E, Brown TS, Rose MW, **Stojadinovic A**, Becker KL, McGuigan FX. Correlation of procalcitonin and cytokine expression with dehiscence of wartime extremity wounds. *Journal of Bone and Joint Surgery Am* 2008 Mar; 90(3):580-8.
64. **Stojadinovic A**, Henry LR, Howard RS, Gurevich-Uvena J, Makashay MJ, Coppit GL, Shriver CD, Solomon NP. Prospective Trial of Voice Outcomes Following Thyroidectomy: Evaluation of Patient-Reported and Clinician-Determined Voice Assessments in Identifying Post-Thyroidectomy Dysphonia. *Surgery* 2008; Jun; 143(6):732-42. Epub 2008 Mar 28.
65. **Stojadinovic A**, Nissan A, Shriver CD, Lenington S, Gur D. Electrical impedance scanning for breast cancer risk stratification in young women. *IFMBE Proceedings* 17, pp. 675-678, 2007.
66. Nissan A, Peoples GE, Abu Wassal B, Adair CF, Prus Diana, Howard RS, Lenington SG, Fields SI, Freund HR, Peretz T, Burch HB, Shriver CD, **Stojadinovic A**. Prospective Trial Evaluating Electrical Impedance Scanning of Thyroid Nodules prior to Thyroidectomy: Final Results. *Annals of Surgery* May 2008; 247(5):843-853.

67. Gates JD, Benavides LC, Shriver CD, Peoples GE, **Stojadinovic A**. Thyroid Ultrasound in all patients undergoing parathyroidectomy? J Surg Res. 2009 Aug; 155(2):254-60.
68. Henry LR, Solomon NP, Howard R, Gurevich-Uvena J, Horst LB, Coppit G, Orlikoff, Libutti SK, Shaha AR, **Stojadinovic A**. The functional impact on voice of sternothyroid muscle division during thyroidectomy. Annals of Surgical Oncology 2008; Jul 15(7):2027-33.
69. **Stojadinovic A**, Carlson JW, Schultz GS, Davis T, Elster EA. Topical advances in wound care, Society of Gynecol Oncol 2008 Nov;111(2 Suppl):S70-80. Epub 2008 Sep 14. Review.
70. Carlson JW, **Stojadinovic A**, Ennis W, Diegelmann R, Attinger C. Multidisciplinary panel discussion of a gynecologic oncology patient: Preventing wound complications. Gynecol Oncol 2008 Nov; 111(2 Suppl):S98-80.
71. **Stojadinovic A**, Nissan A, Protic M, Bilchik A, Peoples GE. Alternative perspectives on the rationale for lymphatic mapping for sentinel lymph node identification in colon cancer. Annals of Surgery May 2008; 247(5):902-904
72. Amin A, Benavides LC, Holmes JP, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Storrer CE, Jama YH, Craig D, **Stojadinovic A**, Ponniah S, Peoples GE. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol Immunother. 2008 Dec; 57(12):1817-25.
73. Benavides LC, Gates JD, Carmichael MG, Patel R, Holmes JP, Hueman MT, Mittendorf EA, Craig D, **Stojadinovic A**, Ponniah S, Peoples GE. The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-0. Clin Cancer Res. 2009 Apr 15; 15(8):2895-904.
74. Henry LR, **Stojadinovic A**, Swain S, Prindiville S, Cordes R, Soballe PW. The influence of gene expression profile on breast cancer decisions. J Surg Oncol. 2009 May 1; 99(6):319-23.
75. Hawksworth J, **Stojadinovic A**, Gage F, Tadaki DK, Pedue PW, Forsberg J, Davis T, Dunne JR, DeNobile JW, Brown TS, Elster EA. Inflammatory biomarkers in combat wound healing. Ann Surg 2009; Dec; 250(6):1002-7.
76. Gates JD, Benavides LC, **Stojadinovic A**, Mittendorf EA, Holmes JP, Carmichael MG, McCall S, Milford AL, Merrill GA, Ponniah S, Peoples GE. Monitoring circulating tumor cells in cancer vaccine trials. Hum Vaccine. 2008 Sep-Oct; 4(5):389-92.
77. **Stojadinovic A**, Elster EA, Anam K, Tadaki D, Amare M, Zins S, Davis TA. Angiogenic responses to extracorporeal shock wave treatment in murine skin isografts. Angiogenesis 2008; 11(4):369-80.
78. Holmes JP, Gates JD, Benavides LC, Hueman MT, Carmichael MG, Patil R, Craig D, Mittendorf EA, **Stojadinovic A**, Ponniah S, Peoples GE. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence. From US Military Cancer Institute Clinical Trials Group I-01 and I-02. Cancer 2008; 113:1666-75.
79. Benavides L, Gates J, Carmichael M, Patil R, Holmes J, Hueman M, Mittendorf E, Craig D, **Stojadinovic A**, Ponniah S, Peoples GE. The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clinical cancer Research 2009 Apr 15;15(8):2895-904. Erratum in: Clin Cancer Res. 2009 Sep 1;15(17):5601.
80. Pelz JO, **Stojadinovic A**, Nissan A, Hohenberger W, Esquivel J. Evaluation of a peritoneal surface disease score in patients with colon cancer with peritoneal carcinomatosis. Journal of Surgical Oncology 2009 Jan 1; 99(1):9-15.

81. Esquivel J, Nissan A, **Stojadinovic A**. Cytoreductive surgery and heated intra-peritoneal chemotherapy in the treatment of peritoneal carcinomatosis of colorectal origin: The need for practice altering data. *Journal of Surgical Oncology* 2008 Nov 1; 98(6):397-398.
82. Bilchik AJ, **Stojadinovic A**, Wainberg Z, Hecht JR. Targeted lymph node evaluation in colorectal cancer: A decade of progress! *J Surg Oncol*. 2009 Apr 1; 99(5):273-4.
83. Vertrees A, Greer L, Pickett C, Nelson J, Wakefield W, **Stojadinovic A**, Shriver CD. Modern management of complex open abdominal wounds of war: A 5-Year Experience. *Journal of the American College of Surgeons* 2008; 207: 801-9.
84. **Stojadinovic A**, et al. Combat Wound Initiative Program. *Military Medicine*. 2010 July; 175 (Supplement 1):18-21.
85. Nissan A, **Stojadinovic A**, Garofalo A, Esquivel J, Piso P. Evidence-based medicine in the treatment of peritoneal carcinomatosis: Past, Present and Future. *Journal of Surgical Oncology* 2009 Sep 15; 100(4):335-44. Review.
86. Nissan A, Protic M, Bilchik A, Eberhardt J, Peoples GE, **Stojadinovic A**. Predictive Model of Outcomes of Targeted Nodal Assessment in Colorectal Cancer. *Annals of Surgery* 2010 Feb; 25(2):265-74.
87. **Stojadinovic A**, Peoples GE, Libutti SK, Henry LR, Eberhardt J, Howard RS, Gur D, Elster EA, Nissan A. Development of a Clinical Decision Model for Thyroid Nodules. *BMC Surg*. 2009 Aug 10; 9(1):12.
88. Davis TA, **Stojadinovic A**, Anam K, Amare M, Naik S, Peoples GE, Tadaki D, Elster EA. Extracorporeal shock wave therapy suppresses the early pro-inflammatory immune response to a severe cutaneous burn injury. *International Wound J*. 2009 Feb; 6(1):11-21.
89. Forsberg JA, Pepek JM, Wagner S, Wilson K, Flint J, Andersen RC, Tadaki D, Gage FA, **Stojadinovic A**, Elster EA. Heterotopic ossification in high-energy wartime extremity injuries, prevalence and risk factors. *J Bone Joint Surg Am*. 2009; 91(5):1084-1091.
90. Dunne JR, Hawksworth JS, **Stojadinovic A**, Gage F, Tadaki DK, Perdue PW, Forsberg J, Davis T, Denobile JW, Brown TS, Elster EA. Peri-operative blood transfusion in Combat Casualties: A Pilot Study. *Journal of Trauma-Injury Infection & Critical Care*. 66(4) Supplement: S150-S156, April 2009.
91. Elster EA, **Stojadinovic A**, Forsberg JA, Shawen S, Andersen R, Schaden W. Extracorporeal Shock Wave Therapy for Nonunion of the Tibia. *Journal of Orthopaedic Trauma* 2010 Mar; 24(3):133-41.
92. Elster EA, Pearl JP, DeNobile JW, Perdue PW, **Stojadinovic A**, Liston WA, Dunne JR. Transforming An Academic Military Treatment Facility into a Trauma Center: Lessons Learned from Operation Iraqi Freedom. *EPlasty Journal* 2009; 9; ISSN: 1937-5719, e31.
93. Gillern SM, Chua TC, **Stojadinovic A**, Esquivel J. KRAS status in patients with colorectal cancer peritoneal carcinomatosis and its impact on outcome. *Am. J. Clin. Oncol*. 2010 Oct; 33(5): 456-60.
94. Vertrees A, Wakefield M, Pickett C, Greer L, Wilson A, Gillern S, Nelson J, Aydelotte J, **Stojadinovic A**, Shriver C. Outcomes of primary repair and primary anastomosis in war-related colon injuries. *J Trauma* 2009 May; 66(5):1286-91; discussion 1291-3.
95. Enewold L, Zhu K, Ron E, Marrogi AJ, **Stojadinovic A**, Peoples GE, Devesa SS. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. *Cancer Epidemiol Biomarkers Prev*. 2009 Mar; 18(3):784-91.
96. Plunkett AR, Shields C, **Stojadinovic A**, Buckenmaier CC. Awake thyroidectomy under local anesthesia and dexmedetomidine infusion. *Mil Med*. 2009 Jan; 174(1):100-2.

97. Cohen T, Prus D, Shia J, Abu-Wasel B, Pinto MG, Freund HR, **Stojadinovic A**, Grakov A, Peretz T, Nissan A. Expression of P53, P27 and KI-67 in colorectal cancer patients of various ethnic origins: clinical and tissue microarray based analysis. *J Surg Oncol*. 2008 Apr 1; 97(5):416-22.
98. **Stojadinovic A**, Peoples GE, Jurgens JS, Howard RS, Schuyler B, Kwon KH, Henry LR, Shriver CD, Buckenmaier CC. Standard versus pH-adjusted and lidocaine supplemented radiocolloid for patients undergoing sentinel-lymph-node mapping and biopsy for early breast cancer (PASSION-P Trial): A double blind, randomized controlled trial. *Lancet Oncology* 2009 Sep; 10(9):849-54.
99. Solomon N. P., Helou L. B., **Stojadinovic A**. Clinical versus laboratory ratings of voice using the CAPE-V. *Journal of Voice* 2010 April 28; 25(1):e7-e14.
100. Veljkovic R, Protic ML, Gluhovic A, Potic Z, Milosevic Z, **Stojadinovic A**. Prospective clinical trial of factors predicting the early development of incisional hernia following midline laparotomy. *J Am Coll Surg* 2010; 210:210-219.
101. Buckenmaier CC 3rd, Croll SM, Shields CH, Shockey SM, Bleckner LL, Malone G, Plunkett A, McKnight GM, Kwon NH, Joltes R, **Stojadinovic A**. Advanced regional anesthesia morbidity and mortality grading system: Regional Anesthesia Outcomes Reporting (ROAR). *Pain Medicine* 2009; Sep; 10(6):1115-22.
102. **Stojadinovic A**, Shockey SM, Croll SM, Buckenmaier CC 3rd. Quality of reporting of regional anesthesia outcomes in the literature. *Pain Medicine* 2009 Sep 10(6):1123-31.
103. Buckenmaier CC 3rd, Kwon KH, Howard RS, McKnight GM, Shriver CD, Fritz W, Garguilo G, Joltes KH, **Stojadinovic A**. Double-Blinded, Placebo Controlled Prospective Randomized Trial Evaluating the Efficacy of Paravertebral Block With and Without Continuous Paravertebral Block Analgesia in Outpatient Breast Cancer Surgery. *Pain Medicine* 2010 May; 11(5):790-9.
104. Chen SL, Steel SR, Eberhardt J, Zhu K, Bilchik A, **Stojadinovic A**. Lymph node ratio as a quality and prognostic indicator in Stage III colon cancer. *Annals of Surgery* 2011 Jan; 253 (1):82-7.
105. **Stojadinovic A**, Eberhardt J, Brown TS, Hawksworth JS, Gage F, Tadaki DF, Forsberg JA, Davis TA, Potter BK, Dunee JR, Elster EA. Development of a Bayesian model to estimate outcomes in combat wounded. *J Multi-Disciplinary Healthcare* 2010 August; 3: 125-135 DOI 10.2147/JMDH.S11537.
106. Henry LR, Helou LB, Solomon NP, Howard RS, Gurevich-Uvena J, Coppit G, **Stojadinovic A**. Functional voice outcomes after thyroidectomy: An assessment of the Dysphonia Severity Index (DSI) after thyroidectomy. *Surgery* 2010 Jun; 147(6):861-70.
107. **Stojadinovic A**, Nissan A, Eberhardt J, Chua TC, Pelz JOW, Esquivel J. Development of a Bayesian Belief Network model for personalized prognostic risk assessment in colon carcinomatosis. *Am Surg* 2011 Feb; 77(2):221-30.
108. **Stojadinovic A**, Potter BK, Eberhardt J, Shawen SB, Andersen RC, Forsberg JA, Elster EA, Schaden W. Development of a Bayesian classifier for osseous non-union or delayed union fractures. *J Bone Joint Surg Br Am* 2011; 93: 187-194.
109. Zhou J, Enewold L, **Stojadinovic A**, Clifton T, Potter JF, Peoples GE, Zhu K. Incidence rates of exocrine and endocrine pancreatic cancers in the United States. *Cancer Causes and Control* 2010 Jun; 21(6):853-61.
110. **Stojadinovic A**, Eberhardt C, Henry L, Eberhardt J, Peoples GE, Nissan A, Shriver CD. Development of a Bayesian Classifier for Breast Cancer Risk Stratification: A Feasibility Study. *ePlasty Open Access Journal* 2010 March 29;10:203-216.

- 111. Stojadinovic A**, Ahuja N, Nazarian SM, Segev DL, Jacobs L, Wang Y, Eberhardt J, Zeiger MA. Translational Research in Surgical Disease. Arch Surg 2010 Feb; 145(2):187-96.
- 112.** Wasif N, Faries MB, Saha S, Turner RR, Wiese D, McCarter MD, Shen P, **Stojadinovic A**, Bilchik AJ. Predictors of occult nodal metastasis in colon cancer: results from a prospective multicenter trial. Surgery. 2010 Mar; 147(3):352-7.
- 113.** Utz ER, Elster EA, Tadaki DK, Gage F, Perdue PW, Forsberg JA, **Stojadinovic A**, Hawksworth JS, Brown TS. Metalloproteinase Expression is Associated with Traumatic Wound Failure. J Surg Res. 2010 Apr; 159:633-9.
- 114.** Helou LB, Solomon NP, Henry LR, Coppit G, Howard R, **Stojadinovic A**. The role of listener experience in CAPE-V ratings of post-thyroidectomy voice. American Journal of Speech-Language Pathology. 2010 Aug; 19(3):248-58.
- 115.** Bilchik A, **Stojadinovic A**. Invited Critique - Is it time to move beyond lymph node evaluation in staging colon cancer? Comment on "Preoperative Tattooing and Improved Lymph Node Retrieval Rates From Colectomy Specimens in Patients With Colorectal Cancers." Archives of Surgery, 2010 Sep; 145(9):830-1.
- 116.** Eberhardt JS, **Stojadinovic A**, Radano T, Eppel J. Intelligent Health Informatics: The Promise. *Perspectives in Health Information Management* (Summer 2010): 1-2.
- 117.** Alavi MR, Ravizee A, Burgess R, Antonic V, Izadjoo M, **Stojadinovic A**. Resistance carrying plasmid in a traumatic wound. J Wound Care. 2010 Jul; 19(7):306-10.
- 118.** Bilchik A, Nissan A, Wainberg Z, Shen P, McCarter M, Protic M, Howard R, Elashoff D, Tyler J, Peoples GE, **Stojadinovic A**. Surgical quality and nodal ultrastaging is associated with long-term disease-free survival in early colorectal cancer: an analysis of 2 international multicenter prospective trials. Ann Surg. 2010 Sep; 252(3):467-74; discussion 474-6.
- 119.** Ottomann C, Hartmann B, Tyler J, Maier H, Thiele R, Schaden W, **Stojadinovic A**. Prospective randomized trial of accelerated re-epithelization of skin graft donor sites using extracorporeal shock wave therapy. J Am Coll Surg. 2010 Sep; 211(3):361-7.
- 120.** Gates JD, Clifton GT, Benavides LC, Sears AK, Carmichael MG, Hueman MT, Holmes JP, Jama YH, Mursal M, Zacharia A, Ciano K, Khoo S, **Stojadinovic A**, Ponniah S, Peoples GE. Circulating regulatory T cells (CD4(+)/CD25(+)/FOXP3(+)) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide. Vaccine. 2010 Nov 3; 28(47):7476-82.
- 121:** Holmes JP, Clifton GT, Patil R, Benavides LC, Gates JD, **Stojadinovic A**, Mittendorf EA, Ponniah S, Peoples GE. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2011 Feb 1;117(3):463-71.
- 122.** Sheppard FR, Keiser P, Craft DW, Gage F, Robson M, Brown TS, Petersen K, Sincock S, Kasper M, Hawksworth J, Tadaki D, Davis TA, **Stojadinovic A**, Elster E. The majority of US combat casualty soft-tissue wounds are not infected or colonized upon arrival or during treatment at a continental US military medical facility. Am J Surg. 2010 Oct; 200(4):489-95.
- 123.** Awan S, Helou L, **Stojadinovic A**, Solomon N. Tracking Voice Change after Thyroidectomy: Application of Spectral/Cepstral Analyses. Clinical Linguistics & Phonetics 2011 Mar; 25(4):302-20.
- 124.** Esquivel J, Chua TC, **Stojadinovic A**, Melero JT, Levine EA, Gutman M, Howard R, Piso P, Nissan A, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Shen P, Stewart JH, Sugarbaker PH, Barone RM, Hoefer R, Morris DL, Sardi A, Sticca RP. Accuracy and clinical relevance of computed

tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: A multi-institutional study. *J Surg Oncol*. 2010 Nov 1; 102(6):565-70.

125. Ottomann C, **Stojadinovic A**, Lavin PT, Gannon FH, Heggeness MH, Thiele R, Schaden W, Hartmann B. Prospective Randomized Phase II Trial of Accelerated Re-epithelialization of Superficial 2nd degree (IIa°) Burn Wounds using ESWT. *Annals of Surgery* 2012 Jan; 255(1):23-9.

126. Pelz JOW, Chua TC, Esquivel E, **Stojadinovic A**, Doerfer J, Morris DL, Maeder U, Germer C-T, Kerscher. Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified According to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin. *BMC Cancer* 2010, 10:689; doi: 10.1186/1471-2407-10-689.

127. Couch K. **Stojadinovic A**. Negative Pressure Wound Therapy in the Military: Lessons Learned. *Plastic and Reconstructive Surgery*. 2011; 127 (Supl): 117S-130S.

128. Mazeh H, Mizrahi I, Halle D, Ilyayev N, **Stojadinovic A**, Trink B, Mitrani-Rosenbaum S, Roistacher M, Ariel I, Eid A, Freund HR, Nissan A. Development of a MicroRNA-Based Molecular Assay for the Detection of Papillary Thyroid Carcinoma in Aspiration Biopsy Samples. *Thyroid* 2011 Feb; 21(2):111-8.

129. Esquivel J, **Stojadinovic A**, Levine EA. The American Society of Peritoneal Surface Malignancies (ASPSM). *Ann Surg Oncol* 2010 Dec; 18 Suppl 3:S218-9.

130. Zhou J, Enewold L, Peoples GE, Clifton GT, Potter JF, **Stojadinovic A**, Zhu K. Trends in cancer screening among Hispanic and white non-Hispanic women, 2000-2005. *J Womens Health (Larchmt)*. 2010 Dec; 19(12):2167-74. Epub 2010 Nov 1.

131. Mittermayr R, Hartinger J, Antonic V, Meinl A, Pfeifer S, **Stojadinovic A**, Schaden W, Redl H. Extracorporeal Shock Wave Therapy (ESWT) Minimizes Ischemic Tissue Necrosis Irrespective of Application Time and Promotes Tissue Revascularization by Stimulating Angiogenesis. *Ann Surg*. 2011 May; 253(5):1024-32.

132. Tsukamoto T, Antonic V, El Hajj II, **Stojadinovic A**, Binion DG, Izadjoo MJ, Yokota H, Pape HC, Bauer AJ. Novel model of peripheral tissue trauma-induced inflammation and gastrointestinal dysmotility. *Neurogastroenterol Motil*. 2011 Apr; 23(4):379-86, e164.

133. Alaiyan B, Ilyayev N, **Stojadinovic A**, Izadjoo M, Roistacher M, Pavlov V, Tzivin V, Halle D, Pan H, Trink B, Gure AO, Nissan A. Differential Expression of Colon Cancer Associated Transcript-1 (CCAT1) along the colonic adenoma-carcinoma sequence. *BMC Cancer*. 2013 Apr 17; 13(1):196.

134. Figer A, Nissan A, Shani A, Borovick R, Steiner M, Baras M, Freund HR, Sulkes A, **Stojadinovic A**, Peretz T. Mature Results of a Prospective Randomized Trial Comparing 5-Fluorouracil with Leucovorin to 5-Fluorouracil with Levamisole as Adjuvant Therapy of Stage II and III Colorectal Cancer- The Israel Cooperative Oncology Group (ICOG) Study. *Journal of Cancer* 2011; 2: 177-185.

135. Zhang B, Wear DJ, **Stojadinovic A**, Izadjoo MJ. Sequential Real Time PCR Assays Applied to Identification of Genomic Signatures in Formalin-Fixed Paraffin-Embedded Tissues: A Case Report about *Brucella*-induced Osteomyelitis. *Military Medicine* 2013; 178: 88-94.

136. Steele SR, Chen SL, **Stojadinovic A**, Nissan A, Zhu K, Peoples GE, Bilchik A. The Impact of Age on Quality Measure Adherence in Colon Cancer. *J Am Coll Surg*. 2011 Jul; 213(1):95-103.

137. **Stojadinovic A**, Summers TA, Eberhardt J, Cerussi A, Grundfest W, Peterson CM, Brazaitis M, Krupinski E, Freeman H. Consensus recommendations for advancing breast cancer: risk identification and screening in ethnically diverse younger women. *J Cancer*. 2011 Apr 20; 2:210-27.

138. Solomon NP, Helou LB, Dietrich-Burns K, **Stojadinovic A**. Do obesity and weight loss affect vocal function? *Semin Speech Lang*. 2011 Feb; 32(1):31-42.

139. Nissan A, **Stojadinovic A**, Mitrani-Rosenbaum S, Halle D, Grinbaum R, Roistacher M, Bochem A, Dayanc EB, Ritter G, Gomceli I, Bostanci EB, Akoglu M, Chen YT, Old LJ, Gure AO. Colon cancer associated transcript-1 (CCAT1): A novel RNA expressed in malignant and pre-malignant human tissues. *Int J Cancer*. 2012 April; 130 (7):1598-606.
140. Zachary D. Taylor, Rahul S. Singh, David B. Bennett, Priyamvada Tewari, Colin P. Kealey, Neha Bajwa, Martin O. Culjat, **Alexander Stojadinovic**, Jean-Pierre Hubschman, Elliott R. Brown, Warren S. Grundfest. THz Medical Imaging: *in vivo* Hydration Sensing. *IEEE Transactions on THz Science and Technology*. 2011 Sep; 1(1):201-219.
141. Antonic V, Mittermayr R, Schaden W, **Stojadinovic A**. Evidence Supporting Extracorporeal Shock Wave Therapy for Acute and Chronic Soft Tissue Wounds. *Wounds* 2011; 23(7):204-215.
142. Stevens KA, **Stojadinovic A**, Helou LB, Solomon NP, Howard RS, Shriver CD, Buckenmaier CC, Henry LR. The Impact of Recurrent Laryngeal Neuromonitoring on Multi-Dimensional Voice Outcomes Following Thyroid Surgery? *J Surg Oncol*. 2012 Jan;105(1):4-9.
143. Man YG, Grinkemeyer M, Izadjoo M, **Stojadinovic A**. Malignant transformation and stromal invasion from normal or hyperplastic tissues: true or false? *J Cancer*. 2011; 2:413-24.
144. Man YG, Izadjoo M, Song G, **Stojadinovic A**. In situ malignant transformation and progenitor-mediated cell budding: two different pathways for breast ductal and lobular tumor invasion. *J Cancer*. 2011; 2:401-12.
145. Solomon NP, Helou LB, Makashay MJ, **Stojadinovic A**. Aerodynamic Evaluation of the Post-thyroidectomy Voice. *J Voice*. 2012 Jul; 26(4):454-461.
146. Kim HS, Lo SC, Wear DJ, **Stojadinovic A**, Weina PJ, Izadjoo MJ. Improvement of anti-Burkholderia mouse monoclonal antibody from various phage-displayed single-chain antibody libraries. *J Immunol Methods*. 2011 Jul 20; 372:146-161.
147. Zhou J, Enewold L, Peoples GE, McLeod DG, Potter JF, Steele SR, Clive KS, **Stojadinovic A**, Zhu K. Colorectal, prostate, and skin cancer screening among Hispanic and White non-Hispanic men, 2000-2005. *J Natl Med Assoc*. 2011 Apr; 103(4):343-50.
148. Man YG, Fu SW, Liu AJ, **Stojadinovic A**, Izadjoo MJ, Chen L, Gardner WA. Aberrant Expression of Chromogranin A, miR-146a, and miR-146b-5p in Prostate Structures with Focally Disrupted Basal Cell Layers: An Early Sign of Invasion and Hormone-refractory Cancer? *Cancer Genomics Proteomics* 2011 Sep; 8(5):235-44.
149. Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, Gates JD, Sears AK, **Stojadinovic A**, Ponniah S, Peoples GE. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. *Cancer* 2012 May 15; 118(10):2594-602
150. Enewold LR, Zhou J, Devesa SS, Berrington de Gonzalez A, Anderson WF, Zahm SH, **Stojadinovic A**, Peoples GE, Marrogi AJ, Potter JF, McGlynn KA, Zhu K. Thyroid Cancer Incidence among Active Duty U.S. Military Personnel, 1990-2004. *Cancer Epidemiol Biomarkers Prev*. 2011 Nov; 20(11):2369-76.
151. Arciero CA, Shiue ZS, Gat JD, Peoples GE, Dackiw APB, Tufano RP, Libutti SK, Zeiger MA, **Stojadinovic A**. Preoperative thyroid ultrasound is indicated in patients undergoing parathyroidectomy for primary hyperparathyroidism. *J Cancer* 2012; 3:1-6.
152. Alavi MR, Antonic V, Ravizee A, Weina PJ, Izadjoo M, **Stojadinovic A**. An enterobacter plasmid as a new genetic background for the transposon Tn131. *Infect Drug Resist* 2011; 4:209-13.

153. Song G, Ren J, **Stojadinovic A**, Chen W, Sahab Z, Fu SW, Man YG. Conjunction of tumor cells with lymphocytes: Implications for tumor invasion and metastases. *Cancer Epidemiol* 2012 Aug; 36(4):354-63. Epub 2012 Jan 18.
154. Short SS, **Stojadinovic A**, Nissan A, Wainberg Z, Dhall D, Yao K, Bilchik A. Adjuvant treatment of early colon cancer with micrometastases: Results of a National Survey. *J Surg Oncol* 2012 Aug 1; 106(2):119-22. doi: 10.1002/jso.23057. Epub 2012 Feb 3.
155. Tewari P, Kealey CP, Bennett DB, Bajwa N, Barnett KS, Singh RS, Culjat MO, **Stojadinovic A**, Grundfest WS, Taylor ZD. *In vivo* THz Imaging of Rat Skin Burns. *Journal of Biomedical Optics*. 2012 Apr; 17(4):040503.
156. Zhang B, Wear DJ, Kim HS, Weina P, **Stojadinovic A**, Izadjoo M. Development of hydrolysis probe-based real-time PCR for identification of virulent gene targets of *Burkholderia pseudomallei* and *B. mallei*--a retrospective study on archival cases of service members with melioidosis and glanders. *Mil Med*. 2012 Feb; 177(2):216-21.
157. **Stojadinovic A**, Zeiger M. Forward for translation research seminars. *J Surg Oncol*. 2012 Apr 1; 105(5):437.
158. Eberhardt J, Bilchik A, **Stojadinovic A**. Clinical decision support systems: Potential with pitfalls. *J Surg Oncol*. 2012 Apr 1; 105(5):502-10.
159. Mullenix PS, Huddleston SJ, **Stojadinovic A**, Trachiotis GD, Alexander EP. A new heart: Somatic stem cells and myocardial regeneration. *J Surg Oncol*. 2012 Apr 1; 105(5):475-80.
160. Radowsky JS, Baines L, Howard RS, Shriver CD, Buckenmaier Iii CC, **Stojadinovic A**. Pain Ratings by Patients and Their Providers of Radionucleotide Injection for Breast Cancer Lymphatic Mapping. *Pain Med*. 2012 May; 13(5): 670-6.
161. Nissan A, Protic M, Bilchik AJ, Howard RS, Peoples GE, **Stojadinovic A**. United States Military Cancer Institute Clinical Trials Group (USMCI GI-01) Randomized Controlled Trial Comparing Targeted Nodal Assessment and Ultra-staging to Standard Pathological Evaluation for Colon Cancer. *Ann Surg* 2012 Sep; 256 (3): 412-427.
162. Langan RC, Ripley RT, Davis JL, Prieto PA, Datrice N, Steinberg SM, Bratslavsky G, Rudloff U, Kammula US, **Stojadinovic A**, Avital I. Liver directed therapy for renal cell carcinoma. *J Cancer* 2012; 3:184-90.
163. Henry L, Helou L, Solomon N, Chang A, Libutti S, **Stojadinovic A**. Current Practice Patterns Regarding the Conduct of Thyroidectomy and Parathyroidectomy amongst Surgeons - A Survey Study. *J Cancer* 2012; 3:207-16.
164. Ray S, Langan RC, Mullinax JE, Koizumi T, Xin HW, Wiegand GW, Anderson AJ, **Stojadinovic A**, Thorgeirsson S, Rudloff U, Avital I. Establishment of human ultra-low passage colorectal cancer cell lines using spheroids from fresh surgical specimens suitable for in vitro and in vivo studies. *J Cancer* 2012; 3:196-206.
165. Mittermayr R, Antonic V, Hartinger J, Kaufmann H, Redl H, Téot L, **Stojadinovic A**, Schaden W. Extracorporeal shock wave therapy (ESWT) for wound healing: Technology, mechanisms, and clinical efficacy. *Wound Repair Regen*. 2012 Jul; 20(4):456-65.
166. Webb RC, Howard RS, **Stojadinovic A**, Gaitonde DY, Wallace MK, Ahmed J, Burch HB. The Utility of Serum Thyroglobulin Measurement at the Time of Remnant Ablation for Predicting Disease-Free Status in Patients with Differentiated Thyroid Cancer: A Meta-Analysis Involving 3947 Patients. *J Clin Endocrinol Metab*. 2012 Aug; 97(8):2754-63. Epub 2012 May 25.

167. Henry LR, Abad JD, **Stojadinovic A**. The voice, not the nerve, is the functionally relevant endpoint. *J Surg Oncol*. 2012 Dec; 106(8): 1005-6. doi: 10.1002/jso.23208. Epub 02 Jul 2012.
168. Langan RC, Mullinax JE, Ray S, Raiji MT, Schaub N, Xin HW, Koizumi T, Steinberg SM, Anderson A, Wiegand G, Butcher D, Anver M, Bilchik AJ, **Stojadinovic A**, Rudloff U, Avital I. Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers. *J Cancer*. 2012; 3:231-40.
169. **Stojadinovic A**, Nissan A, Wainberg Z, Shen P, McCarter M, Protic M, Howard RS, Steele SR, Peoples GE, Bilchik A. Time-Dependent Trends in Lymph Node Yield and Impact on Adjuvant Therapy Decisions in Colon Cancer Surgery: An International Multi-Institutional Study. *Annals of Surgical Oncology* 2012 Dec; 19(13): 4178-85.
170. **Stojadinovic A**, Pribitkin E, Rosen D, Edwards M, Byrd DR. Unilateral vs. Bilateral Parathyroidectomy: A Healthy Debate. *J Am Coll Surg*. 2012 Aug; 215(2):300-2.
171. Carcoforo P, Raiji M, Langan R, Lanzara S, Portinari M, Maestroni U, Palini G, Zanzi M, Bonazza S, Pedriali M, Feo C, **Stojadinovic A**, Avital I. Infiltrating Lobular Carcinoma of the Breast Presenting as Gastrointestinal Obstruction: A Mini Review. *J Cancer* 2012; 3:328-332.
172. Radowsky JS, Helou LB, Howard RS, Solomon NP, **Stojadinovic A**. Racial disparities in voice outcomes after thyroid and parathyroid surgery. *Surgery* 2013 Jan; 153(1):103-110.
173. **Stojadinovic A**, Bilchik A, Smith D, Eberhardt JS, Ward EB, Nissan A, Johnson EK, Protic M, Peoples GE, Avital I, Steele SR. Clinical Decision Support and Individualized Prediction of Survival in Colon Cancer: Bayesian Belief Network Model. *Ann Surg Oncol*. 2013 Jan; 20(1):161-74.
174. Brücher BL, Bilchik A, Nissan A, Avital I, **Stojadinovic A**. Tumor response criteria: are they appropriate? *Future Oncol*. 2012 Aug; 8(8):903-6.
175. Alavi MR, **Stojadinovic A**, Izadjoo MJ. An overview of biofilm and its detection in clinical samples. *J Wound Care*. 2012 Aug; 21(8):376-83.
176. Avital I, Brücher BL, Nissan A, **Stojadinovic A**. Randomized clinical trials for colorectal cancer peritoneal surface malignancy. *Surg Oncol Clin N Am*. 2012 Oct; 21(4):665-88.
177. Solomon NP, Awan SN, Helou LB, **Stojadinovic A**. Acoustic analyses of thyroidectomy-related changes in vowel phonation. *J Voice*; 2012 Nov; 26(6): 711-20.
178. Carcoforo P, Raiji M, Palini GM, Pedriali M, Maestroni U, Soliani G, Detroia Z, Zanzi MV, Manna AL, Crompton JG, Langan RC, **Stojadinovic A**, Avital I. Primary anorectal melanoma: An update. *J Cancer* 2012; 3:449-53.
179. Schaub NP, Alimchandani M, Quezadi M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, **Stojadinovic A**, Rudloff U, Alexander HR, Avital I. A novel nomogram for peritoneal mesothelioma predicts survival. *Ann Surg Oncol*. 2013 Feb; 20(2):555-61
180. Solomon NP, Helou LB, Henry LR, Howard RS, Coppit G, Shaha AR, **Stojadinovic A**. Utility of the Voice Handicap Index as an Indicator of Postthyroidectomy Voice Dysfunction. *J Voice*. 2013 Jan 4. doi:p11: S0892-1997(12)00184-1. 10.1016/j.jvoice.2012.10.012. [Epub ahead of print]
181. Man Y, **Stojadinovic A**, Mason J, Avital I, Bilchik A, Bruecher B, Protic M, Nissan A, Izadjoo M, Zhang X, Jewett A. Tumor-Infiltrating Immune Cells Promoting Tumor Invasion and Metastasis: Existing Theories. *J. Cancer* 2013; 4(1): 84-95. doi:10.7150/jca.5482
182. Chen L, Li Y, Fu Y, Peng J, Mo M-H, Stamatakis M, Teal CB, Brem RF, **Stojadinovic A**, Grinkemeyer M, McCaffrey TA, Man Y, Fu SW. Role of Deregulated microRNAs in Breast Cancer Progression Using FFPE Tissue. *PLoS ONE* 2013; 8(1): e54213. doi:10.1371/journal.pone.0054213

- 183.** Bilchik A, Nissan A, Protic M, Wainberg Z, Wasserberg N, Avital I, **Stojadinovic A**. Ultra-staging Of Node Negative (N0) Colon Cancer: Preliminary Results Of An International Prospective Clinical Trial. *J Clin Oncol* 30: 2012 (Suppl 34; Abstract 484).
- 184.** **Stojadinovic A**, Avital I, Steele S. Special Issue on Precision Risk Stratification-Based Screening in Colorectal Cancer. *J. Cancer* 2013; 4(3): 170-171. doi:10.7150/jca.5882
- 185.** Itzhak Avital, Russell C. Langan, Thomas A. Summers, Scott R. Steele, Scott A. Waldman, Vadim Backman, Judy Yee, Aviram Nissan, Patrick Young, Craig Womeldorph, Paul Mancusco, Renee Mueller, Khristian Noto, Warren Grundfest, Anton J. Bilchik, Mladjan Protic, Martin Daumer, John Eberhardt, Yan Gao Man, Björn LDM Brücher, **Alexander Stojadinovic**. Evidence-based Guidelines for Precision Risk Stratification-Based Screening (PRSBS) for Colorectal Cancer: Lessons learned from the US Armed Forces: Consensus and Future Directions. *J. Cancer* 2013; 4(3): 172-192. doi:10.7150/jca.5834
- 186.** Thomas Summers, Russell C. Langan, Aviram Nissan, Björn L.D.M Brücher, Anton J. Bilchik, Mladjan Protic, Martin Daumer, Itzhak Avital, **Alexander Stojadinovic**. Serum-Based DNA Methylation Biomarkers in Colorectal Cancer: Potential for Screening and Early Detection. *J. Cancer* 2013; 4(3): 210-216. doi:10.7150/jca.5839.
- 187.** Vlado Antonic, **Alexander Stojadinovic**, Kent E. Kester, Peter J Weina, Björn LDM Brücher, Mladjan Protic, Itzhak Avital, Mina Izadjoo. Significance of Infectious Agents in Colorectal Cancer Development. *J. Cancer* 2013; 4(3): 227-240. doi:10.7150/jca.5835.
- 188.** Russell C. Langan, John E. Mullinax, Manish T. Raiji, Trevor Upham, Thomas Summers, **Alexander Stojadinovic**, Itzhak Avital. Colorectal Cancer Biomarkers and the Potential Role of Cancer Stem Cells. *J. Cancer* 2013; 4(3): 241-250. doi:10.7150/jca.5832
- 189.** BLDM Brücher, **A. Stojadinovic**, A. Bilchik, M. Protic, M. Daumer, A. Nissan, A. Itzhak. Patients at Risk for Peritoneal Surface Malignancy of Colorectal Cancer Origin: The Role of Second Look Laparotomy. *J. Cancer* 2013; 4(3): 262-269. doi:10.7150/jca.5831
- 190.** Haggi Mazeh, Ido Mizrahi, Nadia Ilyayev, David Halle, Bjoern Brücher, Anton Bilchik, Mladjan Protic, Martin Daumer, **Alexander Stojadinovic**, Avital Itzhak, Aviram Nissan. The Diagnostic and Prognostic Role of microRNA in Colorectal Cancer - a Comprehensive review. *J. Cancer* 2013; 4(3): 281-295. doi:10.7150/jca.5836
- 191.** T. Wallace, I. Avital, **A. Stojadinovic**, B. Brucher, E. Coté, J. Yu Multi-Parametric MRI-Directed Focal Salvage Permanent Interstitial Brachytherapy for Locally Recurrent Adenocarcinoma of the Prostate: A Novel Approach. *J. Cancer* 2013; 4(2): 146-151. doi:10.7150/jca.5419
- 192.** Kam Y, Rubinstein A, Naik S, Djavsarov I, Halle D, Ariel I, Gure AO, **Stojadinovic A**, Pan H, Tsvin V, Nissan A, Yavin E. Detection of a long non-coding RNA (CCAT1) in living cells and human adenocarcinoma of colon tissues using FIT-PNA molecular beacons. *Cancer Lett.* 2013 Feb 14. pii: S0304-3835(13)00126-2.
- 193.** Xin HW, Ambe CM, Hari DM, Wiegand GW, Miller TC, Chen JQ, Anderson AJ, Ray S, Mullinax JE, Koizumi T, Langan RC, Burka D, Herrmann MA, Goldsmith PK, **Stojadinovic A**, Rudloff U, Thorgeirsson SS, Avital I. Label-retaining liver cancer cells are relatively resistant to sorafenib. *Gut.* 2013 Dec; 62(12): 1777-86.
- 194.** Arciero CA, Henry LR, Howard RS, Peoples GE, Bilchik AJ, Avital I, Buckenmaier III CC, **Stojadinovic A**. Technical Effects of Adding 1 % Lidocaine to Technetium Sulfur Colloid for Sentinel

Lymphatic Mapping in Early Breast Cancer: Analysis of Data from a Double-blind Randomized Controlled Trial. *Ann Surg Oncol*. 2013 Aug; 20(8):2548-55.

195. Awan SN, Solomon NP, Helou LB, **Stojadinovic A**. Spectral-cepstral estimation of dysphonia severity: external validation. *Ann Otol Rhinol Laryngol*. 2013 Jan; 122(1):40-8.

196. Avital I, Summers TA, Steele SR, Waldman S, Nissan A, Bilchik AJ, Protic M, Man YG, Brücher BL, **Stojadinovic A**. Colorectal cancer stem cells as biomarkers: Where it all starts? *J Surg Oncol*. 2013 Jun; 107(8):791-3

197. Andaya AA, Enewold L, Zahm SH, Shriver CD, **Stojadinovic A**, McGlynn KA, Zhu K. Race and Colon Cancer Survival in an Equal-Access Healthcare System. *Cancer Epidemiol Biomarkers Prev*. 2013 Jun; 22(6):1030-6.

198. Langan RC, Lagisetty KH, Atay S, Pandalai P, **Stojadinovic A**, Rudloff U, Avital I. Surgery for Li Fraumeni Syndrome: Pushing the Limits of Surgical Oncology. *Am J Clin Oncol*. 2013 Apr 3. [published on-line]

199. Steele S, Bilchik A, Eberhardt J, Kalina P, Nissan A, Johnson E, Avital I, **Stojadinovic A**. Using machine-learned bayesian belief networks to predict perioperative risk of clostridium difficile infection following colon surgery. *Interact J Med Res*. 2012 Sep 19;1 (2):e6. doi:10.2196 / ijm.2131.

200. Feng SH, **Stojadinovic A**, Izadjoo M. Distinctive stages and strain variations of *A. baumannii* biofilm development under shear flow. *J Wound Care*. 2013 Apr; 22(4):173-81.

201. Falch C, **Stojadinovic A**, Hann-von-Weyhern C, Protic M, Nissan A, Faries MB, Daumer M, Bilchik AJ, Itzhak A, Brücher BL. Anorectal Malignant Melanoma: Extensive 45-Year Review and Proposal for a Novel Staging Classification. *J Am Coll Surg*. 2013 Aug; 217(2): 324-35.

202. Taylor ZD, Garritano J, Tewari P, Diebold E, Sung S, Bajwa N, Nowroozi B, **Stojadinovic A**, Llombart N, Brown ER, Grundfest WS. Active THz Medical Imaging Using Broadband Direct Detection. *Proc. SPIE 8624, Terahertz, RF, Millimeter, and Sub-millimeter-Wave Technology and Applications VI*, 862403 (March 27, 2013); doi:10.1117/12.2012070

203. Sawyer AJ, Wesolowski D, Gandotra N, **Stojadinovic A**, Izadjoo M, Altman S, Kyriakides TR. A peptide-morpholino oligomer conjugate targeting *Staphylococcus aureus* *gyrA* mRNA improves healing in an infected mouse cutaneous wound model. *Int J Pharm*. 2013 Sep 10; 453(2): 651-5.

204. Radowsky JS, Howard RS, Burch HB, **Stojadinovic A**. Impact of Degree of Extra-Thyroidal Extension of Disease on Papillary Thyroid Cancer Outcome. *Thyroid*. 2014 Feb; 24(2):241-4.

205. Rio PD, Vicente D, Maestroni U, Totaro A, Pattacini GM, Avital I, **Stojadinovic A**, Sianesi M. A comparison of minimally invasive video-assisted parathyroidectomy and traditional parathyroidectomy for parathyroid adenoma. *J Cancer*. 2013 Jul 3; 4(6):458-63.

206. Xin HW, Ambe CM, Ray S, Kim BK, Koizumi T, Wiegand GW, Hari D, Mullinax JE, Jaiswal KR, Garfield SH, **Stojadinovic A**, Rudloff U, Thorgeirsson SS, Avital I. Wnt and the cancer niche: paracrine interactions with gastrointestinal cancer cells undergoing asymmetric cell division. *J Cancer*. 2013 Jul 2; 4(6):447-57.

207. Potter BK, Hwang PF, Forsberg JA, Hampton CB, Graybill JC, Peoples GE, **Stojadinovic A**. Impact of margin status and local recurrence on soft tissue sarcoma outcomes. *J Bone Joint Surg Am*. 2013 Oct 16; 95(20):e1511-8.

208. Antonic V, **Stojadinovic A**, Zhang B, Izadjoo MJ, Alavi M. *Pseudomonas aeruginosa* induces pigment production and enhances virulence in a white phenotypic variant of *Staphylococcus aureus*. *Infect Drug Resist*. 2013 Nov 6; 6:175-86.

- 209.** Liu B, Xu N, Man Y, Shen H, Avital I, **Stojadinovic A**, Liao DJ. Apoptosis in Living Animals Is Assisted by Scavenger Cells and Thus May Not Mainly Go through the Cytochrome C-Caspase Pathway. *J Cancer*. 2013 Nov 15; 4(9):716-723.
- 210.** Fang C, Man YG, Cuttitta F, Steller-Stevenson W, Salomon D, Mazar A, Kulesza P, Rosen S, Avital I, **Stojadinovic A**, Jewett A, Jiang B, Mulshine J. Novel Phenotypic Fluorescent Three-Dimensional Co-Culture Platforms for Recapitulating Tumor in vivo Progression and for Personalized Therapy. *J Cancer*. 2013 Dec 1; 4(9):755-763.
- 211.** **Stojadinovic A**. Fellow pays tribute to ACS and Citizen Surgeons. Published 01 December 2013. Bulletin of the American College of Surgeons. <http://bulletin.facs.org/2013/12/fellow-pays-tribute-to-ac-s-and-citizen-surgeons/>
- 212.** O'Connor V, Kitagawa Y, **Stojadinovic A**, Bilchik AJ. Targeted lymph node assessment in gastrointestinal neoplasms. *Curr Probl Surg*. 2014 Jan; 51(1):9-37.
- 213.** **Stojadinovic A**, Avital I, Wallace TJ, Peoples GE, Steele S. Special issue on current challenges and future directions in monitoring responses after treatment of primary cancer. *J Cancer*. 2014 Jan 1; 5(1):1-2.
- 214.** McKeown E, Nelson DW, Johnson EK, Maykel JA, **Stojadinovic A**, Nissan A, Avital I, Brücher BL, Steele SR. Current Approaches and Challenges for Monitoring Treatment Response in Colon and Rectal Cancer. *J Cancer*. 2014 Jan 1; 5(1):31-43.
- 215.** Walker AS, Zwintser NP, Johnson EK, Maykel JA, **Stojadinovic A**, Nissan A, Avital I, Brücher BL, Steele SR. Future Directions for Monitoring Treatment Response in Colorectal Cancer. *J Cancer*. 2014 Jan 5; 5(1):44-57.
- 216.** Wallace TJ, Torre T, Grob M, Yu J, Avital I, Brücher B, **Stojadinovic A**, Man YG. Current Approaches, Challenges and Future Directions for Monitoring Treatment Response in Prostate Cancer. *J Cancer*. 2014 Jan 1; 5(1):3-24.
- 217.** Graham LJ, Shupe MP, Schneble EJ, Flynt FL, Clemenshaw MN, Kirkpatrick AD, Gallagher C, Nissan A, Henry L, **Stojadinovic A**, Peoples GE, Shumway NM. Current Approaches and Challenges in Monitoring Treatment Responses in Breast Cancer. *J Cancer*. 2014 Jan 5; 5(1):58-68.
- 218.** Shupe MP, Graham LJ, Schneble EJ, Flynt FL, Clemenshaw MN, Kirkpatrick AD, **Stojadinovic A**, Peoples GE, Shumway NM. Future Directions for Monitoring Treatment Responses in Breast Cancer. *J Cancer*. 2014 Jan 5; 5(1):69-78.
- 219.** Mazeh H, Cohen O, Mizrahi I, Hamburger T, **Stojadinovic A**, Abu-Wasel B, Alaiyan B, Freund HR, Eid A, Nissan A. Prospective validation of a surgical complications grading system in a cohort of 2114 patients. *J Surg Res*. 2014 May 1; 188(1):30-6.
- 220.** Centeno JA, Rogers DA, van der Voet GB, Fornero E, Zhang L, Mullick FG, Chapman GD, Olabisi AO, Wagner DJ, **Stojadinovic A**, Potter BK. Embedded fragments from U.S. Military personnel-chemical analysis and potential health implications. *Int J Environ Res Public Health*. 2014 Jan 23; 11(2):1261-78.
- 221.** **Stojadinovic A**. GERD Often Caused by High Blood Calcium and Hyperparathyroidism
Posted on January 15, 2014 by Alexander Stojadinovic, MD, FACS.
<http://blog.parathyroid.com/gerd-high-calcium/>
- 222.** Steele SR, Park GE, Johnson EK, Martin MJ, **Stojadinovic A**, Maykel JA, Causey MW. The impact of age on colorectal cancer incidence, treatment, and outcomes in an equal-access health care system. *Dis Colon Rectum*. 2014 Mar;57(3):303-10.

- 223.** Kim HY, **Stojadinovic A**, Izadjoo MJ. Immunization, hybridoma generation, and selection for monoclonal antibody production. *Methods Mol Biol.* 2014; 1131:33-45.
- 224.** Kim HY, **Stojadinovic A**, Izadjoo MJ. Affinity maturation of monoclonal antibodies by multi-site-directed mutagenesis. *Methods Mol Biol.* 2014; 1131:407-20.
- 225.** Chen JY, Kuo SJ, Liaw YP, Avital I, **Stojadinovic A**, Man YG, Mannion C, Wang J, Chou MC, Tsai HD, Chen ST, Hsiao YH. Endometrial cancer incidence in breast cancer patients correlating with age and duration of tamoxifen use: a population based study. *J Cancer.* 2014 Jan 23; 5(2):151-5.
- 226.** Kim H, Makin I, Skiba J, Ho A, Housler G, **Stojadinovic A**, Izadjoo M. Antibacterial efficacy testing of a bioelectric wound dressing against clinical wound pathogens. *Open Microbiol J.* 2014 Feb 21; 8:15-21.
- 227.** **Stojadinovic A**. Fellow pays tribute to ACS and citizen surgeons. *Bull Am Coll Surg.* 2013 Dec; 98(12):15-8.
- 228.** Avital I, **Stojadinovic A**, Wang H, Mannion C, Cho WC, Wang J, Man YG. Isolation of stem cells using spheroids from fresh surgical specimen: an analytic mini-review. *Cancer Genomics Proteomics.* 2014 Mar-Apr; 11(2):57-65.
- 229.** Vicente DA, Solomon NP, Avital I, Henry LR, Howard RS, Helou LB, Coppit GL, Shriver CD, Buckenmaier CC, Libutti SK, Shaha AR, **Stojadinovic A**. Voice Outcomes after Total Thyroidectomy, Partial Thyroidectomy, or Non-Neck Surgery Using a Prospective Multifactorial Assessment. *J Am Coll Surg.* 2014 Jul; 219(1):152-63.
- 230.** **Stojadinovic A**, Avital I, Peoples GE, Steele S. Special Issue on Current Challenges and Future Directions in Monitoring Recurrence after Treatment of Primary Cancer. *J Cancer.* 2014 Mar 15; 5(4):260-261.
- 231.** Schneble EJ, Graham LJ, Shupe MP, Flynt FL, Banks KP, Kirkpatrick AD, Nissan A, Henry L, **Stojadinovic A**, Shumway NM, Avital I, Peoples GE, Setlik RF. Future Directions for the Early Detection of Recurrent Breast Cancer. *J Cancer.* 2014 Mar 16; 5(4):291-300.
- 232.** Schneble EJ, Graham LJ, Shupe MP, Flynt FL, Banks KP, Kirkpatrick AD, Nissan A, Henry L, **Stojadinovic A**, Shumway NM, Avital I, Peoples GE, Setlik RF. Current Approaches and Challenges in Early Detection of Breast Cancer Recurrence. *J Cancer.* 2014 Mar 16; 5(4):281-290.
- 233.** Walker AS, Johnson EK, Maykel JA, **Stojadinovic A**, Nissan A, Brucher B, Champagne BJ, Steele SR. Future Directions for the Early Detection of Colorectal Cancer Recurrence. *J Cancer.* 2014 Mar 16; 5(4):272-280.
- 234.** Young PE, Womeldorph CM, Johnson EK, Maykel JA, Brucher B, **Stojadinovic A**, Avital I, Nissan A, Steele SR. Early Detection of Colorectal Cancer Recurrence in Patients Undergoing Surgery with Curative Intent: Current Status and Challenges. *J Cancer.* 2014 Mar 15; 5(4):262-271.
- 235.** Holfeld J, Zimpfer D, Albrecht-Schgoer K, **Stojadinovic A**, Paulus P, Dumfarth J, Thomas A, Lobenwein D, Tepeköylü C, Rosenhek R, Schaden W, Kirchmair R, Aharinejad S, Grimm M. Epicardial shock-wave therapy improves ventricular function in a porcine model of ischaemic heart disease. *J Tissue Eng Regen Med.* 2016 Dec; 10(2):1057-1064.
- 236.** Steele SR, Bilchik A, Johnson EK, Nissan A, Peoples GE, Eberhardt JS, Kalina P, Petersen B, Brücher B, Protic M, Avital I, **Stojadinovic A**. Time-dependent Estimates of Recurrence and Survival in Colon Cancer: Clinical Decision Support System Tool Development for Adjuvant Therapy and Oncological Outcome Assessment. *Am Surg.* 2014 May; 80(5):441-53.

- 237.** Maestroni U, Vicente D, Del Rio P, Ziglioli F, Dinale F, Campobasso D, Ferretti S, **Stojadinovic A**, Avital I. Laparoscopic adrenalectomy for large adrenal masses: a challenge or a routine? *Minerva Chir.* 2014 Apr; 69(2):59-64.
- 238.** Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrupp D, Pandalai P, **Stojadinovic A**, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial. *J Surg Oncol.* 2014 Sep; 110(3):275-84.
- 239.** Gill AA, Zahm SH, Shriver CD, **Stojadinovic A**, McGlynn KA, Zhu K. Colon Cancer Lymph Node Evaluation Among Military Health System Beneficiaries: An Analysis by Race/Ethnicity. *Ann Surg Oncol.* 2015 Jan; 22(1):195-202.
- 240.** Gill AA, Enewold L, Zahm SH, Shriver CD, **Stojadinovic A**, McGlynn KA, Zhu K. Colon Cancer Treatment: Are There Racial Disparities in an Equal-Access Healthcare System? *Dis Colon Rectum.* 2014 Sep; 57(9):1059-1065.
- 241.** Bilchik AJ, Wainberg ZA, Nissan A, Slamon DJ, Protic M, Avital I, Chen HW, Chen D, Sim M, Elashoff D, **Stojadinovic A**. Value of Primary Tumor Gene Signatures in Colon Cancer When National Quality Standards are Adhered to: Preliminary Results of an International Prospective Multicenter Trial. *Ann Surg Oncol.* 2015 Feb; 22(2):535-42.
- 242.** Norman J, Politz D, Lopez J, Boone D, **Stojadinovic A**. Surgical Cure of Primary Hyperparathyroidism Ameliorates Gastroesophageal Reflux Symptoms. *World J Surg.* 2015 Mar; 39(3):706-12.
- 243.** Song G, Hsiao H, Wang JL, Mannion C, **Stojadinovic A**, Avital I, Fu SW, Mason J, Chen W, Jewett A, Li H, Man YG. Differential Impact of Tumor-infiltrating Immune Cells on Basal and Luminal Cells: Implications for Tumor Invasion and Metastasis. *Anticancer Res.* 2014 Nov; 34(11):6363-80.
- 244.** Wang J, Zuo Y, Man YG, Avital I, **Stojadinovic A**, Liu M, Yang X, Varghese RS, Tadesse MG, Ressim HW. Pathway and network approaches for identification of cancer signature markers from omics data. *J Cancer.* 2015 Jan 1; 6(1):54-65.
- 245.** Shachar Y, Adileh M, Keidar A, Eid L, Hubert A, Temper M, Azam S, Beny A, Grednader T, Khalaileh A, Yuval JB, **Stojadinovic A**, Avital I, Nissan A. Management of Inguinal Involvement of Peritoneal Surface Malignancies by Cytoreduction and HIPEC with Inguinal Perfusion. *J Cancer.* 2015 Jan 18; 6(3):243-6.
- 246.** Mizrahi I, Mazeh H, Grinbaum R, Beglaibter N, Wilschanski M, Pavlov V, Adileh M, **Stojadinovic A**, Avital I, Gure AO, Halle D, Nissan A. Colon Cancer Associated Transcript-1 (CCAT1) Expression in Adenocarcinoma of the Stomach. *J Cancer.* 2015 Jan 1; 6(2):105-10.
- 247.** DelRio PD, Maestroni U, Sianesi M, Viani L, Vicente D, **Stojadinovic A**, Avital I. Minimally invasive video-assisted thyroidectomy for papillary thyroid cancer: a prospective 5-year follow-up study. *Tumori* 2015 Mar-Apr; 101(2):144-7.
- 248.** Lavotshkin S, Jalas JR, Torisu-Itakura H, Ozao-Choy J, Lee JH, Sim MS, **Stojadinovic A**, Wainberg Z, Bifulco CB, Fox BA, Bilchik AJ. Immunoprofiling for Prognostic Assessment of Colon Cancer: a Novel Complement to Ultrastaging. *J Gastrointest Surg.* 2015 Jun; 19(6):999-1006.
- 249.** Vicente D, Avital I, **Stojadinovic A**. Role of multi-modality therapy in peritoneal carcinomatosis and visceral metastasis: a case report and review of the literature. *World J Surg Oncol.* 2015 Jun 30; 13(1):2.

- 250.** Protic M, **Stojadinovic A**, Nissan A, Wainberg Z, Steele SR, Chen DC, Avital I, Bilchik AJ. Prognostic Effect of Ultra-Staging Node-Negative Colon Cancer Without Adjuvant Chemotherapy: A Prospective National Cancer Institute-Sponsored Clinical Trial. *J Am Coll Surg*. 2015 Sep; 221(3):643-51.
- 251.** Xin HW, Ambe CM, Miller TC, Chen JQ, Wiegand GW, Anderson AJ, Ray S, Mullinax JE, Hari DM, Koizumi T, Godbout JD, Goldsmith PK, **Stojadinovic A**, Rudloff U, Thorgeirsson SS, Avital I. Liver Label Retaining Cancer Cells Are Relatively Resistant to the Reported Anti-Cancer Stem Cell Drug Metformin. *J Cancer*. 2016 Jun 6; 7(9):1142-51.
- 252.** Haffner N, Antonic V, Smolen D, Slezak P, Schaden W, Mittermayr R, **Stojadinovic A**. Extracorporeal shockwave therapy (ESWT) ameliorates healing of tibial fracture non-union unresponsive to conventional therapy. *Injury*. 2016 Jul; 47(7):1506-13.
- 253.** Protic M, Veljkovic R, Bilchik AJ, Popovic A, Kresoja M, Nissan A, Avital I, **Stojadinovic A**. Prospective randomized controlled trial comparing standard analgesia with combined intra-operative cystic plate and port-site local anesthesia for post-operative pain management in elective laparoscopic cholecystectomy. *Surg Endosc*. 2017 Feb 31;27(2):704-713.
- 254.** Ellison LM, Man Y, **Stojadinovic A**, Xin H, Avital I. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis. *Chin J Cancer Res*. 2017 Feb; 29(1):86-92.
- 255.** Gaitonde SG, Nissan A, Protic M, **Stojadinovic A**, Wainberg ZA, Chen DA, Bilchik AJ. Sex-Specific Differences in Colon Cancer When Quality Measures Are Adhered To: Results from International, Prospective, Multicenter Clinical Trials. *J Am Coll Surg*. 2017 Jul;225(1):85-92.
- 256.** Wang X, Zhi X, Yang Z, Tian H, Li Y, Li M, Zhao W, Zhang C, Wang T, Liu J, Shen D, Zheng C, Zhao D, Yang S, Qi J, Xin H, **Stojadinovic A**, Avital I, Lee LJ, Rao J, Zhang W. A novel serum-based biomarker panel has complementary ability to preclude presence of early lung cancer for low dose CT (LDCT). *Oncotarget*. 2017 Jul 11;8(28):45345-45355.
- 257.** Flaherty DC, Jalas JR, Sims MS, **Stojadinovic A**, Protic M, Lee DJ, Bilchik AJ. The Negative Impact of Body Mass Index on the Tumor Microenvironment in Colon Cancer: Results of a Prospective Trial. *Ann Surg Oncol*. 2018 May; 25(5):1374-1380.
- 258.** Wallace TJ, Qian J, Avital I, Bay C, Man Y, Wellman LL, Moskaluk C, Troyer D, Ramnani D, **Stojadinovic A**. Technical Feasibility of Tissue Microarray (TMA) Analysis of Tumor-Associated Immune Response in Prostate Cancer. *J Cancer* 2018; Jun 4;9(12):2191-2202.

Chapters / Textbooks

Avital I, **Stojadinovic A**, Pisters PWT, Kelsen DP, Willett CG. Gastric Cancer, 10th Edition of *Cancer: Principles and Practice of Oncology*.

Avital I, Brucher B, **Stojadinovic A**. Randomized Clinical Trials for Colorectal Cancer Peritoneal Surface Malignancy. *Surgical Oncology Clinics of North America: Treatment of Peritoneal Surface Malignancies*, October 2012, Volume 21, Number 4.

Stojadinovic A, Hoos A, Brennan MF, Conlon KC. Pancreatic cancer: An evidence-based approach in *Unbound Surgery*, TN Pappas GP Purcell (eds). Unbound Medicine, 2004 available at <http://www.unboundsurgery.com>

Vertrees A, Elster EA, **Stojadinovic A**. Improving surgical pain management with multidisciplinary care. *Military Advanced Regional Anesthesia and Analgesia Handbook*, Borden Institute, 2008, Washington, D.C. available at <http://www.arapmi.org/maraa-book-project.html>

Associate Editor, *Advances in Wound Care: Volume 1*
Translational Medicine: From Benchtop to Bedside to Community and Back
Section 1: Military Wound Care
Copyright 2010 by Mary Ann Liebert Inc.

Video Motion Picture

Stojadinovic A, Bains MS. Ivor-Lewis esophagectomy. American College of Surgeons 2001.
Stojadinovic A, Brennan MF. Resection of Retroperitoneal Liposarcoma.

Abstracts:

1. **Stojadinovic A**, Molloy M, d'Avis J, Jaques DP. Completion thyroidectomy for differentiated thyroid carcinoma. Gary P. Wratten Surgical Symposium 1993.
2. **Stojadinovic A**, Gomez ER, Jackson MR. The role of intra-arterial urokinase for acute limb-threatening ischemia. Gary P. Wratten Surgical Symposium 1994.
3. **Stojadinovic A**, Kiang J, Smallridge R, Galloway R, Shea-Donohue T. Heat shock protein-72 induction protects rat small intestinal mucosa from ischemia / reperfusion injury. Gary P. Wratten Surgical Symposium 1995.
4. **Stojadinovic A**, Smallridge R, Shea-Donohue T. U74389F limits intestinal ischemia / reperfusion injury in rats. Gary P. Wratten Surgical Symposium 1996.
5. **Stojadinovic A**, Smallridge R, Galloway R, Shea-Donohue T. Mechanism of a 21-aminosteroid, U74389, protection against intestinal ischemia / reperfusion injury; role of leukotriene B4. *Gastroenterology* 1995; 108(4): A328.
6. **Stojadinovic A**, Kiang J, Smallridge R, Galloway R, Shea-Donohue T. Heat shock protein-72 induction protects rat intestinal mucosa from ischemia / reperfusion injury. *Gastroenterology* 1995; 108(4): A-327.
7. **Stojadinovic A**, Matin D, Starnes BW, Smallridge R, Shea-Donohue T. Rapid restitution of ischemic damage by the 21-aminosteroid U74389, in rat small intestine. *Gastroenterology* 1996; A-333.
8. **Stojadinovic A**, Lawson SA, Jaques DP, Shriver CD. Physiologic response to hepatic cryosurgery in the treatment of unresectable hepatic tumors. Gary P. Wratten Surgical Symposium, 1997.
9. **Stojadinovic A**, Karpoff HM, Antonescu CR, Shah JP, Singh B, Spiro RH, Dumornay W, Shaha AR. Dermatofibrosarcoma Protuberans of the Head and Neck. Abstract #32. SSO 2000, New Orleans, LA.
10. **Stojadinovic A**, Hoos A, Karpoff HM, Leung DHY, Antonescu CR, Brennan MF, Lewis JJ. Soft tissue tumors of the abdominal wall: analysis of patterns of disease and treatment modalities. Gary P Wratten Surgical Symposium, Washington, D.C., 2000.
11. **Stojadinovic A**, Hoos A, Ghossein RA, Urist M, Leung DHY, Spiro R, Shah JP, Brennan MF, Singh B, Shaha AR. Hurthle cell carcinoma: A 60-year experience. Abstract # 36. SSO 2001, Washington, D.C.
12. **Stojadinovic A**, Jaques DP, Leung DHY, Healey JH, Brennan MF. Amputation for recurrent soft tissue sarcoma of the extremity: indications and outcome. Abstract # 72. SSO 2001, Washington, D.C.
13. Klauber-DeMore N, **Stojadinovic A**, Mann B, Coit DG. Deep pelvic nodal metastases of malignant melanoma: multifactorial analysis of prognostic indicators. Abstract# P60. SSO 2001, Washington, D.C.
14. **Stojadinovic A**, Hoos A, Ghossein RA, Urist M, Leung DHY, Spiro R, Shah JP, Brennan MF, Singh B, Shaha AR. Hurthle cell carcinoma: A 60-year experience. Gary P Wratten Surgical Symposium, Augusta, GA, 2001.
15. Bains MS, **Stojadinovic A**, Minsky B, Rusch V, Turnbull A, Korst R, Ginsberg R, Kelsen DP, Ilson DH. Phase II trial of preoperative combined modality therapy for locally advanced esophageal carcinoma. American Society for Thoracic Surgeons 2001, San Diego, CA.
16. **Stojadinovic A**, Fields SI, Shriver CD, Lenington S, Ginor R, Peoples GE, Burch HB, Peretz T, Freund HR, Nissan A. Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: A Prospective Study. Society of Surgical Oncology, New York City, 2004.

17. **Stojadinovic A**, Nissan A, Gallimidi Z, Lenington S, Logan W, Zuley M, Yeshaya A, Shimonov M, Melloul M, Fields S, Allweis T, Ginor R, Gur D, Shriver CD. Electrical Impedance Scanning for the Early Detection of Breast Cancer in Young Women: Preliminary Results of 1,103 Patients Taking Part in a Multi-Center Prospective Trial. *Breast Cancer Research and Treatment* 2004; 88(Suppl 1, Sept):S10.
18. **Stojadinovic A**, Margolin M, Singh M, Akin M, Pulliam R, Platt L. A Novel Technique for Primary Breast Cancer Screening in Young Women. 2005 Annual Clinical Meeting of the American College of Obstetrics and Gynecology.
19. **Stojadinovic A**, Moskovitz O, Gallimidi Z, Fields S, Brooks AD, Brem R, Mucciola RN, Singh M, Shriver CD. Prospective Study of electrical impedance for identifying young women at risk for breast cancer. 2005 ASCO Annual Meeting Proceedings June 1; 23:16S-692.
20. **Stojadinovic A**, T. Peretz, A. Nissan, S. Fields, A. Yeshaya, M. Shimonov, T. Allweis, O. Moskovitz, R. Mucciola, M. Singh, Z. Gallimidi, Y. Pappo, A. Brooks, F. Sperber, R. Brem, M. Sklair-Levy, R. Manassa, Abu Rachmi, M. Maniscalco-Theberge, H. Rockette, C. Shriver, D. Gur. Breast Cancer Risk Stratification for Young Women: Prospective Multi-Center Validation Study of Electrical Impedance Scanning. The International Cancer Symposium of the Israel Society of Surgical Oncology – ISSO, Israel Surgical Association, Eilat, Israel. November 2005.
21. Grinbaum R, Gure AO, Roytacher M, Eisenberg I, Ritter G, Old LJ, **Stojadinovic A**, Freund HR, Peretz TY, Mitrani-Rosenbaum S, Nissan A. Real time-polymerase chain reaction (PCR) improves sensitivity of lymphatic staging in colon cancer patients. American Association of Cancer Research, Washington, D.C., April 2006. American Association of Cancer Research, Washington, D.C., April 2006.
22. **Stojadinovic A**, Hamsher C, Shriver CD, Hooke JA, Kovatich AJ, Ponniah S, Peoples GE, Moroni M. Correlation of ORP150 with hormone receptor and nodal status in invasive breast cancer. American Association of Cancer Research, Washington, D.C., April 2006. American Association of Cancer Research, Washington, D.C., April 2006.
23. Schaden W, Thiele R, Köpl C, Pusch M, Nissan A, Attinger CE, Maniscalco-Theberge ME, Peoples GE, Elster EA, **Stojadinovic A**. Shock Wave Therapy for Acute and Chronic Soft Tissue Wounds: A Feasibility Study. Annual Academic Surgical Congress, 2nd Annual Meeting, Phoenix, AZ February 6-9, 2007.
24. Forsberg JA, Elster EA, **Stojadinovic A**, Andersen RC, Nylén ES, Becker KL, Brown TS, Rose M, McGuigan FX, Cytokine expression correlates with wound dehiscence in wartime extremity injuries, Academic Surgical Congress, 2nd Annual Meeting, Phoenix, AZ February 6-9, 2007.
25. Amin A, Holmes JP, Hueman MT, Khoo S, Storer CE, Smith A, Jama Y, Craig D, Ponniah S, Peoples GE. Assessment of pathologic and immunologic patterns among patients with clinical recurrence and vaccination with a preventative HER2/neu peptide vaccine. 29th Annual Wratten Surgical Symposium, Honolulu, HI, 7-9 May 2007.
26. Amin A, **Stojadinovic A**, Mittendorf EA, Holmes JP, Hueman MT, Ponniah S, Peoples GE. Assessment of pathologic and immunologic patterns among patients with clinical recurrence and vaccination with a preventative HER2/neu peptide vaccine. 29th Annual Wratten Surgical Symposium, Honolulu, HI, 7-9 May 2007.
27. Driscoll IR, Hwang PF, Fuenfer MM, Shriver CD, **Stojadinovic A**, Aydelotte JD. High velocity penetrating wounds to the Neck: Lessons learned from the battlefield in Afghanistan and Iraq. 29th Annual Wratten Surgical Symposium, 7-9 May 2007.

28. Solomon NP, Gurevich-Uvena J, Makashay MJ, Coppit GL, Battiatia AP, Shriver CD, **Stojadinovic A**. Voice outcomes following thyroidectomy. The Voice Foundation's 36th Annual Symposium, Philadelphia, PA, 29 May – 3 June 2007.
29. **Stojadinovic A**, Nissan A, Protic M, Adair CF, Prus D, Usaj S, Howard R, Radovanovic D, Breberina M, Shriver CD, Grinbaum R, Nelson JM, Brown TA, Freund HR, Potter JF, Peretz T, Peoples GE. Prospective Randomized Study Comparing Sentinel Lymph Node Evaluation with Standard Pathological Evaluation for the Staging of Colon Carcinoma: Results from the United States Military Cancer Institute Clinical Trials Group Study GI-01. Israel Surgical Society Meeting 6-7 June 2007.
30. Schaden W, Thiele R, Köpl C, Pusch M, Nissan A, Attinger CE, Maniscalco-Theberge ME, Peoples GE, Elster EA, **Stojadinovic A**. Shock Wave Therapy for Acute and Chronic Soft Tissue Wounds: A Feasibility Study. Veith Symposium. 14-18 November 2007.
31. Hird LC, Gates JD, Carmichael MG, Holmes JP, Mittendorf EA, **Stojadinovic A**, Ponniah S, Peoples GE. Impact of Trastuzumab treatment on HER2/neu peptide vaccination: Preliminary results for combination immunotherapy. Academic Surgical Congress, 3rd Annual Meeting, Huntington Beach, CA, February 12-15, 2008.
32. Hawksworth J, Kasper MR, Gage F, Brown T, Tadaki DK, Perdue PW, Forsberg J, **Stojadinovic A**, Elster EA. Quantitative bacteriology and wound failure in high energy penetrating war injuries. Academic Surgical Congress, 3rd Annual Meeting, Huntington Beach, CA, February 12-15, 2008.
33. Hawksworth J, **Stojadinovic A**, Gage F, Tadaki DK, Perdue PW, Forsberg J, Davis T, Brown T, Elster EA. Inflammatory Biomarkers in Combat Wound Healing. Academic Surgical Congress, 3rd Annual Meeting, Huntington Beach, CA, February 12-15, 2008.
34. Gates JA, Hird LC, Shriver CD, Peoples GE, **Stojadinovic A**. Preoperative thyroid ultrasound in all patients undergoing parathyroidectomy? Academic Surgical Congress, 3rd Annual Meeting, Huntington Beach, CA, February 12-15, 2008.
35. **Stojadinovic A**, Pelz JOW, Nissan A, Hohenberger W, Esquivel E. Peritoneal surface malignancy of colonic origin: Pre-operative staging classification. 3rd International Symposium on Regional Cancer Therapies, Palm Desert, CA, February 16-18, 2008.
36. **Stojadinovic A**, Carlson JW, Schultz GS, Davis T, Elster EA. Topical advances in wound care, Society of Gynecologic Oncologists Annual Meeting. Tampa, FL March 8, 2008.
37. Henry LR, Solomon NP, Howard R, Gurevich-Uvena J, Horst LB, Coppit G, Orlikoff, Libutti SK, Shaha AR, **Stojadinovic A**. The functional impact on voice of sternothyroid muscle division during thyroidectomy. *Annals of Surgical Oncology* 2008; 15 Suppl (2): p. 48.
38. **Stojadinovic A**, Hawksworth J, gage F, Tadaki DK, Perdue PW, Forsberg JA, Davis T, Dunne JP, DeNobile JW, Brown TS, Elster EA. Inflammatory cytokine and chemokine expression, and quantitative bacteriology and wound failure in high-energy penetrating war injuries. World Union of Wound Healing Societies, Toronto, Canada, 4-8 June 2008.
39. Leonard R. Henry, Leah B. Horst, Nancy Pearl Solomon, Robin Howard, Joyce Gurevich-Uvena, George Coppit, **Alexander Stojadinovic**. Functional Voice Outcomes After Thyroidectomy: An Assessment of the Dysphonia Severity Index (DSI) and its Utility in Predicting Post-operative Voice Dysfunction. American Associations of Endocrine Surgeons. May 3-5 2009. Madison, WI.
40. Horst L, Littlefield P, Chang A, Solomon N, Henry L, **Stojadinovic A**, Coppit G. Otolaryngology practice patterns in the context of post-thyroidectomy voice impairment. ENT world Congress, Brazil, 1-5 June 2009.

41. Horst L, Henry L, Solomon N, Coppit G, Howard S, **Stojadinovic A**. Ratings of post-thyroidectomy voice quality by experienced and inexperienced listeners. ENT world Congress, Brazil, 1-5 June 2009
42. Solomon, N. P., Horst, L. B., Makashay, M. J., Henry, L. R., **Stojadinovic, A**. Aerodynamic voice assessment before and after thyroidectomy. Talk presented at the Voice Foundation's 38th Annual Symposium: Care of the Professional Voice. Philadelphia, PA. June 2009.
43. Stevens KA, Henry LR, Horst LB, Solomon NP, Coppit G, Shriver CD, **Stojadinovic A**. What is the Clinical Utility of Recurrent Laryngeal Neuromonitoring During Thyroidectomy? Society of Surgical Oncology Annual Meeting, St Louis, MO. 3-7 March 2010.
44. Buckenmaier CC, Kwon KH, Howard RS, McKnight GM, Shriver CD, **Stojadinovic A**. Double-Blinded, Placebo Controlled Prospective Randomized Trial Evaluating the Efficacy of Continuous Paravertebral Catheter Anesthesia with Paravertebral Block in Breast Cancer Surgery. Society of Surgical Oncology Annual Meeting, St Louis, MO. 3-7 March 2010.
45. Webb RC, Howard RS, **Stojadinovic A**, Burch HB. Post Operative Thyroglobulin Level: Significant Marker of Recurrent Papillary Thyroid Carcinoma. Society of Surgical Oncology Annual Meeting, St Louis, MO. 3-7 March 2010.
46. Hwang PF, Hampton CB, Potter BK, Shoemaker RG, Graybill JC, Forsberg JA, Schaefer RA, Peoples GE, **Stojadinovic A**. Impact of Local Recurrence on Extremity and Pelvic Soft Tissue Sarcoma Survival. Society of Surgical Oncology Annual Meeting, St Louis, MO. 3-7 March 2010.
47. Clifton GT, Clive K, Holmes JP, Patil R, Benavides LC, Gates JD, Mittendorf EA, **Stojadinovic A**, Ponniah S, Peoples GE. Cumulative Findings from the E75 Peptide Vaccine Adjuvant Trials in Breast Cancer. Society of Surgical Oncology Annual Meeting, St Louis, MO. 3-7 March 2010.
48. Takeshi Tsukamoto, R. Savanh Chanthaphavong, Ihab I. El Hajj, **Alexander Stojadinovic**, ,Hiroyuki Yokota, Hans-Christoph Pape, Timothy Billiar, Anthony J. Bauer. Tissue Trauma Induction of Gastrointestinal Ileus: An Innovative Murine Survival Model of Combat Injury and Its Consequences. American Gastroenterology Association Digestive Disease Week, New Orleans, LA. 1-5 May 2010.
49. Hosan Kim, Justin Jay, Mohammad R. Alavi, Vanessa Marcel, **Alexander Stojadinovic**, Mina J. Izadjoo. Whole Genome Sequencing of Emerging Wound Infections. Comprehensive Wound Center Center 4th Annual Translational to Clinical (T2C) Wound Care Conference. The Ohio Union, Ohio State University Medical Center, Columbus Ohio. 08-09 APR 2011.
50. Mohammad R. Alavi, Vlado Antonic, Mina J. Izadjoo, **Alexander Stojadinovic**. Characterization of Bacterial Biofilms from Emerging Wound Infections. Comprehensive Wound Center Center 4th Annual Translational to Clinical (T2C) Wound Care Conference. The Ohio Union, Ohio State University Medical Center, Columbus Ohio. 08-09 APR 2011.
51. Mina J. Izadjoo, Mohammad R. Alavi, Vlado Antonic, Vanessa Marcel, Hosan Kim, Hyung-Yong Kim, **Alexander Stojadinovic**. An Overview of Laboratory Operations of the Combat Wound Initiative Program. Comprehensive Wound Center Center 4th Annual Translational to Clinical (T2C) Wound Care Conference. The Ohio Union, OSU Medical Center, Columbus Ohio. 08-09 APR 2011.
52. Mohammad R. Alavi, Adrien Ravizee, Robert Burgess, Vlado Antonic, Mina J. Izadjoo, **Alexander Stojadinovic**. Isolation of an Antibiotic Resistance Carrying Plasmid from a Bacterial Isolate from a Combat Related Wound. Comprehensive Wound Center Center 4th Annual Translational to Clinical (T2C) Wound Care Conference. The Ohio Union, Ohio State University Medical Center, Columbus Ohio. 08-09 APR 2011.

53. Ball S, Barendse A, Bither C, Blankenship C, Bolenbaucher RM, Brunken SL, Cain B, Coakley TA, Comptom L, Couch K, Crumbley D, Culler D, Elster E, Giles T, Hanas C, Joyner KD, Liston W, Madore A, May S, Moore T, **Stojadinovic A**, Warren W. Advanced Wound Care Formulary (Operational) Working Group. SAWC/WHC Symposium on Advanced Wound Care Spring 2011, Dallas, TX 15 APR 2011.
54. **Stojadinovic A**, Ottoman C, Hartmann B, Thiele R, Lavin PT, Schaden W. Prospective Trials of ESWT for Soft Tissue Indications. 14th Congress of the International Society of Medical Shockwave Treatment. Kiel, Germany, June 9th-11th 2011.
55. **Stojadinovic A**. Targeted Nodal Assessment in Colorectal Carcinoma. 16th Annual Scientific Meeting of the Academy of Studenica, Novi Sad, Serbia, 1-3 July 2011.
56. **Stojadinovic A**. Colon Cancer Associated Transcript-1 (CCAT1): A Novel RNA Expressed in Malignant and Pre-malignant Human Tissues. Targeted Nodal Assessment in Colorectal Carcinoma. 16th Annual Scientific Meeting of the Academy of Studenica, Novi Sad, Serbia, 1-3 July 2011.
57. **Stojadinovic A**. Extracorporeal Shock Wave Therapy: Soft Tissue Indications. 16th Annual Scientific Meeting of the Academy of Studenica, Novi Sad, Serbia, 1-3 July 2011.
58. Inhibition of multi-drug resistant *Acinetobacter Baumannii* by non-viral expression of human Cathelicidin in bioengineered skin tissue. Comer AR, Centanni JM, Johnston CE, He LK, Schlosser SJ, VanWinkle KF, Gibson AL, Szilagyi A, Li L, Shankar R, Izadjoo M, **Stojadinovic A**, Feng SH, Allen-Hoffman BL. American College of Wound Healing and Tissue Repair. Chicago, IL, 4-5 AUG 2011.
59. Steele SR, Bilchik A, Johnson EK, Nissan A, Peoples GE, Eberhardt JS, Kalina P, Peterson B, **Stojadinovic A**. Time-Dependent Estimates of Recurrence and Survival in Colon Cancer: Decision Support Tool Development for Adjuvant Therapy and Oncological Outcome Assessment. Western Surgical Association Meeting, Tucson, AZ, 13-16 NOV 2011.
60. **Stojadinovic A**, Nissan A, Wainberg Z, Shen P, McCarter M, Protic M, Howard RS, Steele SR, Peoples GE, Bilchik A. Time-Dependent Trends in Lymph Node Yield and Impact on Adjuvant Therapy Decisions in Colon Cancer Surgery: An International Multi-Institutional Study. Pacific Coast Surgical Association, 83rd Annual Meeting. e-Poster Session, 18 FEB 2012.
61. Steele S, Eberhardt J, Kalina P, Nissan A, Avital I, Bilchik A, Johnson E, **Stojadinovic A**. Personalized Estimates of *Clostridium Difficile* Infection Following Colon Resection: Using Bayesian Belief Networks to Predict Peri-operative Risk. Pacific Coast Surgical Association, 83rd Annual Meeting. e-Poster Session, 18 FEB 2012.
62. Schaub NP, Alimchandani M, Quezado M, Kalina PM, Eberhardt JS, Alexander HR, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Hughes MS, Rudloff U, Kammula US, Phan GQ, **Stojadinovic A**, Avital I. Bayesian Belief Model for Peritoneal Mesothelioma after Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Accurately Predicts Survival. 65th Annual Cancer Symposium. Society of Surgical Oncology. 21-24 March 2012. Orlando, FL.
63. Henry LR, Helou LB, Solomon NP, Chang A, Libutti S, **Stojadinovic A**. Technical Variations in the Conduct of Thyroidectomy and Parathyroidectomy amongst Surgeons – A Survey Study. 65th Annual Cancer Symposium. Society of Surgical Oncology. 21-24 March 2012. Orlando, FL.
64. Nissan A, Protic M, Bilchik AJ, Howard RS, Peoples GE, **Stojadinovic A**. United States Military Cancer Institute Clinical Trials Group (USMCI GI-01) Randomized Controlled Trial Comparing Targeted Nodal Assessment and Ultra-staging to Standard Pathological Evaluation for Colon Cancer. 132nd Annual Meeting of the American Surgical Association. San Francisco, CA. 26-28 APR 2012.

65. Antonic V, **Stojadinovic A**, Izadjoo M, Alavi M. Pigment production in a white phenotypic variant of *Staphylococcus Aureus*. Society of Advanced Wound Care. Baltimore, MD 11-14 SEP 2012.
66. Hyung-Yong Kim, **Alexander Stojadinovic**, Mina J. Izadjoo. Critical Importance of Measuring Cytokine, Chemokine, and Growth Factor Levels in Wound Fluids. Society of Advanced Wound Care. Baltimore, MD 11-14 SEP 2012.
67. Hosan Kim, Inder Makin, Jeff Skiba, Amy Ho, **Alexander Stojadinovic**, Mina Izadjoo. Antibacterial Efficacy Testing of a Bioelectric Wound Dressing Against Clinical Wound Isolates. Society of Advanced Wound Care. Baltimore, MD 11-14 SEP 2012.
68. Binxue Zhang, Ellen La Morena, Vanessa Marcel, Wendell Thomas, Haroun Hebron, **Alexander Stojadinovic**, Mina Izadjoo. Rapid Identification of *Candida albicans* - An Opportunistic Fungal Pathogen for Delayed Wound Healing. Society of Advanced Wound Care. Baltimore, MD 11-14 SEP 2012.
69. Shaw-Huey Feng, **Alexander Stojadinovic**, Mina Izadjoo. Characterization of *Acinetobacter baumannii* Clinical Isolates on Biofilm Development. Society of Advanced Wound Care. Baltimore, MD 11-14 SEP 2012.
70. Shaw-Huey Feng, Allen Comer, Lynn Allen-Hoffmann, **Alexander Stojadinovic**, Mina Izadjoo. Effects of Antimicrobial Peptides in Preventing and Disrupting Biofilm Formation by *Acinetobacter baumannii*. Society of Advanced Wound Care. Baltimore, MD 11-14 SEP 2012.
71. Wendell Thomas, Vanessa Marcel, **Alexander Stojadinovic**, Mina Izadjoo. Automated Wound Pathogen Diagnostic Capability at Diagnostics and Translational Research Center. Society of Advanced Wound Care. Baltimore, MD 11-14 SEP 2012.
72. Andrew Sawyer, Themis Kyriakides, **Alexander Stojadinovic**, Mina Izadjoo, Sidney Altman. A Novel Methodology for Inactivation of Wound Pathogens. Society of Advanced Wound Care. Baltimore, MD 11-14 SEP 2012.
- "Dr. Mina Izadjoo, COL Alexander Stojadinovic, Dr. Sidney Altman and the Henry M. Jackson Foundation for the Advancement of Military Medicine received **1st place in the Laboratory Research Poster** category at the 4th annual Fall Symposium of the Society of Advanced Wound Care. DTRC presented nine abstracts, the most of any organization at this prestigious scientific meeting. The abstract that won the award was titled "A Novel Methodology for Inactivation of Wound Pathogens." This work was done in collaboration with Dr. Sidney Altman, a Nobel laureate from Yale University.*
73. Bilchik A, Nissan A, Protic M, Wainberg Z, Wasserberg N, Avital I, **Stojadinovic A**. Ultra-staging Of Node Negative (N0) Colon Cancer: Preliminary Results Of An International Prospective Clinical Trial. J Clin Oncol 30: 2012 (Suppl 34; Abstract 484).
- 73.** Paolo Del Rio, Diego Vicente, Umberto Maestroni, Anna Totaro, Gian Pattacini, Itzhak Avital, **Alexander Stojadinovic**, Mario Sianesi. A Prospective Observational Trial Comparing Minimally Invasive Video-Assisted Parathyroidectomy with Traditional Parathyroidectomy for Sporadic Primary Hyperparathyroidism. The Endocrine Society – ENDO 2013. San Francisco, CA 15-18 JUN 2013.
- 74.** Diego Vicente, Umberto Maestroni, Paolo Del Rio, Francesco Ziglioli, Francesco Dinale, Davide Campobasso, Stefania Ferretti, **Alexander Stojadinovic**, Itzhak Avital. Laparoscopic Adrenalectomy for Large Incidentalomas: A Challenge or a Routine? The Endocrine Society – ENDO 2013. San Francisco, CA 15-18 JUN 2013.
- 75. Alexander Stojadinovic**, Mladjan Protic, Aviram Nissan, Zev Wainberg, Scott R. Steele, David Chen, Nir Wasserberg, Dan Seror, Sarah Morgenstern, Itzhak Avital, Anton Bilchik. Prognostic effect of

ultra-staging node negative (pN0) colon cancer without adjuvant chemotherapy: Prospective NCI Clinical Trial 5RO1CA090848. Western Surgical Association Annual Meeting, Salt Lake City, Utah, 03-05 NOV 2013.

76. Udo Rudloff, Russell C. Langan, John E. Mullinax, Seth M. Steinberg, Tatiana Beresnev, Carole C. Webb, Melissa Walker, Mary Ann Toomey, David Schrump, Prakash Pandalai, **Alexander Stojadinovic**, Itzhak Avital. Impact of Maximum Cytoreduction plus Regional Chemotherapy on Outcome of Gastric Cancer Patients with Peritoneal Carcinomatosis: Preliminary results from the GYMSSA trial (Randomized Study comparing Gastrectomy, Metastasectomy, Intraperitoneal Chemotherapy plus Systemic Chemotherapy versus Systemic Chemotherapy alone). Western Surgical Association Annual Meeting, Salt Lake City, Utah, 03-05 NOV 2013.

77. Hong-Wu Xin, Chenwi M. Ambe, Tyler C. Miller, Jin-Qiu Chen, Gordon W. Wiegand, Andrew J. Anderson, Satyajit Ray, John E. Mullinax, Danielle M. Hari, Tomotake Koizumi, Jessica D. Godbout, Paul K. Goldsmith, **Alexander Stojadinovic**, Udo Rudloff, Snorri S. Thorgeirsson, Itzhak Avital. Metformin and Sorafenib have Synergistic Effects on Liver Cancer Cells but Variable Effects on Stem-Like Liver Cancer Cells. Western Surgical Association Annual Meeting, Salt Lake City, Utah, 03-05 NOV 2013.

78. Diego A. Vicente, Nancy P. Solomon, Itzhak Avital, Leonard R. Henry, Robin S. Howard, George L. Coppit, Craig D. Shriver, Chester C. Buckenmaier, Steven K. Libutti, Ashok R. Shaha, **Alexander Stojadinovic**. VOCAL (Voice Outcomes Appraisal, Longitudinal) Trial: A Prospective Longitudinal Multimodal Evaluation Comparing Voice Outcomes in Patients Undergoing Total Thyroidectomy, Partial Thyroidectomy, and Non-Neck Surgery. Western Surgical Association Annual Meeting, Salt Lake City, Utah, 03-05 NOV 2013.

79. Mladjan Protic, Radovan Veljkovic, Anton J. Bilchik, Ana Popovic, Aviram Nissan, Itzhak Avital, **Alexander Stojadinovic**. Prospective Randomized Controlled Trial Comparing Standard Oral Analgesia with Multi-modal Targeted Operative and Port-Site Local Anesthesia for Post-Operative Pain Management in Elective Laparoscopic Cholecystectomy. Western Surgical Association Annual Meeting, Salt Lake City, Utah, 03-05 NOV 2013.

80. Anton J. Bilchik, Zev A. Wainberg, Aviram Nissan, Dennis J. Slamon, Mladjan Protic, Itzhak Avital, Hsiao-Wang Chen, David Chen, **Alexander Stojadinovic**. Value of Primary Tumor Gene Signatures in Colon Cancer When National Quality Standards are Adhered to: Preliminary Results of an International Prospective Multi-Center Trial. Society of Surgical Oncology Annual Meeting, Phoenix, AZ 12-15 MAR 2014.

81. Anton Bilchik, Mladjan Protic, Aviram Nissan, Zev Wainberg, Scott Steele, David Chen, Itzhak Avital, **Alexander Stojadinovic**. Prognostic Effect of Ultra-staging Node Negative (N0) Colon Cancer without Adjuvant Chemotherapy: Prospective NCI Clinical Trial 5RO1CA090848. American College of Surgeons Clinical Congress, 26-30 OCT 2014, San Francisco, CA.

Presentations:

1. **Stojadinovic A**, Molloy M, d'Avis J, Jaques DP. Completion thyroidectomy for differentiated thyroid carcinoma. Gary P. Wratten Surgical Symposium, Breckenridge, CO, 1993.
2. **Stojadinovic A**, Gomez ER, Jackson MR. The role of intra-arterial urokinase for acute limb-threatening ischemia. Gary P. Wratten Surgical Symposium, Cloudcroft NM, 1994.

3. **Stojadinovic A**, Kiang J, Smallridge R, Galloway R, Shea-Donohue T. Heat shock protein-72 induction protects rat small intestinal mucosa from ischemia / reperfusion injury. Gary P. Wratten Surgical Symposium, Boston, MA, 1995.
4. **Stojadinovic A**, Kiang J, Smallridge R, Galloway R, Shea-Donohue T. Heat shock protein-72 induction protects against ischemia/reperfusion injury in rat small intestine. Division of Medicine Grand Rounds, WRAIR, Washington D.C., March 1995.
5. **Stojadinovic A**, Kiang J, Smallridge R, Galloway R, Shea-Donohue T. Heat shock protein-72 induction protects against ischemia/reperfusion injury in rat small intestine. Charles A. Hufnagel Research Award Competition, USUHS, Bethesda, MD, April 1995.
6. **Stojadinovic A**, Smallridge R, Galloway R, Shea-Donohue T. Mechanism of a 21-aminosteroid, U74389, protection against intestinal ischemia / reperfusion injury. American Gastroenterology Association, San Diego, CA, May 1995.
7. **Stojadinovic A**, Kiang J, Smallridge R, Galloway R, Shea-Donohue T. Heat shock protein-72 induction protects rat intestinal mucosa from ischemia / reperfusion injury. American Gastroenterology Association, San Diego, CA, May 1995.
8. **Stojadinovic A**. Intestinal ischemia / reperfusion injury: new therapeutic approaches. First Annual San Antonio Trauma Symposium, San Antonio, TX, Sept 1995.
9. **Stojadinovic A**, Smallridge R, Shea-Donohue T. U74389F limits intestinal ischemia / reperfusion injury in rats. Gary P. Wratten Surgical Symposium, Breckenridge, CO 1996.
10. **Stojadinovic A**, Matin D, Starnes BW, Smallridge R, Shea-Donohue T. Rapid restitution of ischemic damage by the 21-aminosteroid U74389, in rat small intestine. American Gastroenterology Association, San Francisco, CA May 1996.
11. **Stojadinovic A**, Lawson SA, Jaques DP, Shriver CD. Physiologic response to hepatic cryosurgery in the treatment of unresectable hepatic tumors. Gary P. Wratten Surgical Symposium, 1997.
12. **Stojadinovic A**, Karpoff HM, Antonescu CR, Shah JP, Singh B, Spiro RH, Dumornay W, Shaha AR. Dermatofibrosarcoma Protuberans of the Head and Neck. SSO 2000, New Orleans, LA.
13. **Stojadinovic A**, Hoos A, Karpoff HM, Leung DHY, Antonescu CR, Brennan MF, Lewis JJ. Soft tissue tumors of the abdominal wall: analysis of patterns of disease and treatment modalities. Gary P Wratten Surgical Symposium, Washington, D.C., 2000.
14. **Stojadinovic A**, Hoos A, Ghossein RA, Urist M, Leung DHY, Spiro R, Shah JP, Brennan MF, Singh B, Shaha AR. Hurthle cell carcinoma: A 60-year experience. SSO 2001, Washington, D.C.
15. **Stojadinovic A**, Jaques DP, Leung DHY, Healey JH, Brennan MF. Amputation for recurrent soft tissue sarcoma of the extremity: indications and outcome. SSO 2001, Washington, D.C.
16. Klauber-DeMore N, **Stojadinovic A**, Mann B, Coit DG. Deep pelvic nodal metastases of malignant melanoma: multifactorial analysis of prognostic indicators. SSO 2001, Washington, D.C. (Poster)
17. **Stojadinovic A**, Hoos A, Ghossein RA, Urist M, Leung DHY, Spiro R, Shah JP, Brennan MF, Singh B, Shaha AR. Hurthle cell carcinoma: A 60-year experience. New York Surgical Society, 2001.
18. **Stojadinovic A**, Hoos A, Ghossein RA, Urist M, Leung DHY, Spiro R, Shah JP, Brennan MF, Singh B, Shaha AR. Hurthle cell carcinoma: A 60-year experience. Gary P Wratten Surgical Symposium, Augusta, GA, 2001.
19. Bains MS, **Stojadinovic A**, Minsky B, Rusch V, Turnbull A, Korst R, Ginsberg R, Kelsen DP, Ilson DH. Phase II trial of preoperative combined modality therapy for locally advanced esophageal carcinoma. American Society for Thoracic Surgeons 2001, San Diego, CA.

20. **Stojadinovic A**, Kiang JG, Tsokos GC, Shea - Donohue, T. Constitutive Nitric Oxide Synthase Inhibition Prevents Hyperthermia - Induced Multiorgan Expression of HSP - 72. American Gastroenterology Association (DDW) 2001, Atlanta, GA. (Poster).
21. **Stojadinovic A**, Bains M. Ivor-Lewis Esophagectomy (Video). Cine Clinics, American College of Surgery, 2001.
22. **Stojadinovic et al.** Utility of a surgical morbidity and mortality grading system to describe short-term outcome following esophagectomy. Gastroenterology-Surgery Board, Walter Reed Army Medical Center, September 2001.
23. **Stojadinovic A**, Fields SI, Shriver CD, Lenington S, Ginor R, Peoples GE, Burch HB, Peretz T, Freund HR, Nissan A. Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: A Prospective Study. Society of Surgical Oncology, New York City, 2004.
24. **Stojadinovic A**. Forward Surgery in Operation Iraqi Freedom. Trauma Surgery Symposium, Uniformed Services University of the Health Sciences, August 2004.
25. **Stojadinovic A**. Current Concepts in Forward Surgery and Damage Control, Grand Rounds, Memorial Sloan Kettering Cancer Center, October 2004.
26. **Stojadinovic A**. The Role of Routine Electrical Impedance Scanning for the Identification of Increased Breast Cancer Risk in Women Under Age 40. Dru Carlson Memorial Symposium, Los Angeles, CA, November 2004.
27. **Stojadinovic A**, Nissan A, Gallimidi Z, Lenington S, Logan W, Zuley M, Yeshaya A, Shimonov M, Melloul M, Fields S, Allweis T, Ginor R, Gur D, Shriver CD. Electrical Impedance Scanning for the Early Detection of Breast Cancer in Young Women: Preliminary Results of 1,103 Patients Taking Part in a Multi-Center Prospective Trial. J Clin Oncol 2004, 27th Annual San Antonio Breast Cancer Symposium, 2004.
28. **Stojadinovic A**, Margolin M, Singh M, Akin M, Pulliam R, Platt L. A Novel Technique for Primary Breast Cancer Screening in Young Women. 2005 Annual Clinical Meeting of the American College of Obstetrics and Gynecology, San Francisco, CA.
29. **Stojadinovic A**. Current Concepts in Forward Surgery and Damage Control. Hadassah University Hospital Mount Scopus, Israel. Department of Surgery Grand Rounds - Invited Lecture. August 2005.
30. **Stojadinovic A**. Colon Sentinel Lymph Node Mapping: Practical Surgical Applications. Hadassah University Hospital Mount Scopus, Israel. Department of Surgery Grand Rounds - Invited Lecture. August 2005.
31. **Stojadinovic A**. Electrical Impedance Scanning for the Identification of Young Women at Increased Risk of Breast Cancer. T-Scan Technology Symposium and Update, 2005 Invited Lecture. Tel Aviv, Israel. August 2005.
32. **Stojadinovic A**. Breast Cancer Update: Screening and Risk Identification in Young Women. September, 2005. Grand Rounds, Malcolm Grow Air Force Medical Center.
33. **Stojadinovic A**. Prognostic Significance of Surgical Margins for Adult Soft Tissue Sarcoma. Annual Meeting of the Society of Surgical Oncologists of Serbia. Belgrade, Serbia. October 2005.
34. **Stojadinovic A**. An emerging technology for breast cancer risk identification in young women. National Breast Cancer Update, Buenos Aires, Argentina, November 2005.

35. **Stojadinovic A.** Colon Sentinel Lymph Node Mapping: Practical Surgical Applications. The International Cancer Symposium of the Israel Society of Surgical Oncology – ISSO, Israel Surgical Association, Eilat, Israel - Invited Lecture. November 2005.
36. **Stojadinovic A,** T. Peretz, A. Nissan, S. Fields, A. Yeshaya, M. Shimonov, T. Allweis, O. Moskovitz, R. Mucciola, M. Singh, Z. Gallimidi, Y. Pappo, A. Brooks, F. Sperber, R. Brem, M. Sklair-Levy, R. Manassa, Abu Rachmi, M. Maniscalco-Theberge, H. Rockette, C. Shriver, D. Gur. Breast Cancer Risk Stratification for Young Women: Prospective Multi-Center Validation Study of Electrical Impedance Scanning. The International Cancer Symposium of the Israel Society of Surgical Oncology – ISSO, Israel Surgical Association, Eilat, Israel. November 2005.**Stojadinovic A.** Breast Cancer Update: Novel Approaches to Screening in Young Women. Annual Meeting of the 38th Parallel Medical Society, Seoul, Korea, October 2006.
38. **Stojadinovic A.** Current Concepts in Forward Surgery and Damage Control. Annual Meeting of the 38th Parallel Medical Society, Seoul, Korea, October 2006.
39. **Stojadinovic A.** Colon Cancer Screening and Improved Staging through Targeted Nodal Assessment. Annual Meeting of the 38th Parallel Medical Society, Seoul, Korea, October 2006.
40. **Stojadinovic A.** Management of Battlefield Casualties with Extracorporeal Shock Wave Therapy. 7th Annual Wound Healing: Science and Industry, Saint Thomas, U.S. Virgin Islands, Dec. 2006.
41. Schaden W, Thiele R, Kölbl C, Pusch M, Nissan A, Attinger CE, Maniscalco-Theberge ME, Peoples GE, Elster EA, **Stojadinovic A.** Shock Wave Therapy for Acute and Chronic Soft Tissue Wounds: A Feasibility Study. Annual Academic Surgical Congress, 2nd Annual Meeting, Phoenix, AZ February 6-9, 2007.
42. Forsberg JA, Elster EA, **Stojadinovic A,** Andersen RC, Nylén ES, Becker KL, Brown TS, Rose M, McGuigan FX, Cytokine expression correlates with wound dehiscence in wartime extremity injuries, Academic Surgical Congress, 2nd Annual Meeting, Phoenix, AZ February 6-9, 2007.
43. **Stojadinovic A,** Mittendorf EA, Holmes JP, Hueman MT, Ponniah S, Peoples GE. Quantification and Phenotypic Characterization of Circulating Tumor Cells for Monitoring Response to Preventive Vaccine-based Immunotherapy for Breast Cancer. Society of Surgical Oncology; 60th Annual Cancer Symposium, Washington, D.C., March 17th 2007.
44. Forsberg JA, Andersen RC, Nylén ES, Elster EA, **Stojadinovic A,** Rose M, Brown TS, Becker KL, McGuigan FX, Procalcitonin and cytokine expression correlates with wound dehiscence in wartime extremity injuries. Resident Research Competition, National Naval Medical Center, Bethesda, MD 20 Apr 2007.
45. Amin A, Holmes JP, Hueman MT, Khoo S, Storer CE, Smith A, Jama Y, Craig D, **Stojadinovic A,** Ponniah S, Peoples GE. Assessment of pathologic and immunologic patterns among patients with clinical recurrence and vaccination with a preventative HER2/neu peptide vaccine. 29th Annual Wratten Surgical Symposium, Honolulu, HI, 7-9 May 2007.
46. Amin A, **Stojadinovic A,** Mittendorf EA, Holmes JP, Hueman MT, Ponniah S, Peoples GE. Assessment of pathologic and immunologic patterns among patients with clinical recurrence and vaccination with a preventative HER2/neu peptide vaccine. 29th Annual Wratten Surgical Symposium, Honolulu, HI, 7-9 May 2007.
47. Driscoll IR, Hwang PF, Fuenfer MM, Shriver CD, **Stojadinovic A,** Aydelotte JD. High velocity penetrating wounds to the Neck: Lessons learned from the battlefield in Afghanistan and Iraq. 29th Annual Wratten Surgical Symposium, 7-9 May 2007.

48. Solomon NP, Gurevich-Uvena J, Makashay MJ, Coppit GL, Battiatia AP, Shriver CD, **Stojadinovic A**. Voice outcomes following thyroidectomy. The Voice Foundation's 36th Annual Symposium, Philadelphia, PA, 29 May – 3 June 2007.
49. **Stojadinovic A**, Nissan A, Protic M, Adair CF, Prus D, Usaj S, Howard R, Radovanovic D, Breberina M, Shriver CD, Grinbaum R, Nelson JM, Brown TA, Freund HR, Potter JF, Peretz T, Peoples GE. Prospective Randomized Study Comparing Sentinel Lymph Node Evaluation with Standard Pathological Evaluation for the Staging of Colon Carcinoma: Results from the United States Military Cancer Institute Clinical Trials Group Study GI-01. Israel Surgical Society 6-7 June 2007.
50. **Stojadinovic A**. Novel technologies for the detection of breast cancer. Elaine Goldman Lichtman Memorial Symposium in Oncology. Sharett Institute of Oncology, Hadassah University Hospital, Kiryat Hadassah, Jerusalem, Israel. 11 June 2007.
51. **Stojadinovic A**, Nissan A, Shriver CD, Lenington S, Gur D. Electrical impedance scanning for breast cancer risk stratification in young women. 13th International Conference on Electrical Bioimpedance, Graz, Austria, August 2007.
52. **Stojadinovic A**. Shock Wave Therapy for Acute and Chronic Soft Tissue Wounds: A Feasibility Study. Veith Symposium. 14-18 November 2007.
53. **Stojadinovic A**, Elster EA, Anam K, Tadaki D, Amare M, Zins S, Davis TA. Angiogenic response to extracorporeal shock wave treatment in murine skin isografts. Wound Healing: Science and Industry. 14-16 December 2007.
54. Hird LC, Gates JD, Carmichael MG, Holmes JP, Mittendorf EA, **Stojadinovic A**, Ponniah S, Peoples GE. Impact of Trastuzumab treatment on HER2/neu peptide vaccination: Preliminary results for combination immunotherapy. Academic Surgical Congress, 3rd Annual Meeting, Huntington Beach, CA, February 12-15, 2008.
55. Hawksworth J, Kasper MR, Gage F, Brown T, Tadaki DK, Perdue PW, Forsberg J, **Stojadinovic A**, Elster EA. Quantitative bacteriology and wound failure in high energy penetrating war injuries. Academic Surgical Congress, 3rd Annual Meeting, Huntington Beach, CA, February 12-15, 2008.
56. Hawksworth J, **Stojadinovic A**, Gage F, Tadaki DK, Perdue PW, Forsberg J, Davis T, Brown T, Elster EA. Inflammatory Biomarkers in Combat Wound Healing. Academic Surgical Congress, 3rd Annual Meeting, Huntington Beach, CA, February 12-15, 2008.
57. Gates JA, Hird LC, Shriver CD, Peoples GE, **Stojadinovic A**. Should thyroid ultrasound be performed on all patients undergoing minimally invasive parathyroid surgery (MIPS)? Academic Surgical Congress, 3rd Annual Meeting, Huntington Beach, CA, February 12-15, 2008.
58. **Stojadinovic A**, Esquivel J. Clinical trials with regional cancer therapies: Phase III trial comparing best available systemic therapy to cytoreduction, hyperthermic intra-peritoneal Mitomycin C and best available systemic therapy in patients with limited peritoneal dissemination of colon adenocarcinoma. 3rd International Symposium on Regional Cancer Therapies, Palm Desert, CA, February 16-18, 2008.
59. **Stojadinovic A**, Carlson JW, Schultz GS, Davis T, Elster EA. Topical advances in wound care, Society of Gynecologic Oncologists Annual Meeting. Tampa, FL March 8, 2008.
60. Henry LR, Solomon NP, Howard R, Gurevich-Uvena J, Horst LB, Coppit G, Orlikoff, Liutti SK, Shaha AR, **Stojadinovic A**. The functional impact on voice of sternothyroid muscle division during thyroidectomy. Annual Meeting of the Society of Surgical Oncology, Chicago, IL, March 2008.
61. **Stojadinovic A**, Hawksworth J, gage F, Tadaki DK, Perdue PW, Forsberg JA, Davis T, Dunne JP,

- DeNobile JW, Brown TS, Elster EA. Inflammatory cytokine and chemokine expression, and quantitative bacteriology and wound failure in high-energy penetrating war injuries. World Union of Wound Healing Societies, Toronto, Canada, 4-8 June 2008.
62. **Stojadinovic A.** Advances in complex Wound Care. Integrated Wound Care Course. National Naval Medical Center, Bethesda, MD, 15 October 2008.
63. **Stojadinovic A.** UCLA Department of Surgery Grand Rounds Visiting Professor. Individualized approaches to the surgical care of combat casualties. 22 October 2008.
64. **Stojadinovic A**, Nissan A, Eberhardt J, Esquivel J. Development of a clinically relevant Bayesian Belief Network model-derived personalized prognostic risk assessment tool for colon carcinomatosis. International Workshop on Peritoneal Surface Malignancy. Lyon, France. 18 November 2008.
65. **Stojadinovic A.** Diagnostics, Biomarkers and Complex War Wounds. 9th Annual Wound Healing: Science and Industry, Saint Thomas, U.S. Virgin Islands, December 2008.
66. **Stojadinovic A**, Eberhardt J, Elster EA. Application of data mining and artificial intelligence techniques to complex clinical data sets. Lab Automation 2009, Palm Springs, CA, January 2009.
67. **Stojadinovic A**, Nissan A, Eberhardt J, Esquivel J. Development of a Bayesian Belief Network Model for Personalized Prognostic Risk Assessment in Colon Carcinomatosis. Fourth International Symposium on Regional Cancer Therapies. Marco Island, Florida, February 2009.
68. **Stojadinovic A**, Esquivel J. USMCI and ACOSOG NCI/CTEP Protocol 8214 Pilot/Phase III Randomized Trial Comparing Best Available Systemic Therapy to Cytoreduction + HIPEC + Best Available Systemic Therapy in Patients with Limited Peritoneal Dissemination of Colon Adenocarcinoma.
69. Henry L, Horst L, Howard R, Solomon N, Eberhardt C, Coppit G, Shaha A, **Stojadinovic A.** Validation of the Voice Handicap Index in predicting voice outcomes after thyroidectomy. Annual Meeting of the Society of Surgical Oncology, Phoenix, AZ, March 2009.
70. Henry L, Horst L, Howard R, Gurevich-Uvena J, Coppit G, Felix T, Solomon N, **Stojadinovic A.** Functional voice outcomes after thyroidectomy: Are early reported voice symptoms related to durable laryngoscopic abnormalities? Annual Meeting of the Society of Surgical Oncology, Phoenix, AZ, March 2009.
71. **Stojadinovic A.** Lessons learned in forward surgery. Austin Jewish Academy. 08 May 2009.
72. **Stojadinovic A.** Personalized medicine approaches to combat casualty care: Combat Wound Initiative Program. Hadassah Hebrew University Medical Center, Israel. August 2009.
73. Stevens KA, Henry LR, Horst LB, Solomon NP, Coppit G, Shriver CD, **Stojadinovic A.** What is the Clinical Utility of Recurrent Laryngeal Neuromonitoring During Thyroidectomy? Society of Surgical Oncology Annual Meeting, St Louis, MO. 3-7 March 2010.
74. Buckenmaier CC, Kwon KH, Howard RS, McKnight GM, Shriver CD, **Stojadinovic A.** Double-Blinded, Placebo Controlled Prospective Randomized Trial Evaluating the Efficacy of Continuous Paravertebral Catheter Anesthesia with Paravertebral Block in Breast Cancer Surgery. Society of Surgical Oncology Annual Meeting, St Louis, MO. 3-7 March 2010. (Presented by LTC CA Arciero)
75. Takeshi Tsukamoto, R. Savanh Chanthaphavong, Ihab I. El Hajj, **Alexander Stojadinovic**, Hiroyuki Yokota, Hans-Christoph Pape, Timothy Billiar, Anthony J. Bauer. Tissue Trauma Induction of Gastrointestinal Ileus: An Innovative Murine Survival Model of Combat Injury and Its

- Consequences. American Gastroenterology Association Digestive Disease Week, New Orleans, LA. 1-5 May 2010. (Presented by Dr Anthony Bauer).
76. **Stojadinovic A**, Crumley D, Couch K. Development of an Inter-Service Complex Wound and limb Salvage Center within the DoD. Diabetic Limb Salvage. Washington, D.C. 15 October 2010.
77. **Stojadinovic A**. Evidence supporting ESWT for soft tissue indications. Distinguished Speaker. Comprehensive Wound Center 4th Annual Translational to Clinical (T2C) Wound Care Conference. The Ohio Union; OSU Medical Center, Columbus Ohio. 08-09 APR 2011.
78. **Stojadinovic A**. Evidence supporting ESWT for soft tissue indications. Invited Speaker. SAWC/WHS Symposium on Advanced Wound Care Spring 2011, Dallas, TX 15 APR 2011.
79. **Stojadinovic A**, Ottoman C, Hartmann B, Thiele R, Lavin PT, Schaden W. Prospective Trials of ESWT for Soft Tissue Indications. 14th Congress of the International Society of Medical Shockwave Treatment. Kiel, Germany, June 9th-11th 2011.
80. **Stojadinovic A**. Targeted Nodal Assessment in Colorectal Carcinoma. 16th Annual Scientific Meeting of the Academy of Studenica, Novi Sad, Serbia, 1-3 July 2011.
81. **Stojadinovic A**. Colon Cancer Associated Transcript-1 (CCAT1): A Novel RNA Expressed in Malignant and Pre-malignant Human Tissues. Targeted Nodal Assessment in Colorectal Carcinoma. 16th Annual Scientific Meeting Academy of Studenica, Novi Sad, Serbia, 1-3 July 2011.
82. **Stojadinovic A**. Extracorporeal Shock Wave Therapy: Soft Tissue Indications. 16th Annual Scientific Meeting of the Academy of Studenica, Novi Sad, Serbia, 1-3 July 2011.
83. **Stojadinovic A**. Translational Research in Wound Healing. National Medical Association, Washington, D.C., 24 July 2011.
84. **Stojadinovic A**. Disaster Preparedness and Management in Forward Surgery. American College of Wound Healing and Translational Research. Chicago, IL, 04 AUG 2011.
85. Steele SR, Bilchik A, Johnson EK, Nissan A, Peoples GE, Eberhardt JS, Kalina P, Peterson B, **Stojadinovic A**. Time-Dependent Estimates of Recurrence and Survival in Colon Cancer: Decision Support Tool Development for Adjuvant Therapy and Oncological Outcome Assessment. Western Surgical Association Meeting, Tucson, AZ, 13-16 NOV 2011.
86. **Stojadinovic A**. The Golden Hour and Beyond in Modern Combat Casualty Care. Military Healthcare Convention and Conference. San Diego, CA, 04-08 NOV 2011.
87. **Stojadinovic A**. Mass Casualty Following Natural and Man Made Disasters – Lessons Learned from Iraq. Controversies, Problems, and Techniques in Surgery. New York, NY. 15-17 DEC 2011
88. **Stojadinovic A**. When to Close the Open Abdomen, managing Loss of Domain. Controversies, Problems, and Techniques in Surgery. New York, NY. 15-17 DEC 2011
89. **Stojadinovic A**. Judge at the 2012 Austin Jewish Academy Science Fair, Austin, TX. 25 JAN 2012.
90. **Stojadinovic A**. Keynote Address: 2012 Austin Jewish Academy Science Fair. 25 JAN 2012.
91. **Stojadinovic A**, Nissan A, Wainberg Z, Shen P, McCarter M, Protic M, Howard RS, Steele SR, Peoples GE, Bilchik A. Time-Dependent Trends in Lymph Node Yield and Impact on Adjuvant Therapy Decisions in Colon Cancer Surgery: An International Multi-Institutional Study. Pacific Coast Surgical Association, 83rd Annual Meeting, Napa, CA. e-Poster Session, 18 FEB 2012.
92. **Stojadinovic A**. New Frontiers in Colon Cancer. Invited speaker, Israeli Society of Surgical Oncology. Ceasarea, Israel. 22-23 FEB 2012.
93. Schaub NP, Alimchandani M, Quezado M, Kalina PM, Eberhardt JS, Alexander HR, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Hughes MS, Rudloff U, Kammula US, Phan GQ, **Stojadinovic A**,

- Avital I. Bayesian Belief Model for Peritoneal Mesothelioma after Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Accurately Predicts Survival. 65th Annual Cancer Symposium. Society of Surgical Oncology. 21-24 March 2012. Orlando, FL. (presented by Nicholas Schaub).
94. Nissan A, Protic M, Bilchik AJ, Howard RS, Peoples GE, **Stojadinovic A**. United States Military Cancer Institute Clinical Trials Group (USMCI GI-01) Randomized Controlled Trial Comparing Targeted Nodal Assessment and Ultra-staging to Standard Pathological Evaluation for Colon Cancer. 132nd Annual Meeting of the **American Surgical Association**. San Francisco, CA. 26-28 APR 2012. (presented by Stojadinovic A).
95. **Stojadinovic A**. Keynote Lecture, Shockwave stimulation of skin healing. 15th Congress of the International Society for Medical Shockwave Treatment. Cartagena, Colombia. 04-07 JUL 2012.
96. **Stojadinovic A**. Inflammatory biomarkers in wound failure. American College of Wound Healing and Tissue Repair. Chicago, IL. 26-28 JUL 2012.
97. **Stojadinovic A**. In pursuit of the ultimate question in clinical research: So what? Grand rounds invited lecture. University of Washington, Seattle, WA. 22 AUG 2012.
98. Radowsky J, **Stojadinovic A**, Howard RS, Burch HB. Impact of Degree of Extra-thyroidal Extension of Disease on Papillary Thyroid Carcinoma Outcome. Quebec City, Canada. 19-23 SEP 2012. (poster presented by Jason Radowsky).
99. Radowsky J, Eberhardt J, Peoples G, Burch HB, **Stojadinovic A**. Bayesian Modeling of a Thyroid Cancer Tumor Registry to Predict Outcomes of Papillary Thyroid Cancer. Annual Meeting of the American Thyroid Association. Quebec City, Canada. 19-23 SEP 2012. (presented by Jason Radowsky).
100. **Stojadinovic A**. Advances in Targeted Nodal Assessment in Colon Cancer. Invited lecture at the 8th Bi-annual International Symposium of the Society of Coloproctology, Belgrade, Serbia. 12 OCT 2012.
101. **Stojadinovic A**. In pursuit of the ultimate question in clinical research: So what? Grand rounds invited lecture. John Wayne Cancer Institute, Santa Monica, CA. 17 OCT 2012.
102. **Stojadinovic A**. Surgical management of metastatic melanoma in the age of targeted therapy. Invited lecturer; 10th Annual Mid-South Cancer Symposium – Curing the Incurable: Risk stratification & Targeted therapy. 09-10 NOV 2012.
103. **Stojadinovic A**. Principles of cytoreductive surgery and heated intra-peritoneal chemotherapy for peritoneal carcinomatosis. Controversies, Problems and Techniques in Surgery – 29th Annual Meeting, Montefiore Medical Center and Albert Einstein College of Medicine. New York, NY. 13-15 DEC 2012.
104. **Stojadinovic A**. Moderator, Scientific Session on Rectal Cancer. Controversies, Problems and Techniques in Surgery – 29th Annual Meeting, Montefiore Medical Center and Albert Einstein College of Medicine. New York, NY. 13-15 DEC 2012.
105. Bilchik A, Nissan A, Protic M, Wainberg Z, Wasserberg N, Avital I, **Stojadinovic A**. Ultra-staging Of Node Negative (N0) Colon Cancer: Preliminary Results Of An International Prospective Clinical Trial. ASCO Gastrointestinal Cancers Symposium. San Francisco, CA. 24-26 January 2013. (poster)
106. Paolo Del Rio, Diego Vicente, Umberto Maestroni, Anna Totaro, Gian Pattacini, Itzhak Avital, **Alexander Stojadinovic**, Mario Sianesi. A Prospective Observational Trial Comparing Minimally Invasive Video-Assisted Parathyroidectomy with Traditional Parathyroidectomy for Sporadic Primary Hyperparathyroidism. The Endocrine Society – ENDO 2013. San Francisco, CA 15-18 JUN

2013. (poster)
107. Diego Vicente, Umberto Maestroni, Paolo Del Rio, Francesco Ziglioli, Francesco Dinale, Davide Campobasso, Stefania Ferretti, **Alexander Stojadinovic**, Itzhak Avital. Laparoscopic Adrenalectomy for Large Incidentalomas: A Challenge or a Routine? The Endocrine Society - ENDO 2013. San Francisco, CA 15-18 JUN 2013. (poster)
108. **Alexander Stojadinovic**. The Quest for Precision Staging in Colon Cancer. Honorary Visiting Professor, University of Novi Sad, Medical Faculty, Novi Sad, Serbia. 24 SEP 2013.
109. **Alexander Stojadinovic**. Tribute to the American College of Surgeons: 100 Years of Citizen Surgeon Service and Leadership. Guest Speaker, American College of Surgeons, President's Dinner. Blue Room – Omni Shoreham Hotel, Washington, D.C. Saturday, October 5th, 2013.
110. **Alexander Stojadinovic**, Mladjan Protic, Aviram Nissan, Zev Wainberg, Scott R. Steele, David Chen, Nir Wasserberg, Dan Seror, Sarah Morgenstern, Itzhak Avital, Anton Bilchik. Prognostic effect of ultra-staging node negative (pN0) colon cancer without adjuvant chemotherapy: Prospective NCI Clinical Trial 5RO1CA090848. Western Surgical Association Annual Meeting, Salt Lake City, Utah, 03-05 NOV 2013. (presented by Anton Bilchik).
111. Udo Rudloff, Russell C. Langan, John E. Mullinax, Seth M. Steinberg, Tatiana Beresnev, Carole C. Webb, Melissa Walker, Mary Ann Toomey, David Schrupp, Prakash Pandalai, **Alexander Stojadinovic**, Itzhak Avital. Impact of Maximum Cytoreduction plus Regional Chemotherapy on Outcome of Gastric Cancer Patients with Peritoneal Carcinomatosis: Preliminary results from the GYMSSA trial (Randomized Study comparing Gastrectomy, Metastasectomy, Intraperitoneal Chemotherapy plus Systemic Chemotherapy versus Systemic Chemotherapy alone). Western Surgical Association Annual Meeting, Salt Lake City, Utah, 03-05 NOV 2013. (presented by Alexander Stojadinovic).
112. Diego A. Vicente, Nancy P. Solomon, Itzhak Avital, Leonard R. Henry, Robin S. Howard, George L. Coppit, Craig D. Shriver, Chester C. Buckenmaier, Steven K. Libutti, Ashok R. Shaha, **Alexander Stojadinovic**. VOCAL (Voice Outcomes Appraisal, Longitudinal) Trial: A Prospective Longitudinal Multimodal Evaluation Comparing Voice Outcomes in Patients Undergoing Total Thyroidectomy, Partial Thyroidectomy, and Non-Neck Surgery. Western Surgical Association Annual Meeting, Salt Lake City, Utah, 03-05 NOV 2013. (presented by Diego Vicente).
113. Mladjan Protic, Radovan Veljkovic, Anton J. Bilchik, Ana Popovic, Aviram Nissan, Itzhak Avital, **Alexander Stojadinovic**. Prospective Randomized Controlled Trial Comparing Standard Oral Analgesia with Multi-modal Targeted Operative and Port-Site Local Anesthesia for Post-Operative Pain Management in Elective Laparoscopic Cholecystectomy. Western Surgical Association Annual Meeting, Salt Lake City, Utah, 03-05 NOV 2013. (presented by Alexander Stojadinovic)
114. **Stojadinovic A**. At the request of Carlos A. Pellegrini, MD, FACS, FRCS(I)(Hon), President of the American College of Surgeons (ACS), Dr. Stojadinovic delivered a tribute to the American College of Surgeons and all Citizen Surgeons at the President's Dinner during the 2013 Clinical Congress in Washington, DC. Fellow pays tribute to ACS and Citizen Surgeons. Published 01 December 2013. Bulletin of the American College of Surgeons. <http://bulletin.facs.org/2013/12/fellow-pays-tribute-to-ac-s-and-citizen-surgeons/>
115. Anton J. Bilchik, Zev A. Wainberg, Aviram Nissan, Dennis J. Slamon, Mladjan Protic, Itzhak Avital, Hsiao-Wang Chen, David Chen, **Alexander Stojadinovic**. Value of Primary Tumor Gene Signatures in Colon Cancer When National Quality Standards are Adhered to: Preliminary Results of an

- International Prospective Multi-Center Trial. Society of Surgical Oncology Annual Meeting, Phoenix, AZ 12-15 MARCH 2014.
116. **Alexander Stojadinovic**. New Frontiers in Colon Cancer Staging. Chinese National Center of Colorectal Disease, the Third Affiliated Hospital, Nanjing University of Chinese Medicine, Nanjing, China 25 JUNE 2014.
117. Anton Bilchik, Mladjan Protic, Aviram Nissan, Zev Wainberg, Scott Steele, David Chen, Itzhak Avital, **Alexander Stojadinovic**. Prognostic Effect of Ultra-staging Node Negative(N0) Colon Cancer without Adjuvant Chemotherapy: Prospective NCI Clinical Trial RO1CA090848. American College of Surgeons Clinical Congress, 26-30 OCT 2014, San Francisco, CA (presented by Anton Bilchik).
118. **Alexander Stojadinovic**. Precision Medicine in Practical Application. Grand Rounds at the Chinese National Center of Colorectal Disease, the Third Affiliated Hospital, Nanjing University of Chinese Medicine, Nanjing, China, 03 AUGUST 2016.
119. **Alexander Stojadinovic**. Transformations in Care for Difficult-to-Treat Diseases. Shanxi Province Health and Family Planning Commission – Shanxi Anti-Cancer Association – International Union for Difficult-to-treat-Diseases – 13th Cancer Chemotherapy Professional General Assembly Academic Conference: Join Together for Better Health, Shanxi Yangquan Medical Herbal Forest Conference Center, Yangquan, Shanxi province, China, 05-08 AUGUST 2016.
120. **Alexander Stojadinovic**. Principles of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis. Xingcheng International Forum on China – United States Diagnosis and Treatment in Gastroenterology, The Fourth Hospital of Changsha and the Xiangya Hospital, Changsha, China, 09 AUGUST 2016.
121. **Alexander Stojadinovic**. Optimizing Quality and Duration of Life in Our Communities. Keynote Presentation and the Providence Saint Joseph Health Oncology Services Advisory Council. Irvine, CA, 12 June 2018.
122. **Alexander Stojadinovic**. Principles and Best Practices of Cytoreductive Surgery and Heated Intra-peritoneal Chemotherapy for Peritoneal Surface Malignancy. Grand Rounds, John Wayne Cancer Institute. Santa Monica, CA, 13 June 2018.

IRB protocols

1. **Title:** A prospective functional voice assessment in patients undergoing thyroid surgery. Memorial Sloan-Kettering Cancer Center. New York, NY. IRB approved, March 2000-July 2001.
 - **Role:** Associate Investigator (Surgical Oncology Fellow)
 - **Status:** Completed
 - **Publications:** **(1) Annals of Surgery 2002; 236(6): 823-832**
2. **Title:** Sentinel Lymph Node Evaluation in Colorectal Cancer
 - **Role:** Principal Investigator, April 2000 – NOV 2011
 - **Status:** Closed
3. **Title:** Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: A Prospective Study. Walter Reed Army Medical Center, Washington, D.C.
 - **Role:** Principal Investigator, September 2002-2008
 - **Status:** Completed
 - **Publications:** **(1) Annals of Surgical Oncology 2005; 12(2):152-160**
 (2) Annals of Surgery May 2008; 247(5):843-853
4. **Title:** Electrical Impedance Imaging for the Early Detection of Breast Cancer in Young Women (Pilot Study). Walter Reed Army Medical Center, Washington, D.C.
 - **Role:** Principal Investigator, August 2002-October 2004
 - **Funding:** Educational grant = \$60,000
 - **Status:** Completed
 - **Publications:** **(1) Proc SPIE 2003; 5034:197-203**
5. **Title:** Double Blinded, Placebo Controlled Prospective Randomized Trial Evaluating the Efficacy of Continuous Paravertebral Catheter with Paravertebral Block in Breast Cancer Surgery. Walter Reed Army Medical Center, Washington, D.C.
 - **Role:** Co-Principal Investigator, October 2002 – April 2008
 - **Status:** Completed
 - **Publications:** **(1) Pain Medicine 2010 May; 11(5):790-9**
6. **Title:** A Prospective Randomized (multi-center) Study Comparing Sentinel Lymph Node (SLN) Evaluation with Standard Pathological Evaluation for the Staging of Colon Carcinoma: USMCI Clinical Trials Group Study GI-01.

- **Role:** Principal investigator, October 2002 – April 2006.
 - **Status:** Completed
 - **Publications:** (1) **Annals of Surgery** June 2007; 245(6):846-857
(2) **Annals of Surgery** May 2008; 247(5):902-904
(3) **Ann Surg** 2012 Sep; 256 (3): 412-427
7. **Title:** Molecular Phenotyping of Bone Marrow and Peripheral Blood Collected as Part of the Walter Reed Army Medical Center Clinical Breast Care Project Tissue Repository Initiative.
- **Role:** Principal Investigator, February 2003 – November 2011
 - **Status:** Closed
8. **Title:** Biological Relevance of SLN Micro-metastasis in Patients with Colon Carcinoma.
- **Role:** Principal Investigator, February 2003-July 2010
 - **Funding:** USMCI grant =\$50,000
 - **Status:** Completed
9. **Title:** A Prospective Functional Voice Assessment and Voice-related Outcome Appraisal in Patients Undergoing Thyroid Surgery.
- **Role:** Principal Investigator, March 2003 – April 2010.
 - **Status:** Completed
 - **Publications:** (1) **Surgery** 2008; Jun; 143(6):732-42
(2) **Annals of Surgical Oncology** 2008; Jul 15(7):2027-33
(3) **American Journal of Speech-Language Path.** 2010 Aug; 19(3):248-58
10. **Title:** A Prospective Appraisal of Voice in Patients Undergoing Thyroid Surgery: Aerodynamic and Perceptual Sequellae
- **Role:** Co-Principal Investigator, April 2003 – April 2013
 - **Status:** Completed
 - **Publications:** (1) **Semin Speech Lang.** 2011 Feb; 32(1):31-42
(2) **J Voice** 2011 Jul 21
11. **Title:** Coexisting Thyroid Disease and Hyperparathyroidism.
- **Role:** Principal Investigator, September 2004 – July 2010
 - **Status:** Completed
 - **Publications:** (1) **J Surg Res.** 2009 Aug; 155(2):254-60.
(2) **J Cancer** 2012; 3:1-6.

12. **Title:** North Atlantic Regional Medical Command Multicenter Trial: Electrical Impedance Imaging for the Early Detection of Breast Cancer in Young Women.

- **Role:** Principal Investigator, October 2004 – April 2013
- **Status:** Completed
- **Publications:** (1) *Journal of Clinical Oncology* 2005 Apr 20; 23(12):2703-15
(2) *Breast Cancer Research and Treatment* 2006 May; 97(2):179-89
(3) *Journal of Surgical Oncology* 2008, Feb 1; 97(2):112-120
(4) *ePlasty Open Access Journal* 2010 March 29;10: 203-216
(5) *J Cancer*. 2011 Apr 20; 2:210-27

13. **Title:** Double Blinded Prospective Randomized Trial of Standard versus pH-adjusted Radiocolloid for Patients Undergoing Sentinel Lymph Node (SLN) Mapping and Biopsy for Breast Cancer / PASSION - P Trial: Ph Adjusted Sulfur-Colloid, Sentinel Initiative On Pain Trial.

- **Role:** Principal Investigator, November 2005-April 2009
- **Status:** Completed
- **Publications:** (1) *Lancet Oncology* 2009 Sep; 10(9):849-54
(2) *Pain Med*. 2012 May; 13(5): 670-6.

14. **Title:** Combat Wound Initiative Collaborative Prospective Randomized Trial: Standard Wound Care versus Standard Wound Care Plus Shock Wave Therapy for Traumatic Wounds of the Extremity.

- **Role:** Principal Investigator, October 2006 – April 2013.
- **Status:** Completed
- **Publications:** (1) *JBJS Am* 2008 Mar; 90(3):580-8
(2) *Society of Gynecol Oncol* 2008 Nov;111(2 Suppl):S70-80
(3) *Gynecol Oncol* 2008 Nov; 111 (2 Suppl):S98-80
(4) *Ann Surg* 2009; Dec; 250(6):1002-7
(5) *Aniogenesis* 2008; 11(4):369-80
(6) *Journal of the American College of Surgeons* 2008; 207: 801-9
(7) *Military Medicine*. 2010 July; 175 (Supplement 1):18-21
(8) *Int Wound J*. 2009 Feb; 6(1):11-21
(9) *J Bone Joint Surg Am*. 2009; 91(5):1084-1091
(10) *J. Trauma-Injury Infect. & Crit. Care*. 66(4) Suppl: S150-S156, April 2009
(11) *EPlasty Journal* 2009; 9; ISSN: 1937-5719, e31
(12) *J Trauma* 2009 May; 66(5):1286-91; discussion 1291-3
(13) *J Multi-Disciplinary Healthcare* 2010 August; 3:125-135
(14) *J Bone Joint Surg Br Am* 2011; 93: 187-194
(15) *J Surg Res*. 2010 Apr; 159:633-9
(16) *J Wound Care*. 2010 Jul; 19(7):306-10

- (17) J Am Coll Surg. 2010 Sep; 211(3):361-7
- (18) Am J Surg. 2010 Oct; 200(4):489-95
- (19) Ann Surg. 2011 May; 253(5):1024-32
- (20) Plastic and Reconstructive Surgery. 2011; 127 (Suppl): 117S-130S
- (21) Wounds 2011; 23(7):204-215
- (22) Neurogastroenterol Motil. 2011 Apr; 23(4):379-86, e164
- (23) Annals of Surgery 2012 Jan; 255(1):23-9
- (24) J Immunol Methods. 2011 Jul 20; 372:146-161
- (25) Infect Drug Resist 2011; 4:209-13
- (26) Journal of Biomedical Optics. 2012 Apr; 17(4):040503
- (27) Mil Med. 2012 Feb; 177(2):216-21
- (28) Wound Repair Regen. 2012 Jul; 20(4):456-65
- (29) J Wound Care. 2012 Aug; 21(8):376-83

15. **Title:** Prospective, Randomized, Single-Blinded, Multi-Center Phase II Trial of the HER2/neu Peptide GP2 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2+ OR the Modified HER2/neu Peptide AE37 + GM-CSF Vaccine versus GM-CSF alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients to Prevent Recurrence.

- **Role:** Principal Investigator, November 2006 – November 2010
- **Status:** Completed
- **Publications:**
 - (1) Cancer Immunol Immunother. 2008 Dec; 57(12):1817-25
 - (2) Clin Cancer Res. 2009 Apr 15; 15(8):2895-904
 - (3) Hum Vaccin. 2008 Sep-Oct; 4(5):389-92
 - (4) Cancer 2008; 113:1666-75
 - (5) Clinical cancer Research 2009 Apr 15; 15(8):2895-904
 - (6) Vaccine 2010 Nov 3; 28(47):7476-82
 - (7) Cancer 2011 Feb 1; 117(3):463-71
 - (8) Cancer 2011 Oct 11. doi: 10.1002/cncr.26574. [Epub ahead of print]

16. **Title:** VOCAL Trial: Voice Outcomes Appraisal, Longitudinal Trial.

- **Role:** Principal Investigator, June 2007- April 2013
- **Funding:** ARAPMI, Congressional Program Grant = \$ 330,000.
- **Status:** Completed
- **Publications:**
 - (1) Journal of Voice 2010 April 28; 25(1):e7-e14
 - (2) Surgery 2010 Jun; 147(6):861-70
 - (3) American J Speech-Language Pathology. 2010 Aug; 19(3):248-58
 - (4) Clinical Linguistics & Phonetics 2011 Mar; 25(4):302-20
 - (5) Semin Speech Lang. 2011 Feb; 32(1):31-42
 - (6) J Surg Oncol. 2012 Jan; 105(1):4-9

- (7) J Cancer 2012; 3:207-16.
- (8) J Surg Oncol. 2012 Dec; 106(8): 1005-6.
- (9) Surgery 2013 Jan; 153(1):103-110.
- (10) J Voice; Nov; 26(6): 711-20.

17. **Title:** Surgical Training and Assessment Tool (STAT): A Multi-center Validation Trial.
 - **Role:** Principal Investigator, June 2007 - May 2009
 - **Status:** Closed
18. **Title:** Sentinel Lymph Node Mapping and Biopsy with 99m-Techetium-Sulfur-Colloid and Isosulfan Blue Dye for the Staging of Rectal Carcinoma.
 - **Role:** Principal Investigator, July 2007 – July 2009
 - **Status:** Closed
19. **Title:** Racial Disparities in Colorectal Cancer Outcomes in the Department of Defense.
 - **Role:** Principal Investigator, August 2007 - April 2013
 - **Status:** Completed
20. **Title:** Multi-marker Profiling Along the Spectrum of Disease in Colorectal Cancer.
 - **Role:** Principal Investigator, August 2007 – November 2011
 - **Status:** Closed
21. **Title:** Independent Predictors of False Negative Targeted Nodal Assessment in Colon Cancer.
 - **Role:** Principal Investigator, August 2007 – August 2010
 - **Status:** Completed
 - **Publications:** **(1) J Surg Oncol. 2009 Apr 1; 99(5):273-4**
 (2) Annals of Surgery 2010 Feb; 25(2):265-74
22. **Title:** Detection of Circulating Tumor Cells in Colorectal Carcinoma.
 - **Role:** Principal Investigator, August 2007 – November 2011
 - **Status:** Closed
23. **Title:** The Frequency and Distribution of Bone and Soft Tissue Sarcoma Subtypes in the Military Health System from 1988-2004.
 - **Role:** Co-Principal Investigator, April 2008 – November 2011
 - **Status:** Closed
24. **Title:** Sarcomas of Soft Tissue and Bone: A Novel Biostatistical Approach to Prognostication and Multi-modality Treatment Decision Making.

- **Role:** Principal Investigator, April 2008 – April 2013
 - **Status:** Completed
25. **Title:** Papillary Thyroid Carcinoma: The Department of Defense Experience.
- **Role:** Principal Investigator, April 2008 – April 2013
 - **Status:** Completed
26. **Title:** Referral and Practice Patterns of Medical Professionals for Patients with Post-Thyroidectomy.
- **Role:** Principal Investigator, October 2008 – November 2011
 - **Status:** Closed
27. **Title:** Cytotoxic T Lymphocyte Recognition of Epithelial Cancer.
- **Role:** Principal Investigator, February 2009 – December 2010
 - **Status:** Closed
28. **Title:** Ethnicity Impacts on Female Breast Cancer Survival – A Retrospective Registry Review.
- **Role:** Principal Investigator, March 2009 – April 2013
 - **Status:** Completed
29. **Title:** United States Military Cancer Institute Clinical Trials Group GI-02: Ultra-Staging of Early Colon Cancer.
- **Role:** Principal Investigator, May 2009 – April 2013.
 - **Status:** Completed
 - **Publications:**
 - (1) J Surg Oncol 2009 Apr 1; 99(5):273-4
 - (2) Annals of Surgery 2010 Feb; 25(2):265-74
 - (3) Annals of Surgery 2011 Jan; 253 (1):82-7
 - (4) Surgery 2010 Mar; 147(3):352-7
 - (5) Archives of Surgery, 2010 Sep; 145(9):830-1
 - (6) Ann Surg. 2010 Sep; 252(3):467-74
 - (7) Annals of Surgical Oncology 2012 Dec; 19(13): 4178-85.
 - (8) Ann Surg 2012 Sep; 256 (3): 412-427.
30. **Title:** Colorectal Cancer Care Quality Measurement System (CCQMS): A Veterans Affairs-Department of Defense (United States Military Cancer Institute).
- **Role:** Principal Investigator, October 2009 – September 2010

- **Status:** Closed
31. **Title:** Auditory Perceptual Rating of Disordered Voices
- **Role:** Associate Investigator, April 2008 – August 2011
 - **Status:** Closed
32. **Title:** Development of a Prognostic Test for Early- Stage Colorectal Cancer using Genetic Programming.
- **Role:** Principal Investigator, March 2010 – Jan 2012
 - **Status:** Closed
33. **Title:** Occult Lymph Node Metastases and Racial Disparities in Colon Cancer Outcomes.
- **Role:** Principal Investigator, February 2010 – November 2011
 - **Status:** Closed
34. **Title:** A Pilot Study to Evaluate the Safety and Efficacy of the NG Tube-Clear Device in Subjects with NG Feeding Tubes.
- **Role:** Principal Investigator, March 2011 - April 2013
 - **Status:** Closed
35. **Title:** Double-Blinded, Single-Site, Pilot Study of NanoDOX™ Hydrogel versus Placebo Hydrogel for Dehiscence Surgical Wounds. (2008-DOX-NT/005).
- **Role:** Associate Investigator, March 2011 - April 2013
 - **Status:** Closed
36. **Title:** Prospective, Randomized, Open Label Trial of NanoDOX™ Hydrogel plus Vacuum Assisted Closure Therapy versus VAC Therapy Alone in Orthopedic Trauma Wounds.
- **Role:** Associate Investigator, March 2011 – April 2013
 - **Status:** Closed
37. **Title:** Clinical and Mechanistic Demonstration of a Bioelectric Dressing System for Non-Healing Wound Management: A Phase II Randomized Trial.
- **Role:** Principal Investigator, March 2012 – April 2013
 - **Status:** Closed

SURGICAL RESEARCH RESIDENTS MENTORED:

2008-2013	Vlado N. Antonic, PhD Doctoral Dissertation: Evaluation of Angiogenic and Anti-inflammatory Effects of Extracorporeal Shockwave Therapy in an Animal Model of Ischemic Skin Flaps, 27 SEP 2013
2012-2013	Dr. Diego Vicente
2011-2012	Dr. Jason Radowsky
2009-2010	Dr. Anthony L. Mark Dr. Paul F. Hwang Dr. Ian Russell Driscoll Dr. Samuel C. Phinney
2008-2009	Dr. Chad M. Cryer Dr. Suzanne Gillern Dr. Reed B. Kuehn Dr. John Christopher Graybill
2007-2008	Dr. Asna A. Amin Dr. Peter Kreishman
2006-2007	Dr. Steven W. Khoo Dr. Byron J. Faler
2005-2006	Dr. Zia A. Dehqanzada Dr. Gilbert Aidinian
2003-2004	Dr. Matthew T. Hueman Dr. Scott R. Golarz
2002-2003	Dr. Jennifer M. Gurney Dr. Shane Ottman

Wartime Leadership:

**Operation Iraqi Freedom, Senior Surgeon, Forward Surgical Team Regimental Support Squadron,
2nd Armored Cavalry Regiment, 1st Armored Division**

Dates of service: March 2003 – March 2004

Scope of responsibility:

- Provided senior surgical expertise for complex life-saving care of the wounded service members.
- Established walking blood bank program implemented across the division.
- As Chief Contracting Officer for Muleskinner Base, Baghdad, IRAQ, established and executed plans for the development of an enduring base camp within a combat zone.
- Created, developed and implemented a surgical Civilian Medical Assistance program to local hospitals bringing surgical oncology care to Iraqis in need.

Performance evaluation (COL Bradley May, Regimental Commander):

- "LTC Stojadinovic's performance of duty while deployed in a combat zone has been absolutely magnificent. He is without a doubt the most talented surgeon I have known during my 23 years of service. As the head surgeon for the 2nd ACR Forward Surgical Team, his talents were invaluable in saving the lives of countless soldiers and Iraqi nationals.
- During the bombing of the United Nations on 19 August 2003, Alex set up the triage stations and then performed life-saving surgery that resulted in 129 UN personnel being saved.
- In addition to his surgical talents as a provider, LTC Stojadinovic volunteered his time to set up and provide oversight to a contracting operation that rebuilt the 2nd largest logistics basecamp in all of Baghdad that housed over 4,000 soldiers, and supported an area footprint of over 8,000 soldiers.
- LTC Stojadinovic's devotion to duty and dedication to saving lives and rebuilding Camp Muleskinner has been absolutely heroic. The best surgeon I have served with in over 23 years of military service.
- Promote this officer immediately to Colonel and place in Command of troops. A great performance by one of our Army's finest leaders, LTC Stojadinovic has unlimited potential for positions of higher responsibility. His keen intellect and unstoppable drive guarantee the success of any mission he is assigned."

Performance evaluation (General Martin E. Dempsey, Division Commander):

- "Brilliant performance in combat by one of the finest Surgeons I've known in 30 years. LTC Stojadinovic provided world class medical care to 2nd ACR and 1st Armored Division Soldiers deployed in support of combat operations during Operation Iraqi Freedom. He is unmatched in

his technique and untiring in his efforts to save the lives of US soldiers and local Iraqi citizens. His willingness to volunteer to perform Civil Medical Assistance visits created an atmosphere of trust and goodwill among the local population that directly contributed to the success of the 2nd ACR mission. A must select for immediate promotion to Colonel and place in Command of a Combat Support Hospital."

Wartime Leadership:

**Chief of Surgery for Task Force 28 Combat Support Hospital
Operation Iraqi Freedom Theater Surgical Consultant**

Dates of service: October 2009 – May 2010

Scope of responsibility:

- Senior surgeon of a deployed Medical Task Force of over 700 personnel.
- Provided health service support for the Iraqi Theater for Baghdad and the Southern Joint area of operations.
- Directed health protection and surgical care for a population of over 200,000.
- Directly contributed to outreach medical operations including cooperative medical engagements throughout Baghdad and the Southern Sector.
- Provided senior surgical consultation to advance healthcare throughout IRAQ.
- Serve as the Theater of Operations Trauma Czar, directing and coordinating MASCAL planning, preparation, training and execution.

Performance evaluation (COL Bruce McVeigh, Task Force Commander):

- "A top 1% officer in every regard; unequivocally the best, most complete Medical Corps Officer and surgeon I have ever served with in over 25 years; absolutely none better. Alex is a singularly outstanding surgeon and Trauma Czar who inspires, coaches, and mentors his subordinates to achieve excellence in patient care and life-saving surgery, despite the ever increasing mission demands.
- His uncanny ability to rapidly assimilate information, assess the most complex trauma and surgical intervention cases for the good of the patient, and then quickly produce and execute a comprehensive and well thought out game plan for life saving measures is legendary.
- Across the full spectrum of medical care in combat, COL Stojadinovic's meticulous oversight and hands on skill set have made the USF-1 Hospital the best in the Iraqi Theater – without question. There is no task that he will ask his subordinates to accomplish that he hasn't first completed himself. Alex continues to demonstrate that he is at the absolute top of his career in word and deed. He has earned the trust and confidence of the entire 28th Combat Support Hospital Task Force and the higher medical Chain of Command in Iraq. Absolute best potential of any Medical Corps Officer I know today.

- I would fight to have him at my side in any assignment. Alex is a future leader of significance in Army Medical Department.
- COL Stojadinovic is a superb physician and leader with truly unbounded potential. He should be selected for key surgical and research assignments and placed in demanding leadership positions.
- Definite General Officer Potential."

Performance evaluation (COL Robert D. Tehnet, Medical Brigade Commander):

- "As my best surgeon in the Iraqi Theater, COL Stojadinovic has been a truly stellar asset in the Task Force 28 Combat Support Hospital medical care continuum. His dedication to mission, professionalism, and team spirit attitude place him head and shoulders above the rest. His surgical skills are exemplary and his leadership skills are equally impressive.
- This stellar clinician is a true force multiplier and he has served this theater health mission in a most exemplary manner. Keep him assigned to positions of increased responsibility; he will continue to shine."

Performance evaluation (General Kenneth W. Hunzeker, USF-1, DCG-S):

- "Exceptional combat performance by the best Medical Task Force and Level III Hospital Chief Surgeon I have ever seen in Iraq. COL Stojadinovic's impact as the Task Force-28 Chief of Surgery has spanned a very large, complex, and diverse organization with multiple component Army and joint Air Force assets working in total synchronization of effort, has been legendary throughout Iraq.
- I would want Alex with me on the most challenging missions and assignments as there is none better in his field. His potential is unlimited. He is a rising superstar that succeeds in all aspects, future General Officer in the making."

Leadership Education, Philosophy and Style:

As a dedicated student of leadership, I developed, through extensive personal experience, a concept for excellence in leadership, which I have refined over 30 years through roles of increasing responsibility and personal growth.

This excellence in leadership roadmap served as the fundamental basis for leadership roles of increasing responsibility that have ranged from mentor to medical students, surgical house staff and researchers in university centers and the basic science laboratories, to training surgical teams on the battlefield. My academic leadership experience has extended from Director of a Division of Surgical Oncology to Vice Chairman of Surgery and leading clinical researcher at the Department of Defense's largest university-affiliated medical center. I have been fortunate to create, develop from ground up, and to advance an internationally recognized United States Military Cancer Institute clinical trials group and Congressionally-funded international translational complex wound research program, and to direct Combat Support Hospital operations in a theater of operations. I have developed long-standing private-public partnerships based on shared vision and mutual trust and, have successfully led international cooperative group clinical trials. Most recently I have been blessed to serve and to transform cancer care within the community.

This **excellence in leadership** roadmap is based on what I deem to be 13 essential attributes, which guide actions as a leader:

- **Energy:** Be passionate about what you do. Inspire your team to action!
- **Education:** Know your job and mentor your team members
- **Ethics:** Don't lie, cheat, or steal. Do the right thing.
- **Empathy and Emotional Intelligence:** Be sensitive to how your words and deeds impact others. Understand your own emotions and the feelings of others.
- **Edge:** Be decisive; make the tough call. Weigh new evidence and remain flexible, but don't fall victim to pathological second guessing.
- **Evidence:** Make reasoned decisions that are evidence-based.
- **Equipoise:** In times of chaos, take your own pulse first, keep a cool head and create equality of distribution of emotional forces.
- **Execution:** Take decisive action via an integrated team approach.
- **Effectiveness:** Find information-driven, meaningful solutions to problems; avoid creating problems (impediments to) for solutions.
- **Error management:** Identify, accept and take responsibility for good-faith errors committed by you and your team members. Learn/teach from these errors.
- **Example:** Set an example for others. Lead from the front.
- **Ethos:** Live and teach the values of our organization.

As we endeavor to inspire and develop the next generation of **forward thinking, innovative leaders**, these core principles of leadership must be within the leader's toolkit:

- **Competence:**

Where we are | **Performance Gap (Manager)** | where we should be | **Opportunity Gap (Leader)** |
where we could be | **Imagination Gap (Innovator / Entrepreneur / Visionary)** | where we should
dream to be

- **Character:** People follow you because of your core set of values, i.e. who you are.
- **Compassion:** Show courtesy and connect on a personal level with those at all levels in your organization.
- **Candor:** Communicating with honesty, authenticity.
- **Consciousness:** Growth of self-concept – achievement / affiliation / power.
- **Courage:** Moral courage to stand up for what is right and to make the tough decisions.

Leadership through Innovation:

Patent Cooperation Treaty (PCT) Patent Application No. PCT/US09/60850 filed 15 October 2009, claiming priority of U.S. Provisional Application No. 61/105,786 filed 15 October 2008 and U.S. Provisional Application No. 61/166,245 filed 2 April 2009

Title: "Clinical Decision Model"

Inventors: Alexander Stojadinovic, Eric Elster, Doug Tadaki, John Eberhardt, Trevor Brown, Thomas Davis, Jonathan Forsberg, Jason Hawksworth, Roslyn Mannon, Aviram Nissan

U.S. Patent Application No. 13/123,406 filed 8 April 2011 claiming priority of PCT/US09/60850

Title: "Clinical Decision Model" (containing claims related to thyroid breast cancer)

Inventors: Alexander Stojadinovic, Eric Elster, Doug Tadaki, John Eberhardt, Trevor Brown, Aviram Nissan

U.S. Patent Application No. 13/123,406 filed 8 April 2011 claiming priority of PCT/US09/60850

Title: "Clinical Decision Model" (containing claims related to breast cancer)

Inventors: Alexander Stojadinovic, Eric Elster, Doug Tadaki, John Eberhardt, Trevor Brown, Aviram Nissan

U.S. Patent Application No. 13/083,090 filed 8 April 2011 claiming priority of PCT/US09/60850

Title: "Clinical Decision Model" (containing claims related to wound healing)

Inventors: Alexander Stojadinovic, Eric Elster, Doug Tadaki, John Eberhardt, Trevor Brown, Thomas Davis, Jonathan Forsberg, Jason Hawksworth

U.S. Patent Application No. 13/083,184 filed 8 April 2011 claiming priority of PCT/US09/60850

Title: "Clinical Decision Model" (containing claims related to transplant glomerulopathy)

Inventors: Alexander Stojadinovic, Eric Elster, Doug Tadaki, John Eberhardt, Trevor Brown, Thomas Davis, Jonathan Forsberg, Jason Hawksworth, Roslyn Mannon

Entrepreneurship:

- Co-Founder of P8-Medicine: A consulting firm specialized in precision medicine that developed software to manage cancer enterprises. P8Medicine serves and assists hospitals and healthcare systems with limited resources to achieve optimal value - defined by access to healthcare and quality of care over the cost of care.
- Founding partner of 3rd Curve Healthcare: Strategic advisory for healthcare providers and independent support service entities locally, regionally and globally. Initiating and developing innovative services and products to support private health systems in Europe, the Middle East, and China.

International Collaborations:

- Exceptional leadership skills, with proven ability to foster a spirit of collaboration through a commitment to transparent communication, shared vision and mutual trust
- Excellent interpersonal skills and proven capacity to build and maintain relationships with faculty and administrators, and with national and international government, foundation and industry leaders.
- Multi-year collaboration with the Clinical Center of Vojvodina, Serbia (REF: Professor Mladjan Protic)
- Multi-year collaboration with the University of Novi Sad (REF: Professor Mladjan Protic)
- Honorary Visiting Professor, University of Novi Sad, Faculty of Medicine
- Co-founder, International Consortium of Research Excellence – organization creating research collaborations in Europe, Israel and USA
- Multi-year collaboration with Hadassah Hebrew University Medical Center (REF: Professor Aviram Nissan)
- Multi-year collaboration with the Third Affiliated Hospital, Nanjing University of Chinese Medicine (REF: Professor Yan Gao Man)
- Vice President, International Union for Difficult-to-Treat Diseases
- Honorary Visiting Full Professor, Chinese National Center of Colorectal Disease, the Third Affiliated Hospital, Nanjing University of Chinese Medicine, Nanjing, China

Inter-Governmental Collaboration:

- Demonstrated excellence in inter-and multi-disciplinary academic pursuits.
- Together with Professor Itzhak Avital, I created multi-disciplinary oncology collaboration between the United States Military Cancer Institute and National Cancer Institute.
- The collaboration brought clinical trials and translational research to military service members and their families affected by cancer.
- Demonstrated commitment to valuing and actively promoting an inclusive, diverse culture.

Private-Public Partnership:

- Demonstrated experience in the procurement and management of sponsored research programs.
- Demonstrated novel approaches to securing programmatic grant funding.
- Led a multi-year, multi-center prospective trial supported by private-public partnership, which enrolled >8,500 ethnically diverse young women to test a novel risk stratifying tool.
- Created and developed a joint research enterprise, private-public partnership to develop clinical decision support systems in healthcare.
- Developed strategic research partnerships to include internationally recognized senior leaders and Nobel Prize laureate
- Raised over \$33M in competitive research funding to establish and direct a translational research program of leading surgeons and scientists (national and international private – public, and university affiliated partnership) to assess and develop promising technologies and treatments to advance complex wound care.

Designing, Developing, Leading Clinical Trials with IRB and FDA Interactions:

- Exceptional planning and organizational skills
- Steadfast commitment to task – strong, indefatigable work effort, tenacious and resilient
- Excellent follow-through, and timely task completion to meaningful outcome
- Conceptualized, designed, and conducted numerous clinical trials and secured ~\$40M in research funding
- I have led numerous single institutional and cooperative multi-center, national and international clinical trials, for example:
 - First prospective clinical trial conceived of, developed, and completed by a fellow during a surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center
 - First cooperative randomized USMCI clinical trial that served as the launch point for a longstanding cooperative multi-center, international RO1-funded, Ultra-staging in Early

- Colon Cancer (USMCI-UECC) Trial.
- First cooperative prospective randomized clinical trial (PRT) of the Army Regional Anesthesia and Pain Management Initiative, which defined the role of regional anesthesia in the surgical treatment of early breast cancer in the DoD.
- Randomized, cooperative, multi-service, single institution clinical trial, first of its kind, with practice-altering outcome. This pivotal PRT has had significant practice-altering impact in the field of breast cancer staging.
- Cooperative multi-center, international NIH-funded UECC Trial. This grant has been continuously funded since 2001 and has not only helped support over 40 peer review publications, but also has led to changes in quality measures in colon cancer.
- Through team building, leadership, influence, executive management and clinical trial experience, I developed and directed an NCI-funded, multi-center, inter-group randomized clinical, and the first of its kind in the U.S., to compare best available systemic therapy to multi-modality therapy in patients with peritoneal carcinomatosis of colonic origin. This study ultimately failed to accrue, and it provided me valuable insights into challenges that must be overcome in pursuing multi-disciplinary clinical trials in oncology.
- Developed a Richmond community-based intervention program for overcoming cultural barriers to breast cancer screening in African American women.
- Formed a Commonwealth of Virginia private-public partnership in research (Bon Secours Cancer Institute, Urology of Virginia, Virginia Urology, University of Virginia, Arizona School of Health Sciences and A.T. Still University) and secured NIH competitive funding to address the provocative question, *How do variations in tumor-associated immune responses among patients from distinct well-defined populations, such as various racial/ethnic or age groups, contribute to differences in cancer outcomes?*

Program Management and Business Finance:

- Managing large multi-center operational budgets.
- Creating pro-formas and business plans for various programs.
- Recruiting talent and negotiating employment agreements.
- Negotiating with private insurance payers.
- Negotiating management agreements with private physicians in the community.

Transforming Systems of Healthcare:

- Developing roadmap for clinical integration – a Coordinated Cancer Care Network – to serve as a model for accountable, value-driven cancer care with this vision: Delivering value through evidence-based, multidisciplinary, comprehensive cancer care that is integrative and innovative, delivered with precision, and driven by cutting edge translational research.

- Developing business model designed to achieve community cancer center NCI designation
- Building a new multi-disciplinary cancer institute
- Developing a business model for national service line
- Leading cancer operations encompassing multiple hospitals within the community
- Developing system-wide multi-disciplinary cancer care teams (Disease Management Teams)
- Integrating rapid recovery clinical pathways (e.g. iCOUGH protocol, Early Recovery after Surgery Protocols) to optimize patient outcomes
- Creating a research division and clinical trial unit
- Recruiting top talent and negotiating employment agreements.
- Building risk assessment and quality performance operations
- Developing and leading multi-disciplinary Tumor Boards
- Negotiating with insurance payers and organizing cancer care under a value-based purchasing model
- Creating evidence-based clinical cancer care pathways supported by cancer providers and private payers designed to improve quality of and access to care, and reimbursement
- Partnering with private industry to develop precision medicine initiatives
- Developing clinical decision support tools for cancer risk identification, screening, treatment and surveillance
- Building tissue biorepositories and research data infrastructure and analytical platforms to support personalized medicine initiatives
- Building a philanthropic effort to support growth of the cancer institute
- Developing marketing plans, advertising campaigns, community outreach programs
- Authoring over 45 peer-reviewed publications within a two-year period with the institutional brand, thereby creating National recognition of the cancer institute
- Securing competitive NCI funding to support research in community healthcare disparities
- Leading institutional efforts to reduce healthcare disparities
- Advancing evidence-based design for cancer center
- Leading system-wide early detection effort with mobile screening units and “walk-in” screening clinics
- Developing of Institute of Precision Medicine
- Developing and implementing clinical cancer dashboards
- Incorporating integrative medicine within the continuum of cancer care
- Building Center of Excellence for Endocrine Tumors
- Building Center of Excellence for Peritoneal Surface Malignancy
- Creating strategic partnerships for Medical Tourism
- Developing Triple Aim enterprise for improving quality of care, reducing cost of

- healthcare and improving the health of the population
- Developing strategic plan for population health promotion, disease prevention, screening
- Organizing and Chairing the First Annual Cancer Summit, focused on Precision Medicine, funded entirely through philanthropy and sponsorship
- Developing strategic partnerships to advance team-based cancer care and research

Building and Leading High Value-to-Volume Servicelines:

- Recognizing endocrine surgery centers are growing at a much slower rate than what is necessary to meet projected needs, I created an Endocrine Surgery Center of Excellence to deliver value, to fill a service gap, and capture market share.
- The Center delivered high-quality, high-volume, multi-disciplinary care utilizing advanced, algorithm-based, clinical treatment pathways, and standardized techniques to improve access to care in a community-based center, to attain superior patient outcomes (cure rates, safety), and to maximize efficiency of care (same day operations, reduced hospital resource utilization).
- I have extensive experience in endocrine surgery including tumors of the thyroid and parathyroid gland, as well as complex resection of recurrent and metastatic pheochromocytoma and adrenal cortical carcinoma

Building and Leading Multi-Disciplinary Teams for Complex Cancer Care:

- With the understanding that carefully selected patients with advanced Stage IV malignancy of epithelial cell origin can benefit from multi-disciplinary care incorporating aggressive surgical oncology techniques I developed surgical expertise in peritoneal surface malignancy and heated regional chemotherapy delivery
- Established the first peritoneal surface malignancy program in the Department of Defense, which combines aggressive surgical therapy with regional intra-abdominal chemotherapy for the treatment of advanced cancer.
- Conceived and developed a peritoneal surface malignancy surgical training program funded by the USMCI that expanded this multi-disciplinary cancer treatment capability across the Department of Defense
- Developed and led the first USMCI-ACOSOG inter-group randomized clinical trial in peritoneal surface malignancy (NIH funded, CTEP).
- Built a center of excellence for peritoneal surface malignancy founded on a collaborative effort comprised of members from all pertinent specialties (medical oncology, radiation oncology, interventional radiology, diagnostic radiology, pathology, palliative medicine, cardio-oncology, precision medicine, integrative medicine, nutritional services,

pharmacy, social work, psychiatry amongst others to provide care for patients with advanced peritoneal surface malignancy along the full-cycle of care